Author: "V. Monivas" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"V. Monivas"' showing total 51 results

Start Over Author "V. Monivas"

51 results on '"V. Monivas"'

1. Usefulness of strain imaging to determine prognosis in pulmonary hypertension

Author: C Arellano-Serrano, P Remior, Juan Francisco Oteo, S Garcia-Gomez, A Martinez Mingo, D Garcia-Rodriguez, Arturo García-Touchard, Susana Mingo, J.F Goicolea, F. Hernandez Perez, A Borrego, S Navarro, Eusebio García-Izquierdo, and V Monivas Palomero
Subjects: Heart transplantation, medicine.medical_specialty, Univariate analysis, Ejection fraction, business.industry, medicine.medical_treatment, medicine.disease, Pulmonary hypertension, Internal medicine, Medical imaging, medicine, Cardiology, Systole, Cardiology and Cardiovascular Medicine, business, Pulmonary wedge pressure, Survival analysis
Abstract: Introduction Pulmonary hypertension (PH) is defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterization (RHC). Purpose To describe classical and myocardial deformation echocardiographic parameters in patients with established PH and to identify prognostic variables Methods We prospectively enrolled 76 patients with mPAP ≥25 mmHg undergoing RHC between 2017 and 2018. All subjects underwent transthoracic echocardiography (TTE) according to the latest ASE/EACVI guidelines the same day of the RHC. Strain analysis was carried out by speckle-tracking echocardiography (QLAB 10.7, Philips). Clinical events during the follow-up were: acute heart failure hospitalization, cardiac transplant and all-cause mortality. Results Mean age was 59±12, 43.4% were women and 49 patients (64.5%) belonged to group 2 of PH. The median follow-up was 288 (ICR 92–534) days. Total number of events was 42 (55.3%, 9 deaths). Variables associated to events are shown in Table 1. All classic LV and RV systolic function and strain parameters were associated with a worse prognosis, being free-wall RV longitudinal strain (RVLS) the only one that remained as a prognostic factor in mutivariate analysis. Other variables associated with a worse prognosis were PCP>15 mmHg and NT-proBNP>1800, the latter being independent predictor of events. The attached figure shows event-free survival curves for the global population divided according to whether or not they belong to group II PH. Conclusions Our data highlight the prognostic value of free-wall RVLS and NT-proBNP in patients with established PH. NT-ProBNP was only useful in group II PH while free-wall RVLS identified patients with a higher risk of events in both groups, mainly in patients with heart disease Free event survival Curves Funding Acknowledgement Type of funding source: None
Published: 2020

2. Evaluation of left ventricular diastolic function in Marfan syndrome using speckle-tracking echocardiography

Author: A. Forteza Gil, A Borrego Hernandez, S. Mingo Santos, V Monivas Palomero, J. Segovia Cubero, C.E. Martin Lopez, J. Gonzalez Mirelis, S Moreno Casado, E Garcia-Izquierdo Jaen, M. A. Cavero Gibanel, C. Mitroi, S Navarro Rico, X Cia Mendioroz, and M Torres Sanabria
Subjects: Marfan syndrome, medicine.medical_specialty, Ejection fraction, business.industry, Diastole, Cardiomyopathy, Speckle tracking echocardiography, medicine.disease, Blood pressure, Tricuspid Valve Insufficiency, Internal medicine, medicine, Cardiology, Cardiovascular Surgical Procedure, Cardiology and Cardiovascular Medicine, business
Abstract: Background/Introduction Previous studies using conventional echocardiographic measurements have reported subclinical left diastolic dysfunction in patients with Marfan syndrome (MFS). Certain speckle-tracking echocardiography (STE) derived parameters have shown good correlation with invasive measurements of LV relaxation. Purpose To evaluate diastolic function in Marfan patients using STE-derived parameters along with traditional diastolic measurements and compare them with healthy controls. Methods We consecutively included 127 MFS patients with normal LV ejection fraction and no previous cardiovascular surgery or significant valvular regurgitation. We also studied 38 healthy controls (age and sex-matched). We performed LV and LA strain analysis using 2D STE (QLAB 10, Philips). Echocardiographic parameters recommended to assess diastolic function (according to ASE/EACVI 2016 guidelines) were also considered. Results Reported use of BB/ARB was 28/39% in MFS patients. According to current guidelines, all participants had normal diastolic function. MFS patients showed lower TDI e' velocities (septal and lateral) and higher average E/e' ratio compared to controls, but still within normal range. Regarding STE-derived measurements, LVGLS, EDLSR and PALS were significantly reduced in MFS. E/EDLSR ratio was higher among MFS patients, reflecting impaired LV relaxation. Interestingly, E/LVGLS was not different between both groups. Conclusion STE-derived parameters showed impaired LV relaxation in MFS patients compared to controls. Our results suggest that STE derived parameters can be markers of early diastolic dysfunction and provide a better insight into Marfan-related cardiomyopathy. STE derived parameters Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Programa de Actividades de I+D de la Comunidad de Madrid
Published: 2020

3. P2472Two-dimensional speckle tracking echocardiography in heart transplant patients: five year follow-up of right and left ventricular function

Author: S. Mingo Santos, A Borrego Hernandez, V Monivas Palomero, J. Segovia Cubero, S Lozano Jimenez, M. Gomez Bueno, L. Alonso Pulpon, M. A. Cavero Gibanel, S Navarro Rico, and J. Goirigolzarri Artaza
Subjects: medicine.medical_specialty, Ventricular function, business.industry, Internal medicine, Cardiology, medicine, Five year follow up, Transplant patient, Speckle tracking echocardiography, Cardiology and Cardiovascular Medicine, business
Abstract: Background Evolution of left and right ventricular (LV and RV) function after heart transplantation (HT) has not been well described. Our objective was to evaluate the normal evolution of echocardiographic parameters of both ventricles and to explore if there is a link between the decrease of strain values and acute rejection (AR) or coronary allograft vasculopathy (CAV) Methods We followed 29 HT recipients with serial echocardiograms performed between 2011 and 2018, with a median follow-up of 5 years. LV global longitudinal strain (LV GLS) was analyzed by speckle tracking in 12 LV segments in 4 and 2 chamber views, and RV free wall longitudinal strain (RV free Wall LS) was measured in 4 chamber view. Acute rejection was diagnosed by EMB following our HT protocol. We take into consideration only moderate or severe rejection episodes (grade ≥2R).The presence of CAV was studied by coronariography or IVUS one year post-HT. Results As shown in the table below, LVEF was preserved from the begining of the follow up while LV GLS reached the normality in the 6th month, and both remained in normal ranges untill the 5th year. Regarding RV function, TAPSE was impaired in the early post-HT period and increased progressively and reached normality 1 year after HT. RV lateral wall LS rose during follow-up as well, reaching normal values 6 months after HT. Nevertheless, we noticed an impairment in this parameter at 5 years (−20.1±2.7, p=0.001), although it remained within normal ranges compared to guidelines reference parameters. We did not find any correlation between any parameter evaluated and the presence of AR or CAV at five years of follow-up. LV and RV function parameters LVEF LV GLS TAPSE FAC RV free wall LS Basal (14 days) 63.0±7.9 −17.2±3.6 12.1±2.9* 43.7±9.8 −19.3±4.2 3 months 65.0±8.6 −17.7±2.8 14.8±3.4* 45.3±8.2 −22.0±4.6 6 months 65.8±9.6 −18.7±3.4 16.1±3.6 44.6±9.6 −24.6±4.9* 1 year 63.5±8.1 −18.1±2.2 17.1±4.1 44.0±8.1 −26.7±7.1* 2 years 63.8±6.8 −18.3±9.0 19.4±3.7 45.3±7.9 −27.6±6.3* 5 years 64.4±7.3 −18.1±3.3 17.9±3.9 46.6±12.1 −20.1±2.8 P (Anova) 0.85 0.85 Conclusion As we show in this series of HT recipients with uneventful postoperative course, all LV and RV function parameters showed normal values 1 year after HT and manteined them during long-term follow-up. The presence of AR or CAV did not have any influence in ventricular function.
Published: 2019

4. P1820New parameters for the evaluation of mechanic and elastic properties of the aortic root in Marfan Syndrome

Author: C. Mitroi, J. Gonzalez Mirelis, J Baena Herrera, E Garcia Izquierdo Jaen, C.E. Martin Lopez, S. Mingo Santos, A. Forteza Gil, V Monivas Palomero, S Navarro Rico, C Aguilera Agudo, and M Torres Sanabria
Subjects: Marfan syndrome, medicine.medical_specialty, business.industry, Aortic root, Internal medicine, cardiovascular system, Cardiology, Medicine, Cardiology and Cardiovascular Medicine, business, medicine.disease
Abstract: Background Elastic properties of the thoracic aorta in patients with Marfan Syndrome (MS) have already been evaluated with classic echocardiographic parameters. In the latest years the use of Speckle-Tracking (STE) ecocardiography has been widely extended. Our aim is to describe and provide new parameters of aortic deformation measured by STE in patients with MS. Methods 95 unoperated adult patients with MS and 32 healthy controls were prospectively enrolled. We measured classic parameters of the aortic root using 2D echocardiography. We calculated the posterior aortic wall systolic excursion at the sinuses of Valsalva and ascending aorta using M Mode in TDI colour; with ST 2D ecocardiography we measured the aortic strain at the sinuses of Valsalva (SV) and the anterior and posterior aortic wall displacement at the SV. Aortic distensibility was calculated using the formula: 1000 * (Ds − Dd)/Dd * 1/(Ps − Pd) in mmHg–1 (Ds: systolic and Dd: diastolic diameters, Ps systolic and Pd diastolic blood pressure). Aortic stiffness index was calculated as Ln((Ps/Pd)/(Ds-Dd)/Dd)). Results As shown in the table bellow, patients with MS had lower aortic strain, aortic anterior and posterior wall displacement and impaired aortic distensibility and stiffness index compared to healthy controls. We found a strong negative linear correlation between aortic root diameter at the SV and aortic root strain (r=−0.56, figure 1). Results of statistical analysis MS (n=95) Controls (n=32) p Age (years) 32.84±12.35 32.41±7.98 0.85 Aortic root diameter at the sinuses of Valsalva (mm) 38.82±5.35 30.92±3.65 Figure 1. Dispersion plot Conclusions Our results suggest that aortic deformation and displacement obtained by STE echocardiography is impaired in MS, showing a reduced distensibility and an increased stiffness of the aortic wall, with a strong negative correlation between aortic root dilation and aortic strain. All these parameters may be useful as additional tools for the diagnosis and follow-up of Marfan patients, and could be useful to to improve the echocardiographic evaluation of the aortic root.
Published: 2019

5. P4374Biventricular systolic function analysis in patients with Marfan Syndrome using speckle-tracking 2D ecocardiography

Author: J. Gonzalez Mirelis, S Navarro Rico, J Baena Herrera, C. Mitroi, V Monivas Palomero, S. Mingo Santos, A. Forteza Gil, M Torres Sanabria, C Aguilera Agudo, C.E. Martin Lopez, and E Garcia Izquierdo Jaen
Subjects: Marfan syndrome, Speckle pattern, medicine.medical_specialty, business.industry, Internal medicine, medicine, Cardiology, In patient, Systolic function, Cardiology and Cardiovascular Medicine, medicine.disease, Tracking (particle physics), business
Abstract: Background Left Ventricular systolic disfunction has already been described in Marfan Syndrome (MS) in patients without valvular dysfunction using 2D and 3D speckle tracking echocardiography (STE). This dysfunction has been related to a more severe causal genetic mutation, which suggest the presence of a primary cardiomiopathy in these patients. Right ventricular function has been less studied so far. We sought to evaluate biventricular function in our cohort of MS patients with 2D-STE. Methods 95 unoperated adult patients with MS and 32 healthy controls were prospectively enrolled. Patients with more than mild mitral or aortic regurgitation were excluded. Using STE we obtanied left ventricular global longitudinal strain (LVGLS) from the average of 16 segments from 4,2 and 3-chamber views and RVGLS values were obtained from the average of 6 segments from the apical 4-chamber view. We also measured classic parameters of systolic biventricular function (LVEF and TAPSE). Results Compared to controls, patients with MFS had significantly lower LVGLS and RVGLS (table 1). Values obtanied for LVGLS in MS patients were at the lower limit of normality stablished in the latest cuantification guidelines, while RVGLS and RV free wall LS were slightly above the limit of normality. LVEF and TAPSE were also slightly diminished in MS patients, though the differences found were clinically not relevant. Results of statistical analysis MS (n=93) Controls (n=32) p Age (years) 32.84±12.4 32.41±7.98 0.85 Aortic Root Diameter Valsalva Sinuses (mm) 38.82±5.35 30.91±5.3 Conclusions Our study suggests that patients with MFS show lower biventricular strain compared with healthy controls. 2D-STE imaging may be useful to detect subclinical changes in cardiac function in patients with MFS and should be added to routine ecocardiographic evaluation in order to improve the follow-up and treatment of these patients.
Published: 2019

6. P622Role of right ventricular strain measured by 2D-echocardiography in the diagnosis of cardiac amyloidosis

Author: M Torres Sanabria, V Monivas Palomero, J. Segovia Cubero, A. Durante Lopez, and S. Mingo Santos
Subjects: medicine.medical_specialty, 2d echocardiography, Cardiac amyloidosis, business.industry, Internal medicine, medicine, Cardiology, Strain (injury), Cardiology and Cardiovascular Medicine, medicine.disease, business
Abstract: Introduction Cardiac amyloidosis (CA) causes a restrictive cardiomyopathy usually associated with a poor prognosis. Two subtypes predominate: systemic (ALCA) and transthyretin (ATTR, either wild type -TTRwt- or mutant -TTRm-). Left ventricle (LV) apical sparing has been extensively studied by speckle-tracking echocardiography (STE) for diagnosis, but right ventricular (RV) deformation pattern has not been described. Purpose To characterize RV involvement in CA patients and to identify which parameters may help in the differential diagnosis between ALCA and ATTR subtypes. Methods 78 patients with CA (47 ALCA, 20 TTRwt, 11 TTRm) and 24 healthy controls were included. We analyzed global longitudinal strain (GLS) in 16 LV and 6 RV segments. LV and RV apical ratios (AR) were obtained. Results LVGLS and Free-Wall RVLS were impaired in all patients (LVGLS: 11.9±2.9% in ALCA, 12.5±3.8% in TTRwt, 14.9±2.7% in TTRm, 21.9±2.6 in controls and Free-Wall RVLS: 13.1±6.8% vs 14.9±4.5% vs 17.2±3.4% vs 22.1±3.1, respectively). LV and RV AR were higher in ALCA as compared to both TTRwt, ATRm and controls (LVAR: 1.1±0.2 vs 0.8±0.2 vs 0.9±0.1 vs 0.7±0.1, p0.96 and RVAR>0.8 showed high accuracy to differentiate between ALCA and ATTR. Conclusion RV disfunction is a common finding in CA. Apical sparing pattern was present in RV strain, similarly to that described in LV and we describe it as an specific finding of ALCA patients. We propose RVAR as an accessible and easy way to differentiate, among different subtypes of amyloidosis based on STE analysis.
Published: 2019

7. P4372Left atrial strain: a potential marker of early diastolic dysfunction in patients with Marfan syndrome

Author: E Garcia-Izquierdo Jaen, S. Mingo Santos, C. Mitroi, S Moreno Casado, A. Forteza Gil, J. Gonzalez Mirelis, D Martinez Lopez, M Torres Sanabria, C.E. Martin Lopez, S Navarro Rico, M. A. Cavero Gibanel, and V Monivas Palomero
Subjects: Marfan syndrome, Atrial strain, medicine.medical_specialty, business.industry, Internal medicine, medicine, Cardiology, Early diastolic, In patient, Cardiology and Cardiovascular Medicine, medicine.disease, business
Abstract: Background/Introduction Previous studies using conventional echocardiographic measurements have reported subclinical left diastolic dysfunction in patients with Marfan syndrome (MFS). Left atrial strain (LAS) has been shown to be an accurate predictor of left ventricular diastolic dysfunction. However, there is no evidence regarding the use of LAS in MFS. Purpose To assess feasibility of LAS and compare LAS derived measurements along with traditional diastolic parameters in MFS patients vs healthy controls. Methods 46 MFS patients (normal LV ejection fraction, no previous cardiovascular surgery, no significant valvular regurgitation) vs. 20 healthy controls (age and sex-matched). We performed LAS analysis using 2D speckle-tracking (QLAB 10, Philips). LA strain was determined as the average value of the longitudinal deformation (7 segments) in the apical 4-chamber view (RR gating). Results LAS analysis was feasible in 40 MFS patients (87%). All participants had normal diastolic function according to current guidelines (ASE/EACVI 2016). MFS patients showed lower TDI e' velocities and higher average E/e' ratio, but still within normal range. Similarly, LVEF was normal but slightly reduced in MFS patients. LA strain and strain rate parameters during reservoir and conduit phase were significantly impaired in MFS patients compared to controls. MFS vs controls MFS patients (n=40) Controls (n=20) p MFS patients (n=40) Controls (n=20) p Age 33.8±12.4 34.4±8.3 0.846 Septal e' (cm/s) 9.7±2.5 11.7±2.3 0.006 Male (%) 24 (60%) 12 (60%) 1.000 Average E/e' ratio 6.8±1.5 5.5±1.1 0.002 SBP (mmHg) 120.3±12.4 120.1±9.4 0.969 TR velocity (cm/s) 208.6±21.4 201.6±22.9 0.390 DBP (mmHg) 72.0±10.1 67.1±6.2 0.069 LAVi (ml/m2) 23.5±7.1 25.5±4.8 0.260 Aortic root (mm) 40.3±4.6 31.7±3.7 Example of LA strain and strain rate Conclusion MFS patients showed a subtle impairment in diastolic function compared to controls. Although further evidence is needed, LAS derived parameters could be early markers of diastolic dysfunction in this group of patients. Acknowledgement/Funding Programa de Actividades de I+D de la Comunidad de Madrid
Published: 2019

8. Poster session 1GENERAL PRINCIPLESP194Ultrasound indexes of adipose tissue and lipid goals attainment in high and very high cardiovascular risk patientsTHE IMAGING EXAMINATIONP195Right ventricular global longitudinal strain provides higher prognostic value than right free wall longitudinal strain in patients with left heart diseaseP196Normal values of echocardiographlc left and right cardiac chambers dimensions as multifactorially determined by sex, level of physical activity, age, BMI, systolic blood pressure and heart rateAnatomy and physiology of the heart and great vesselsP197Echocardiographic phenotypes according to levels of oxygen consumption at peak exercise: findings from the EURO(pean) EX(ercise) population-based studyAnatomy and physiology of the heart and great vesselsP198Systemic vascular resistance and central arterial stiffness in relation to left ventricular geometry and diastolic function in essential hypertensionAssessment of diameters, volumes and massP199Left atrial diameter predicts a new diagnosis of paroxysmal atrial fibrillation in a population presenting with palpitationsP200Interventricular septum thickness and acute coronary syndromes: small differences, big prognostic influence?P201Detection of abdominal aortic aneurysm in a population referred for an ultrasonographyAssessments of haemodynamicsP202The ultrasound vector velocity method transverse oscillation validated in a flowrig with constant and pulsatile flow and in-vivo of blood flow in the ascending aortaASSESSMENT OF SYSTOLIC FUNCTIONP203Different types of left ventrical remodeling in children with arterial hypertensionP204Assessment of myocardial performance index in hypertensive patients with or without hyperuricemiaP205Strain echocardiography detects mild impairment of systolic function in patients with frequent premature ventricular contractionsP206Speckle tracking strain correlates better with functional capacity and hemodynamic burden than ejection fraction in patients with severe heart failureP207Prognostic value of 2D and 3D echocardiographic volumes, ejection fraction and strain as markers of abnormal left ventricular performanceP208Long-term prognostic value of left ventricular ejection fraction assessed by echocardiography and magnetic resonance imaging after acute STEMIP209Assessment of left ventricular function after percutaneous coronary intervention of chronic total occluded coronary artery by speckle tracking and cardiac magnetic resonanceP210Physiologic variations of tricuspid annular plane systolic excursion in healthy subjects: clinical and echocardiographic correlatesP211Predictors of incipient ventricular dysfunction with tyrosine kinase inhibitors in metastatic renal cell carcinomaAssessment of diastolic functionP212Disagreement between the American Society of Echocardiography (ASE) and gastroenterology-based guidelines for the diagnosis of diastolic dysfunction among patients with advanced liver diseaseP213Nomograms for mitral inflow doppler and tissue doppler velocities in caucasian childrenP215Diastolic function is impaired in women with angina pectoris and no obstructive coronary artery disease independently of coronary microvascular functionP216Clinical value of myocardial performance index in patients with isolated diastolic dysfunctionIschemic heart diseaseP217Cardiac imaging strategy is clinically more effective and at lower cost than traditional ETT strategy for the diagnosis of stable coronary artery diseaseP218Does the ESC clinical pretest probability score stratify our patients correctly? Validation with stress echocardiographyP219Incremental value of exercise echocardiography over exercise electrocardiography in a chest pain unit: a decision curve analysisP220A bedside echocardiographic score for risk stratification of ST-elevation myocardial infarction patients undergoing primary percutaneous coronary interventionP221Interventricular and intraventricular dyssynchrony in patients with Q-wave acute myocardial infarctionP222Comparison of tagging and tissue tracking for myocardial strain assessment at 1.5T and 3.0T following ST-segment elevation myocardial infarctionP223Left atrial strain rate evaluated by two-dimensional speckle tracking is predictor of left ventricular arrhythmias in STEMI patients treated by primary PCIP224Impact of percutaneous coronary intervention of chronic total oclussion on left ventricular function using speckle tracking and cardiac magnetic resonanceHeart valve DiseasesP225Clinical and echocardiographic characteristics of patients with low flow severe aortic stenosis and preserved ejection fractionP226Ventricular-arterial interplay in patients with severe aortic stenosis: additional role of wave intensity analysisP227Degenerative aortic stenosis: don't forget the vascular componentP228Reclassifying low gradient aortic stenosis with 3D transesophageal echocardiography and global longitudinal strainP229Importance of mitral regurgitation on pre- and postoperative clinical status and echocardiographic findings in patients with severe aortic stenosis admitted for aortic valve replacementsP230Aorto-septal angle and degenerative aortic stenosis: a case-control study stenosisP231Difference of sST2 level in mitral stenosis compare with control subjectsP232Velocity-time integral of aortic regurgitation: a novel echocardiographic marker in the evaluation of aortic regurgitation severityP233Color doppler 3D echocardiography-derived regurgitant volume in primary mitral regurgitation: a comparison of different techniques with magnetic resonanceP234Outcome of surgery for degenerative mitral regurgitationP235Mitral valve repair or replacement for functional regurgitation and left ventricular dysfunction: clinical and echocardiographic outcomeP236Prevalence, characteristics and prognosis of moderate to severe tricuspid regurgitation in patients with precapillary pulmonary hypertensionP237Management of late bioprosthetic mitral valve thrombosisP238Relationship between pulmonary venous flow and prosthetic mitral valve thrombosisP239Transcatheter aortic valve implantation does not reduce acutely valvuloarterial impedance in an elderly population with degenerative calcific aortic valve stenosisP240Influence of type of prosthesis on mitral regurgitation change after transcatheter aortic valve replacement for aortic stenosisP241The prevalence of valve disease in patients undergoing atrial fibrillation ablationCardiomyopathiesP242The prognostic value of lung ultrasound at discharge in heart failureP243Prognostic value of global longitudinal strain in non-ischaemic dilated cardiomyopathyP244Additional effect of high intensity exercise training to cardiac resynchronization in heart failure: the reduction on left venticular massP245Dobutamine-induced changes of longitundinal strain predicts longterm mortality in severe heart failureP246Myocardial fibrosis is not related to two-dimensional longitudinal strain in dilated cardiomyopathyP247Echocardiographic parameters are predictors of positive genetic study in a Portuguese population with hypertrophic cardiomyopathy: a multicentre studyP248Myocardial deformation techniques for the evaluation of the right ventricle in fabry diseaseP249Borderline hypertrophic cardiomyopathy or athlete's heart: what is the role for genetic testing in athletes?P250Isolated papillary muscle hypertrophy. Clinical, electrocardiographic and morphologic characteristicsP251Prognostic value of the assessment of left atrial deformation in hypertrophic cardiomyopathyP252Assessment of subtle echocardiographic changes may improve risk stratification of arrhythmias in early stages of arrhythmogenic right ventricular cardiomyopathy (ARVC)P253Long-term correlation of electrocardiography with structural echocardiography changes in patients with arrhythmogenic right ventricular cardiomyopathyP254Right ventricular strain and dyssynchrony assessment in arrhythmogenic right ventricular cardiomyopathy: a cardiac magnetic resonance feature-tracking studyP255Association of non compaction and hypertrophic cardiomyopathies, Noonan and long QT syndromesP256Predictors of mortality in patients with acute myocarditisP257Clinical characteristics and natural history of acute myocarditisP258One-beat 3dimensional echocardiography for the assessment of right ventricular function in heart transplant recipientsP259Hemodynamically irrelevant, non-surgery related pericardial effusion is a predictor of mortality in heart transplanted patientsSystemic diseases and other conditionsP260Left ventricular function as a cardiac marker of target organ damage in non-diabetic, never treated hypertensive patients: Camparison with microalbuminuriaP261Subclinical myocardial dysfunction in hypertensive patients with hyperuricemiaP262Can deformation indices (strain/strain rate) establish differential diagnosis in infiltrative cardiomyopathies?P263Prevalence and factors associated with inappropriately high left ventricular mass in patients with rheumatoid arthritisP264Echocardiographic evaluation of patients with end-stage liver disease, the importance of follow up after liver transplantationP265Cardiovasclular involvement in asymptomatic juvenile localized scleroderma patientsP267Can the left ventricular mechanics using speckle tracking echocardiography in pregnancy predict the new onset heart failure?P268What causes impaired exercise tolerance in HFpEF? Relative contribution from LV filling pressure and other factorsCongenital heart diseaseP269Pregnancy in patients with Ebsteins anomaly - echocardiographic and clinical studyP270Double aortic arch anomalies in clinical practiceP271Echocardiography as the essential imaging modality in congenital heart disease - first one to begin with and the one who staysMasses, tumors and sources of embolismP272Can the reduction of wall shear stress in diskinetic myocardial wall segments be used to predict trombogenicity?Diseases of the aortaP273The role of modified transoesophageal echocardiography for optimal access decision making for transcatheter aortic valve replacement proceduresStress echocardiographyP274Is aortic valve resistance different in patients with severe aortic stenosis and left ventricular fraction below 40% with low or high gradient?P275Does wall motion score index in dobutamine stress echocardiography predict syntax score in catheterization lab?P276Sex-related differences in peak stress left ventricular global longitudinal strain during dobutamine stress echocardiography in patients with significant coronary artery diseaseP277Exercise stress echocardiography complications: a 4-year single center experienceP278Reduced baseline left ventricular longitudinal systolic function is a marker of inducible myocardial ischemia in patients undergoing exercise echocardiographyP279Estimation of mean pulmonary arterial pressure based on right ventricle systolic pressure observed from exercise echocardiography among non-pulmonary hypertension with systemic sclerosisTransesophageal echocardiographyP280Transoesophageal echocardiography in patients with neuroendocrine tumour and carcinoid symptoms is safe without intravenous octreotideP281The feasibility and the clinical benefit of the cognitive-behavioral intervention for preparing patients for transesophageal echocardiographic studyP282Dynamic changes of mitral annulus shape in different types of mitral valve prolapse. A three-dimensional transoesophageal studyReal-time three-dimensional TEEP283Severe aortic stenosis: evaluation of effective and anatomy valve by 2D transthoracic echocardiography and 3D transesophageal echocardiographyP2843D-transeosphageal echocardiography usefulness for assessment of cardiac output in intensive care unit: an ultrasound versus thermodilution comparative study for patients under mechanical ventilationP285The predictive value of three-dimensional vena-contracta in determining the number of MitraClip devices needed during the procedure in functional mitral regurgitationTissue Doppler and speckle trackingP286Should the septum be included in the assessment of right ventricular longitudinal strain?P287Can machine learning help to identify heart failure with preserved ejection fraction?P288Concordance of atrial function measurement by 3D volumetric echocardiography and speckle tracking deformation imagingP289Heterogonous regional diastolic function revealed by 2D speckle tracking echocardiography identifies patients with ischemic etiology of left ventricular systolic dysfunctionP290The values from Real time 3-dimensional strain is not independent from preload changesP291Risk stratification in hypertrophic cardiomyopathy. a potential role for speckle-tracking parameters by cardiac magnetic resonanceP292Abnormal longitudinal peak systolic strain in asymptomatic patients with type-I diabetes mellitusP294Strain evaluation of subclinical cardiac dysfunction in patients with myotonic dystrophy type 1P295Heart function assessment in perinatal asphyxia; speckle tracking indices from greyscale recordings perform better than from tissue Doppler recordings, fractional shortening and tissue Doppler indicesP297Longitudinal strain assessed by automatic function imaging - a useful tool in significant coronary artery disease detection in patients with low risk anginaP298Global 2-Dimensional strain as a predictor of mortality in heart transplant patients with cardiac allograft vasculopathyP299Two-dimensional longitudinal strain and strain rate in asymptomatic middle-aged patients with type 2 diabetes mellitus - a pilot study resultsP300Limited accuracy of myocardial deformation imaging in diagnosis of left ventricular segmental dysfunction in patients with acute myocardial infarction: is it only a limitation of the strain software?Computed Tomography & Nuclear CardiologyP301Evaluation of the actual prevalence of myocardial ischemia in patients prior to performing a peripheral vascular surgeryP302Prognostic value of myocardial ischemia detected by myocardial perfusion imaging in asymptomatic patients with diabetes type 2P303Economic cost analysis derived by coronary computed tomography angiography inappropriate indications to rule out coronary heart disease

Author: M Barreiro Perez, IPM Peovska Mitevska, M Corneli, Y Agmon, A Kisko, L Moran, R Onut, E Nestaas, H Guedes, A M Van Berendoncks, R Hinojar, CS Park, E Kowalczyk, S Montserrat, S Sanchez-Martinez, M Sanz, HM Mahmoud, F Laveau, GO Perea, M M Gurzun, P Wejner-Mik, CJH May, K Teramoto, A Cherubini, J F Carvalho, K Wierzbowska-Drabik, A Rohani, R Ferreira, A Hoetink, A Carbonell San Roman, D Stanojevic, M Kaldararova, A M Lesniak-Sobelga, W Kosmala, K Hristova, A Borowiec, S Colunga, F Ognibeni, J L Pena, A Stevanovic, EJ Cho, S F Stampfli, LE Sade, J Y Cho, CRLA Rocon, G Nucifora, M Astrom Aneq, I S Leren, A Zaroui, C Venturini, N Mansencal, L Caballero, AC Gomes, B Biernacka, I Ikonomidis, A Abreu, L Asmarats Serra, L Gargani, D Smith, F Ancona, C Devecchi, S Cersit, S Gunduz, R Rifai, B De Chiara, R Zilberszac, M Penicka, RM Soto-Ruiz, B Naratrekoon, L Reis, D Trifunovic, GJ Morgado, JM Ribeiro, F Antonini-Canterin, RA Spampinato, E Rodriguez Gonzalez, S A Nazir, VA Kuznetsov, S Leao, A Bouzas-Mosquera, R Cano Carrizal, OM Demir, JMG Fernandes, MM Michelsen, M Cantinotti, N Naksuk, S Moustafa, F Ferrara, G Klug, A S Gopal, OH Lie, C Basar, I Trunina, KL Hansen, PJ Carrero, M Madeira, PJ Howlett, A Angelis, M Pellegrino, P Barbier, A Garcia Martin, M Haberka, K Banska, Z Gasior, JL Moya-Mur, S-A Carbonell-San Roman, D Rodriguez-Munoz, A Garcia-Lledo, E Casas-Rojo, JJ Jimenez-Nacher, C Fernandez-Golfin, JL Zamorano-Gomez, A Ravani, C Cefalu, A Maltagliati, B Frigerio, D Sansaro, M Amato, D Baldassarre, F Bandera, G Generati, V Labate, E Alfonzetti, M Guazzi, K Aggeli, N Ioakeimidis, M Abdelrasoul, I Felekos, I Gourgouli, K Aznaouridis, G Rousakis, C Vlachopoulos, D Tousoulis, K Darasz, M Mahmoudi, N Shah, RI Jabr, M Hickman, EW Leatham, CH Fry, R Teixeira, I Almeida, F Caetano, A Fernandes, M Cassandra, M Costa, L Goncalves, AJ Nielsen, MC Carrero, GL Saubidet, SP Peralta, H Moeller-Soerensen, J Kjaergaard, MB Jensen, JT Lund, MM Pedersen, JB Olesen, JA Jensen, MB Nielsen, AS Sharykin, EV Karelina, ND Telezhnikova, H Ozhan, O Kayapinar, ES Albayrak, J Saberniak, L Dejgaard, T Edvardsen, KH Haugaa, U Bal, S Eroglu, B Pirat, H Muderrisoglu, L Muthukumar, SK Saha, RS Toole, S Reinstadler, HJ Feistritzer, B Pernter, A Mayr, WM Franz, S Mueller, B Metzler, S Mingo Santos, V Palomero Monivas, J Gonzalez Mirelis, J Goirigolzarri Artaza, B Zorita Gil, JA Fernandez Diaz, J Goicolea Ruigomez, MA Restrepo Cordoba, L Alonso Pulpon, M D'alto, S Ghio, E Acri, L Carannante, P Argiento, A D'andrea, O Vriz, E Bossone, TH Ho, P Shah, K Murphy, BK Nelluri, H Lee, S Wilansky, F Mookadam, T Peeraphatdit, R Chaiteerakij, KW Klarich, M Scalese, M Melo, N Assanta, M Marotta, M Crocetti, I Spadoni, R Giordano, S Kutty, I Iervasi, ND Mygind, A Pena, D Frestad, N Hoest, E Prescott, BO Romao, IR Rivera, MA Mendonca, AC Carvalho, O Campos, A Amato, VA Moises, A Bashir, K Marshall, M Douglas, B Wasan, S Plein, K Alfakih, C Casanova Rodriguez, R Cadenas Chamorro, D Iglesias Del Valle, A Martin-Penato Molina, J De Juan Baguda, E Prieto Moriche, A Garcia Garcia, E De La Cruz Berlanga, I Plaza Perez, J Peteiro, FJ Broullon, N Alvarez-Garcia, C Barbeito-Caamano, JM Larranaga-Moreira, N Maneiro-Melon, D Martinez-Ruiz, JC Yanez, JM Vazquez-Rodriguez, F Cordeiro, P Magalhaes, M Moz, J Trigo, P Mateus, P Fontes, I Moreira, DV Krinochkin, AV Plusnin, AM Soldatova, A Shetye, JN Khan, A Singh, P Kanagala, DJ Swarbrick, M Graham-Brown, GP Mccann, G Krljanac, L Savic, M Asanin, S Aleksandric, R Lasica, M Srdic, N Zlatic, M Petrovic, I Mrdovic, V Monivas Palomero, B Rivero Arribas, M Dobrovie, JG Da Rocha E Silva, F Bonamigo Thome, R Kluttig, V Schloma, Y Dmitrieva, E Strotdrees, FW Mohr, G Luzza, R Caruso, R Belfiore, A Della Mattia, S Poli, C Zito, S La Carrubba, S Carerj, JF Carvalho, D Caldeira, IR Cruz, B Stuart, R Maia, P Fazendas, H Pereira, I Rakocevic, V Tutos, O Petrovic, M Boricic-Kostic, J Stepanovic, I Jovanovic, M Banovic, B Vujisic-Tesic, L Leite, A Botelho, M Santos, J Nascimento, T Yingchoncharoen, P Vathesatogkit, S Yamwong, P Sritara, J C Bonaque Gonzalez, J Abellan-Huerta, R Rubio-Paton, F Soria, JL Ramos, S Egea, J Garcia-Gomez, JJ Martinez Diaz, JA Castillo, J Vecera, C Mirica, M Kotrc, R Kockova, H Gabriel, G Maurer, R Rosenhek, L Botta, F Musca, O Belli, A Costetti, I Trolese, F Spano, C Russo, C Giannattasio, A Moreo, E Berthelot, MT Le, L Hilpert, D Montani, O Sitbon, X Jais, M Humbert, P Assayag, M Yesin, M Kalcik, MO Gursoy, MA Astarcioglu, S Karakoyun, AC Aykan, M Ozkan, M Tabakci, E Bayam, A Degiovanni, MV Di Ruocco, P Marino, I Rosa, S Stella, M Barletta, C Marini, A Latib, M Montorfano, A Colombo, A Margonato, E Agricola, R Ray, M Gallagher, M Nazir, V Perreso, R Sharma, PS Pang, M Miglioranza, P Landi, FL Dini, E Picano, J Pons Llinares, F Macaya Ten, P Pericas Ramis, O Caldes Llull, A Grau Sepulveda, G Frontera, A Bethencourt, H Santa Clara, V Santos, M Oliveira, P Cunha, G Portugal, P Rio, L Branco, M Mota Carmo, I Paraskevaidis, C Papadopoulos, V Stasinos, J Parissis, J Lekakis, P Rubis, A Gackowski, S Wisniowska-Smialek, A Lesniak-Sobelga, M Kostkiewicz, D Bento, E Correia, L Teles, B Picarra, C Lourenco, R Faria, K Domingues, O Azevedo, V Climent Paya, M Martinez Moreno, JR Gimeno, MJ Oliva, D Saura, J Sanchez Quinones, A Garcia Honrubia, M Valdes, G De La Morena, P Richard, S Guerard, R Brion, P Paul, O Dubourg, M Komajda, R Isnard, M Arslan, P Charron, G Avegliano, S Andres, JP Costabel, P Kuschnir, A Sciancalepore, O Mendoza, G Perea, R Ronderos, RYM Ben Said, TEJ EL Chalbia, SANA Wali, MS Mourali, RACHID Mechmeche, TF Haland, J S Svetlichnaya, SS Shikha, MS Scheinmann, LK Klein, G Prati, G Vitrella, G Allocca, S Cukon Buttignoni, D Muser, G Morocutti, B Pinamonti, G Sinagra, A Proclemer, MDTM Melo, EAB Bocchi, JABAF Araujo, LMMFD Demarchi, CM Mady, BB Biselli, RKF Kalil, VMCS Salemi, RT Tuma, K H Kim, H J Yoon, K J Lee, H Park, J H Kim, Y Ahn, M H Jeong, J G Cho, J C Park, H J Park, H Kozan, A Sezgin, A Aydinalp, T Oezkartal, S Bernhart, AJ Flammer, A Vecchiati, GM Froehlich, F Ruschitzka, FC Tanner, KY Choi, DB Kim, SW Jang, JS Cho, HO Jung, HK Jeon, HJ Youn, M Dekleva, PRL Fortes, BR Passos, AB Rodrigues, IH Sampaio, MCN Oliveira, MG Silva, RAF Cardoso, FA Tofani, MCV Moreira, G Cioffi, O Viapiana, A Dalbeni, E Fracassi, C Di Nora, C Mazzone, A Di Lenarda, M Rossini, C Corros, A Garcia-Campos, M Martin, M Rodriguez-Suarez, V Leon, A Fidalgo, F Lopez-Iglesias, C Moris, JM De La Hera, R Dabrowski, J Wozniak, S Jasek, T Chwyczko, I Kowalik, E Musiej-Nowakowska, H Szwed, R Marinov, G Stamenov, M Mihova, K Chacheva, S Persenska, A Racheva, M Przewlocka-Kosmala, A Rojek, B Karolko, A Mysiak, TH Marwick, P Tittel, M Kardos, V Vrsanska, M Ondriska, V Hraska, M Nosal, J Masura, I Simkova, S Apostolovic, S Salinger-Martinovic, R Jankovic-Tomasevic, D Djordjevic-Radojkovic, T Stanojlovic, V Atanaskovic, M Pavlovic, E Tahirovic, HD Dungen, JL Moya Mur, C Lozano Granero, JJ Jimenez Nacher, A Gonzalez Gomez, C Fraile Sanz, T Segura De La Cal, JL Zamorano Gomez, WW Jansen Klomp, AWJ Van 'T Hof, GJ Brandon Bravo Bruinsma, AJ Spanjersberg, J Grandjean, AP Nierich, J Ferreira, S Lazaro Mendes, R Martins, S Monteiro, M Pego, R Khamene Bagheri, JZ Peruga, M Sobczak, M Plewka, T Wcislo, R Krecki, JD Kasprzak, G Morgado, I Cruz, AR Almeida, I Joao, L Lopes, C Cotrim, G Faganello, C Pandullo, G Russo, C Stefenelli, F Furlanello, L Tarantini, K Suzuki, Y Satoh, K Minami, K Mizukoshi, R Kamijima, S Kou, M Takai, M Izumo, YJ Akashi, J Ayuk, I Geh, T Shah, NC Edwards, RP Steeds, D Miskowiec, K Wdowiak-Okrojek, P Lipiec, M Rosca, A Calin, C Beladan, M Serban, C Ginghina, BA Popescu, M Lombardero, R Henquin, M Tinetti, G Hekimian, M Achkar, A Combes, N Hammoudi, M Al-Ghamdi, A Ghabashi, M H Ezzat, A Al-Amin, G Giraldeau, SI Sarvari, J Marin, C Brambila, L Gabrielli, B Bijnens, M Sitges, N Duchateau, T Erdei, A Fraser, B H Bijnens, G Piella, L Sanchis, R Borras, B Vidal, S Prat, M Azqueta, C Pare, G Grazioli, MH Jung, HS Ahn, JH Kim, A Megias, GL Alonso, A Gonzalez-Gomez, LM Rincon, A Esteban, MA Fernandez Mendez, V Barrios, JL Zamorano, L Van Gaal, C De Block, R Salgado, C Vrints, B Shivalkar, A Pereira, R Santos, L Marques, N Moreno, R Carvalho, M Pires, R Sousa, A Andrade, P Pinto, A Stoylen, D Fugelseth, O Tautu, S Onciul, C Marinescu, D Zamfir, M Dorobantu, V Sanchez Sanchez, P Navas, D Garcia-Cosio, B Diaz, L Carballo-Alzola, F Lombera, J Delgado, M Babcak, N Kishko, A Eitan, D Mutlak, I Kehat, AH Meretta, F Belcastro, E Aguirre, D Rosa, P Zaefferer, O Masoli, ES Srbinovska, MB Bosevski, EA Antova, DPG Pop Gorceva, M Martin Fernandez, SM Costilla Garcia, E Diaz Pelaez, and C Moris De La Tassa
Subjects: education.field_of_study, Multiple kernel learning, business.industry, Population, Diastole, Spec#, General Medicine, 030204 cardiovascular system & hematology, Machine learning, computer.software_genre, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Stress Echocardiography, Unsupervised learning, Radiology, Nuclear Medicine and imaging, Artificial intelligence, Cardiology and Cardiovascular Medicine, education, business, Heart failure with preserved ejection fraction, Isovolumetric contraction, computer, Mathematics, computer.programming_language
Abstract: Purpose: No consensus exists for the diagnosis of heart failure with preserved ejection fraction (HFPEF). Current studies recommend stress echocardiography protocols, but single standard peak or timing measurements are limited towards the complexity of the disease. We show the contribution of a combined analysis of multiple myocardial velocity patterns and investigate their relative relevance for the characterization of HFPEF. Methods: Velocity traces from 55 subjects were examined (69±6 years, 22 healthy, 19 HFPEF and 14 breathless subjects). Data came from tissue Doppler acquisitions at rest and exercise at the basal septum and lateral wall, and were temporally aligned to a common reference for comparison. Each phase of the cycle at each stage of the protocol was identified for analysis (figure). Unsupervised machine learning (multiple kernel learning) was used to characterize this population and automatically determine the relevance of each velocity pattern. Results: The learning found a discrimination algorithm that performed well in agreement with diagnosis based on current guidelines (sens=78.9%, spec=86.3%, K=0.65). The importance given to early diastole at exercise was substantially higher, while the isovolumic contraction was the lowest contributor. The breathless subjects were associated to their closest subgroup. Conclusion: The characterization of HFPEF is improved by a combined analysis of multiple velocity traces from stress echo studies using machine learning. The method additionally suggests features of interest to be used in clinical diagnosis.
Published: 2015

9. Potential Role of Donor-Derived Cell Free DNA as a New Biomarker in Cardiac Allograft Vasculopathy (FreeDNA-CAV)

Author: C Arellano Serrano, M. Gomez Bueno, S. Mingo Santos, M Torres Sanabria, M. Jimenez-Blanco Bravo, F. Hernandez Perez, L Perez Gomez, V Monivas Palomero, J. Segovia Cubero, J F Oteo Dominguez, and C. Mitroi
Subjects: Pulmonary and Respiratory Medicine, Transplantation, medicine.medical_specialty, business.industry, Cardiac allograft vasculopathy, Coronariography, Cell-free fetal DNA, Internal medicine, Concomitant, Troponin I, Cohort, cardiovascular system, medicine, Cardiology, Biomarker (medicine), Surgery, Donor derived, Cardiology and Cardiovascular Medicine, business
Abstract: Purpose There is an unmet need for a noninvasive biomarker for cardiac allograft vasculopathy (CAV), that could obviate the need to perform surveillance coronary angiograms in HT recipients. Donor-derived cell free DNA (ddcf-DNA) has shown a good ability to rule out cellular rejection, but its performance as a biomarker for CAV has not been tested. We sought to evaluate the performance of ddcf-DNA as a biomarker of CAV in a cohort of patients undergoing routine coronariography. Methods We prospectively obtained ddcf-DNA levels in all patients who underwent routine coronary angiography >1 year after HT in our center between Jan and Sept 2019. Patients with concomitant acute rejection (n=5) or multi organ transplant (n=8) were excluded. Ddcf-DNA levels were correlated with CAV degree (ISHLT 2010 classification). Results We included 54 HT recipients (mean age 57 years, 70% men), with a mean of 10.2 years (IQR 4.3-16.9) after transplant. Coronary angiogram showed CAV0 in 59%, CAV1 in 22%, CAV2 in 6% and CAV3 in 13% (41% of patients with any degree of CAV). Median ddcf-DNA values for each CAV group are shown in figure 1A. Median levels did not differ significantly between patients with and without CAV: 0.64% in CAV0 (IQR 0.19-1.26) as compared to 0.525% (IQR 0.12-1.8) in CAV 1, 2 or 3, p=0.94. Area under the ROC curve for CAV diagnosis was 0.51 (Figure 1B). No significant differences were found between patients with "stable CAV" (no new significant coronary lesions since previous angiogram, n=39) and "progressive CAV" (presence of new coronary stenosis, n=15): median values were 0.5% (IQR 0.17-1.1) and 0.87% (IQR 0.12-4.2) respectively, p=0.51. No correlation was found between ddcf-DNA and Troponin I (r=0.03, p=0.86) or NTproBNP levels (r=-0.09, p=0.59). Conclusion In this preliminary experience, ddcf-DNA level did not seem to correlate with CAV, although sample size might be too small to reach definite conclusions. We hope that the ongoing recruiting (n=100) will shed light in this matter.
Published: 2020

10. 4919Validation of ASE/EACVI 2016 guidelines on diastolic function in patients with pulmonary arterial hypertension: can they help us predicting high left ventricular filling pressure?

Author: E Garcia-Izquierdo Jaen, J F Oteo Dominguez, S. Mingo Santos, L. Alonso Pulpon, F. Hernandez Perez, C Arellano Serrano, M. Gomez Bueno, J. Gonzalez Mirelis, S Navarro Rico, V Monivas Palomero, J. Segovia Cubero, A Garcia Touchard, and J Vazquez Lopez-Ibor
Subjects: medicine.medical_specialty, business.industry, Internal medicine, Cardiology, Medicine, In patient, Diastolic function, Cardiology and Cardiovascular Medicine, business, Ventricular filling
Published: 2018

11. Poster session: Dobutamine stress echo

Author: C. Vizza, X. Jeanrenaud, M. Satendra, L. Monti, A. Kovacs, D. Vanoli, V. Charles, A. Kardos, M. Chiarlo, C. Gruner, C. Monaco, A. Kuch-Wocial, K. Mizia-Stec, L. Sargento, D. Kautznerova, N. Resseguier, G. Tamborini, C. Cruz, P. Jurzak, A. Cogo, E. Lira, D. Al Mesned, Y. Aizawa, A. Chmiel, R. Corti, K. Kim, G. N. Elkilany, M. Haarman, R. Badagliacca, R. Weber, R. Bruno, L. Di Pino, I. Kaplanis, D. Kalimanovska-Ostric, D. Tsounis, M. Varoudi, H. Yoon, P. Goncalves, G. Mpitsios, I. Garcia-Lunar, P. Min, R. Mogelvang, K. Gieszczyk-Strozik, A. Blundo, A. Tarr, E. W. Remme, David Garcia-Dorado, V. Petronilli, A. Patel, C. Sousa, R. M. Lang, J. Mcghie, V. Monivas Palomero, C. Nomura, H. Yoshikawa, N. Lagopati, M. Gomberg-Maitland, R. Kalil, H. K. Jeon, K. Mrabet, A. Riberi, C. Zito, A. Khalatbari, D. Tarasov, L. Fusini, P. Marques, S. Hassantash, I. Zimbarra Cabrita, M. Francone, A. Germain, A. Theron, J. Sousa, A. Kantorova, F. Collart, C. J. Vrints, A. Forteza, C. Tamburino, D. Cerna, S. Buccheri, M. Taborsky, I. P. Monte, F. Elmkies, A. Castro Beiras, S. Ranjbar, A. Perpinia, O. A. Tolba, R. Pretre, T. Chua, F. Fedele, M. Calcagnino, D. Dragulescu, M. Greutmann, M. Pepi, M. Bartesaghi, S. Urheim, R. Muscariello, F. Ben Moussa, W. Saib, M. Thameur, J. Ternacle, V. Matzraki, M. Ghannouchi, G. Kocabay, A. Margulescu, R. Sicari, R. Ippolito, M. Kloeckner, A. Toth, J. Gonzalez Mirelis, K. Sugi, M. Geleijnse, T. Otsuka, A. Hervold, S. Benyoussef, B. Basnyat, H. Suomi, L. Gargani, M. Stosic, P. Monney, J. Segovia Cubero, M. Karvandi, P. Sousa, J. Gonzalez-Mirelis, P. Caso, M. Murata, M. Vieira, C. Fulcheri, M. Júlia Maciel, P. Garcia-Pavia, M. Bobbo, J. Sun, B. Nardi, V. Pyrgakis, J. W. Kim, F. Alamanni, D. Ozel, A. Cordovil, S. Cimino, S. Papa, A. Carro, E. Leiballi, S. Karakas, J. Cho, C. Mornos, H. Masai, M. D'angelo, S. Mingo Santos, J. Kang, N. Nishiyama, J. Brugada, W. Tsang, Y. Yoon, B. Herzog, F. Dominguez Rodriguez, G. Ertl, E.R. Valsangiacomo Buechel, H. Shin, M. Palinsky, P. Gaudron, O. Gaemperli, A. Bouzas Mosquera, R. Bogle, J. Rodriguez-Palomares, N. Liel-Cohen, J. Burrello, M. Henein, H. Yilmaz, M. Laine, C. Foucher, K. Tanimoto, P. Schiattarella, G. Teixido, V. Schiano Lomoriello, M. R. El-Shanshory, N. Lousada, T. Minarik, F. Machado, G. Hashimoto, Y. Ishikawa, P. Atkinson, I. Zairi, B. Lee, V. Lanska, T. Biering-Sorensen, D. Vinereanu, H. Dores, M. Nakamura, R. Kockova, A. Chenzbraun, A. Manrique, N. A. Garcia, C. Zimmermann, L. Carpinteiro, H. Youn, J. Guimaraes, P. Meimoun, M. Mohammed, A. Gaspar, G. Styczynski, M. Castella, R. Esposito, A. Karavidas, F. Tosello, J. Mills, J. E. Sanderson, Y. Lau, D. Lee, C. Chin, M. Dostanic, D. Liu, P. Lupinek, T. Sato, M. Lewis, M. Reali, E. Cervesato, A. Apor, D. Sharif, S. Leggio, T. Ono, S. Wos, S. Kadrabulatova, S. Miyoshi, B. Milakovic, M. Gonzalez-Alujas, Y. Y. Lam, W. Tietge, M. Tramarin, L. Balzarini, E.-S. El-Hawary, G. E. Nagib Elkilany, P. Lim, P. Lindqvist, F. Veronesi, G. Flahaut, M. Thomas, A. Redheuil, Y. Ahn, M. Galderisi, M. Cavero Gibanel, J. Roquette, G. D. Lenders, F. Cicogna, P. Nihoyannopoulos, S. Taddei, C. Shahla, O. Mirea, A. Aleixo, E. Altekin, A. Milan, J. Roncalli, V. Mor-Avi, P. Crapanzano, S. Wang, A. Rodrigues, D. De Palma, M. Sitges, J. Peteiro, G. Maldonado, A. Nagy, J. Wang, M. Miglioranza, M. J. Claeys, J. Kluin, R. H. Strasser, J. Masura, B. Pezzuto, S. Aakhus, M C De Knegt, F. Broullon, N. Bhave, Y. Kusunose, R. Domburg, S. Moral Torres, J. Song, G. Carlomagno, P. Carrilho-Ferreira, A. Mornos, K. Sedlacek, Y. Villain, S. Arapi, M. Segetova, T. Le Tourneau, M. Kucuk, H. Tsuruta, J.-L. Monin, L. Badano, C. Mueller, C. Jorge, J. Kautzner, U. Schubert, L. Zhong, B. Suran, J. Clerc, I. Demir, S. Chamuleau, P. Tittel, E. Boussabah, P. Punjabi, L. Guimaraes, C. Magnino, B. Delasalle, D. Leone, J. Gruenenfelder, H. Blafield, F. Thuny, J. Jensen, J. Silva Cardoso, S. Stoebe, S. Sioua, K. Fukuda, M. Nocioni, P. Linden, V. Sanchez, D. Silva, V. Sikula, F. Pizzino, L. Kryze, A. Lebreiro, M. Deljanin-Ilic, A. Arsenio, S. Takatsuki, M. Kaldararova, A. Sikora-Puz, M. Cinello, S. Naffati, M. Pirscova, V. Lisignoli, A. Hagendorff, T. Iwaki, M. Niemann, E. Rees, U. Rosenschein, V. Vrsanska, C. A. Szmigielski, G. L. Nicolosi, G. Di Bella, D. Pfeiffer, R. Giorgi, K. Korpi, E. Paucca, M. Sanchez Garcia, S. Kammoun, M. Rodolico, Arturo Evangelista, I. Baka, J. Lima, C. Yu, B. Hong, C. Fischer, P. Morera, F. C. Tanner, R. Manganaro, M. Mezzapesa, B. Seifert, A. Berruezo, H. Guterman, K. Sveric, U. Wiklund, R. Sant'anna, R. Piazza, L. Oreto, L. Mont, J. Rosso, B. P. Paelinck, S. Severino, J. Park, S. Morhy, S. Mingo, A. Ledakowicz-Polak, L. Arcari, E. E.-S. El-Hawary, E. Caiani, R. Fabregas Casal, A. Bensaid, N. A. E.-A. El-Shitany, F. Veglio, L. Gutierrez, R. Massey, R. Mimo, A. Yanikoglu, A. Al Akhfash, J. Rodriguez Garrido, S. Kovalova, N. Patrascu, M. Liu, B. Bijnens, J.-L. Dubois-Rande, M. Suzuki, I. Garcia Lunar, D. Muraru, S. Iwanaga, R. Borras, R. Karpov, T. Nastasovic, T. Gonzalez-Alujas, M. Jasinski, H. Marques, W. Voelker, D. Maan Hasson, K. Murbrach, J. Yoon, M. Cusma-Piccione, S. Carerj, E. Hopp, D. A. Rees, M. Zielinska, M. Forkmann, M. Sotiropoulos, I. Zegri, Y. Neuder, V. Hraska, R. Iengo, I. Losano, P. Gripari, J. Avierinos, I. Simkova, M. Yaacobi, F. Weidemann, C. Sordelli, H. Jeong, T. Osaki, M. Kubanek, R. Sharma, M. Yamamoto, D. Bettex, J. Sivertsen, G. Bruno, A E Van Den Bosch, P. Kracht, P. L. Van Herck, J. Roos-Hesselink, D. Cozma, E. Teiger, L. Said, B. Freed, A. Loimaala, T. Pinho, L. Pomidori, A. Mantovani, A. Santoro, R. Kadour, R. Calabro, S. Rim, L. Sim, B. Merkely, P. Gueret, R. Jansen, G. Curatolo, C.H. Attenhofer Jost, C. Gambardella, V. Jarvinen, P. Hol, D. Mihalcea, P. Sogaard, D. Peluso, O. Kretschmar, F. Fang, H. Cuellar, F. Maffessanti, R Palma Dos Reis, J. Grapsa, A. Sharif-Rasslan, H. Kwon, P. Novak, R. Gallet, C. Sportouch, O. Enescu, H. Chung, M. Valtonen, D. Dawson, A. G. Fraser, M. Lyra Georgosopoulou, Q. Shang, V. Leonelli, L. Agati, A. Khalil, G. Habib, M. Cavero, A. Ionac, M. Florescu, S. Pescariu, L. Ascione, M. Carmo, A. Marouen, A. D'Andrea, S. Champagne, S. Iliceto, J. P. Halcox, M. Mizia, Z. Gasior, M. Cramer, S F de Marchi, S. Goncalves, L. Dal Bianco, N. Cortez-Dias, U. Richter, I. Santos, U. Naslund, E. Gonzalez Lopez, M. Rover, H. Vago, A. E.-A. El-Shitany, G Teixido Tura, M. Sramko, J. Necas, S. Fennira, M. Gomez Bueno, L. Zakhama, L. Costanzo, H. Zemir, F. Dunstan, R. Pecoraro, R. Hocking, L. Gabrielli, R. Tan, J. Tintera, L. Pratali, V. Monivas, B. Bouzas Zubeldia, B. Segafredo, T. Leiria, R. Mincu, A. Kaczynska, L. Petrescu, J. M. Bosmans, A. Ben Yaala, A. Ploussi, K. Hu, Z. Frikha, L. De Luca, E. Choi, J. Yanez Wonenburger, I. Serbanoiu, C. Iacoboni, J. Trochu, S. Montserrat, X. Luo, E. Pavlukova, D. Martinez Ruiz, G. Lazaros, B. Tan, D. Hudziak, J. Petrovicova, S. Herrmann, P. Biaggi, E. Picano, I. E. Rodrigus, Y. Lam, M. Jeong, M. Fedorco, P. Beltran Correas, C. Felix, L. Polak, C. Wunderlich, S. Hohlfeld, S. Tripepi, M. Haberka, R. Poscia, L. Halmai, A. Luycx-Bore, K. Tunstall, D. Becker, H. Dave, P. Lemarchand, and M. Carvalho
Subjects: Leading edge, business.industry, Reference values, Healthy subjects, Medicine, Radiology, Nuclear Medicine and imaging, Geometry, General Medicine, Edge (geometry), Cardiology and Cardiovascular Medicine, business
Published: 2012

12. Saturday, 25 August 2012

Author: A. Welz, B. V. Antwerp, A Di Cori, A. Hager, P. Hatzigiannis, R. De Lucia, C. Yu, A. Apor, M. Niemann, R. Sampognaro, M. Fiuza, M. G. Charlot, N. Cortez Dias, A. Nagae, A. Maciag, T. Sato, M. Valgimigli, D. Levorato, S. Herrmann, T. Kimura, M. Luedde, V. Tzamou, M. Iwabuchi, C. Rickers, J. Sobierajski, J. Vecera, C. Vlachopoulos, K. Goscinska-Bis, S. Goldsmith, H. Ueno, J. Sosna, G. Malerba, W. Li, H. W. Lee, K. Bogaard, K. Yamada, A. Mateo-Martinez, J. Navarova, M. Zeman, K. Dimopoulos, M. P. Lopez Lereu, E. Pelissero, B. Gersak, J. M. Tolosana, S Manzano Fernandez, P. Mertens, J. J. M. Takkenberg, J. W. Kim, R.T. van Domburg, G. P. Diller, H. M. Yang, F. Gustafsson, P. G. Golzio, G. S. Hwang, J. Brugada, S. Stoerk, J. Hess, Y. Cavusoglu, L. Segreti, M. E. Trucco, C. Jacoby, I. Bafakis, T. Isshiuki, L. Pulpon, S. Pires, L. Paperini, A. Cremonesi, H. Baumgartner, C. Tsioufis, M. Valdes-Chavarri, S. Schaefer, M. Totzeck, A. Bochenek, F. Saia, P. Carrilho-Ferreira, M. Khatib, E. M. W. J. Utens, G. Zucchelli, R. Jenni, E. Gencer, N. Carter, A. Kovacs, C. Linde, V. Monivas, A. Marzocchi, L. Baerfacker, L. Mont, R. Weber, F. J. Enguita, T. L. Bergemann, M. Chudzik, A. Chernyavskiy, D. Dragulescu, S. Orwat, B. J. Choi, P. Opic, C. Torp-Pedersen, F. Gaita, V. A. W. M. Umans, A. Lopez-Cuenca, S. B. Christensen, E. C. Bertolino, D. Tousoulis, F. Weidemann, H. H. Kramer, J. Greenslade, J Cosin Sales, M. Gonzalez Estecha, W. Grosso Marra, T. Katsimichas, J. Hoerer, S. Mingo, M. Hochadel, M. A. Castel, M. S. Lattarulo, E. Y. Yun, K. Fattouch, H. S. Lim, A. Uebing, T. Ulus, J. Radosinska, A. Castro Beiras, J. Peteiro, M. Koren, C. Prados, A. Nunes, C. Rammos, C. Thomopoulos, T. Kameyama, F. Borgia, I. Voges, J. L. Looi, L. Cullen, C. Campo, J. Bis, S. Shiva, H. Kato, N. Frey, E. Andrikou, G. H. Gislason, J. Ruvira, A. Kasiakogias, S. Robalo Martins, A. M. Zimmer, M. H. Yacoub, M. Nobuyoshi, U. Zeymer, K. Hanazawa, F. J. Broullon, B. Petracci, K. Hu, A. Petrescu, A. M. Maceira Gonzalez, K. Harada, L. Swan, C. Felix, H. Inoue, T. Haraguchi, N. Cortez-Dias, S. Bisetti, P. Mitkowski, C. Daubert, H. J. Heuvelman, M. R. Gold, G. P. Kimman, O. Gaemperli, H. C. Lee, Y. Takasawa, V. Monivas Palomero, A. C. Andrade, S. Maddock, W. Budts, M. Penicka, F. J. Ten Cate, M. Czajkowski, C. D. Nguyen, K. Kaitani, K. Kintis, S. Castrovinci, D. Liu, T. Benova, K. W. Seo, B. A. Herzog, A. Ionac, C. Jorge, M. Iacoviello, S. Kuramitsu, Y. Nakagawa, K. U. Mert, A. Manari, S. Brili, R. Alonso-Gonzalez, A. J. Six, J. S. Mcghie, A. Goedecke, M. Kelm, F. C. Tanner, F. Marin, C. I. Santos De Sousa, L. Kober, M. Frigerio, D. Adam, B. E. Backus, U. Hendgen-Cotta, A. Belo, D. Couto Mallon, M. Dewor, M. Madsen, J. H. Shin, M. H. Yoon, L. Maiz, P. Lancellotti, A. Nunes Diogo, G. Ertl, R. Pietura, A. Mornos, M. Than, C. Andersson, C. Izumi, E. Liodakis, N. van Boven, Y. Y. Lam, T. Hansen, W. Roell, T. J. Hong, P. Luedicke, M. Sanchez-Martinez, L. Ruiz Bautista, E. N. Oechslin, T. Klaas, M. T. Martinez, W. A. Helbing, J. L. Januzzi, S. Parra-Pallares, A. Romanov, B. Sax, D. Prokhorova, P. Guastaroba, D. Silva, A. Karaskov, P. Kolkhof, B. Bouzas Zubeldia, T. Rassaf, M. Costa, C. Viczenczova, V. Antoncecchi, A. Kempny, J. Bartunek, I. Kardys, J. H. Ahn, C. Hart, A. Berruezo, C. Vittori, W. Vletter, M. Shigekiyo, S. Knob, V. Marangelli, R. Borras, A E Van Den Bosch, S. Y. Choi, E. Arbelo, G. Lazaros, T. Arita, G. Suchan, T. Nakadate, D. Van Der Linde, E. Pokushalov, K. Ando, J. Neutel, P. Biaggi, C. Mornos, R. Corti, M. Landolina, B. Merkely, B. Malecka, H. J. Hippe, S. J. Tahk, J. Aguilar, G. Piovaccari, M. Lutz, D. Rizopoulos, N. Alvarez Garcia, M. Cipriani, T. Kumamoto, S. Kubota, M. Sitges, B. K. Fleischmann, G. Caccamo, D. Tsiachris, M. A. Russ, F. Mutlu, A. Menozzi, J. C. Choi, J. V. Monmeneu, J. C. Yanez Wonenburger, N. Tribulova, C. Forleo, M. Vinci, J. W. Roos-Hesselink, O. Bodea, T. Domei, P. W. Lee, A. Puzzovivo, M. Heikenwaelder, F. Ferraris, C. Stefanadis, M. Kempa, M. Vanderheyden, A. Birdane, J. A. A. E. Cuypers, I. Andrikou, G. Casella, P. Stock, S. Favale, B. Bijnens, A. Kretschmer, J. Bernhagen, M. A. Cavero Gibanel, S. Datta, M. E. Menting, S. Viani, T. Heuft, M. Cikes, A. J. J. C. Bogers, J. Estornell, M. Pham, A. Nadir, F. J. Pinto, M. Hyodo, D. Flessas, C. Chrysohoou, O. Dewald, B. Ren, K. Wustmann, J. C. Burnett, T. Noto, G. Ruvolo, M. Witsenburg, E. Soldati, G. D. Duerr, L. Alonso Pulpon, J. H. Oh, A. Zabek, B. Albrecht-Kuepper, V. Antonakis, M. B. Nielsen, T. Huttl, B. Bacova, A. Piorkowski, I. Z. Cabrita, A. Fanelli, M. A. Weber, J. Segovia, A. I. Romero-Aniorte, J. H. Choi, V. Dosenko, C. Wackerl, J. H. Ruiter, H. Yokoi, S. Ghio, V. Knezl, F. Monitillo, M. Morello, M. Jerosch-Herold, M. L. Geleijnse, A. Bouzas Mosquera, R. Fabregas Casal, H. Mudra, J. Gruenenfelder, U. Floegel, L. Petrescu, M. A. Gatzoulis, S. Shizuta, J. Brachmann, M. G. Bongiorni, M. Pringsheim, J. Mueller, A. Nagy, R. Giron, W. T. Abraham, Y. Takabatake, F. Toyota, D. Martinez Ruiz, M. Lunati, S. Vargiu, L E De Groot De Laat, V. Shabanov, L. Lioni, R. Kast, D. Bettex, K. S. Cha, J. L. Diago, D. Cozma, H. Lieu, M. Giakoumis, E. Orenes-Pinero, G. Murana, A. Kutarski, A.P.J. van Dijk, G. Speziale, A. Boem, L. M. Belotti, B. Igual, A. M. S. Olsen, and H. Lue
Subjects: business.industry, Medicine, Ancient history, Cardiology and Cardiovascular Medicine, business
Published: 2012

13. 4996Echocardiographic predictors of right ventricular failure after implantation of a left ventricular assist device

Author: C. Parra Esteban, C.E. Martin Lopez, A. Forteza Gil, L. Alonso Pulpon, S. Mingo Santos, V Monivas Palomero, A. Gonzalez Roman, J. Segovia Cubero, J. Goirigolzarri Artaza, F. Hernandez Perez, M. Gomez Bueno, and S. Vilches Soria
Subjects: medicine.medical_specialty, business.industry, Internal medicine, Ventricular assist device, medicine.medical_treatment, Cardiology, Medicine, Right ventricular failure, Cardiology and Cardiovascular Medicine, business
Published: 2017

14. P5276Adult reference doppler values for pulsatile left ventricular assist device cannulas

Author: C. Parra Esteban, A. Gonzalez Roman, S. Vilches Soria, V Monivas Palomero, S. Mingo Santos, J. Segovia Cubero, L. Alonso Pulpon, J. Goirigolzarri Artaza, C.E. Martin Lopez, F. Hernandez Perez, M. Gomez Bueno, and A. Forteza Gil
Subjects: symbols.namesake, medicine.medical_specialty, business.industry, Ventricular assist device, medicine.medical_treatment, Internal medicine, symbols, Pulsatile flow, Cardiology, Medicine, Cardiology and Cardiovascular Medicine, business, Doppler effect
Published: 2017

15. P5241Impact of heart valve surgery on right ventricular function measured by speckle-tracking

Author: A. Forteza Gil, S Navarro Rico, M. Jimenez-Blanco Bravo, M. A. Cavero Gibanel, S. Vilches Soria, J. Gonzalez Mirelis, C Arellano Serrano, S. Mingo Santos, V Monivas Palomero, C.E. Martin Lopez, and C. Parra Esteban
Subjects: Speckle pattern, medicine.medical_specialty, Valve surgery, Ventricular function, business.industry, Internal medicine, Cardiology, Ventricular pressure, Medicine, Cardiology and Cardiovascular Medicine, business, Tracking (particle physics)
Published: 2017

16. 4997Can we predict right ventricular failure after EXCOR implantation using pulmonary pulsatility index?

Author: M. Gomez Bueno, A. Durante Lopez, S. Vilches Soria, J F Oteo Dominguez, J. Goirigolzarri Artaza, F. Hernandez Perez, L. Alonso Pulpon, S. Mingo Santos, V Monivas Palomero, and J. Segovia Cubero
Subjects: medicine.medical_specialty, business.industry, Internal medicine, Cardiology, medicine, Right ventricular failure, Cardiology and Cardiovascular Medicine, Pulsatility index, business
Published: 2017

17. Poster Session 4: Friday 9 December 2011, 14:00-18:00 * Location: Poster Area

Author: M. Wang, G. Yan, W. Yue, C. Siu, H. Tse, A. Perperidis, D. Cusack, A. White, T. Macgillivray, W. Mcdicken, T. Anderson, V. Ryabov, V. Shurupov, T. Suslova, V. Markov, N. Elmstedt, K. Ferm Widlund, B. Lind, L.-A. Brodin, M. Westgren, F. Mantovani, A. Barbieri, F. Bursi, C. Valenti, M. Quaglia, M. Modena, D. Peluso, D. Muraru, L. Dal Bianco, M. Beraldo, E. Solda', M. Tuveri, U. Cucchini, A. Al Mamary, L. Badano, S. Iliceto, A. Goncalves, C. Almeria, P. Marcos-Alberca, G. Feltes, R. Hernandez-Antolin, H. Rodriguez, L. Maroto, J. Silva Cardoso, C. Macaya, J. Zamorano, S. Squarciotta, F. Innocenti, A. Guzzo, S. Bianchi, D. Lazzeretti, E. De Villa, S. Vicidomini, B. Del Taglia, C. Donnini, R. Pini, C. Mennie, A. M. Salmasi, V. Kutyifa, V. Nagy, E. Edes, A. Apor, B. Merkely, S. Nyrnes, L. Lovstakken, H. Torp, B. Haugen, K. Said, A. Shehata, Z. Ashour, S. El-Tobgy, M. Cameli, E. Bigio, M. Lisi, F. Righini, F. Franchi, S. Scolletta, S. Mondillo, E. Gayat, L. Weinert, C. Yodwut, V. Mor-Avi, R. Lang, N. Hrynchyshyn, N. Kachenoura, B. Diebold, R. Khedim, M. Senesi, A. Redheuil, E. Mousseaux, L. Perdrix, S. Yurdakul, V. Erdemir, Y. Tayyareci, K. Memic, O. Yildirimturk, V. Aytekin, M. Gurel, S. Aytekin, L. Gargani, C. Fernandez Cimadevilla, S. La Falce, P. Landi, E. Picano, R. Sicari, M. K. Smedsrud, J. Gravning, C. Eek, L. Morkrid, H. Skulstad, L. Aaberge, B. Bendz, J. Kjekshus, T. Edvardsen, G. Bajraktari, V. Hyseni, B. Morina, A. Batalli, R. Tafarshiku, R. Olloni, M. Henein, O. Mjolstad, S. Snare, L. Folkvord, F. Helland, O. Haraldseth, A. Grimsmo, M. Berry, O. Zaghden, J. Nahum, L. Macron, O. Lairez, T. Damy, A. Bensaid, J. Dubois Rande, P. Gueret, P. Lim, N. Nciri, Z. Issaoui, C. Tlili, I. Wanes, H. Foudhil, F. Dachraoui, J. Grapsa, D. Dawson, P. Nihoyannopoulos, L. Gianturco, M. Turiel, F. Atzeni, P. Sarzi-Puttini, D. Stella, L. Donato, L. Tomasoni, P. Jung, M. Mueller, T. Huber, G. Sevilmis, F. Kroetz, H. Sohn, V. Panoulas, A. Bratsas, R. Raso, G. Tartarisco, G. Pioggia, P. Gargiulo, M. Petretta, A. Cuocolo, M. Prastaro, C. D'amore, E. Vassallo, G. Savarese, C. Marciano, S. Paolillo, P. Perrone Filardi, C. Aggeli, I. Felekos, G. Roussakis, E. Poulidakis, P. Pietri, K. Toutouzas, C. Stefanadis, A. Kaladaridis, I. Skaltsiotis, G. Kottis, D. Bramos, D. Takos, I. Matthaios, I. Agrios, E. Papadopoulou, S. Moulopoulos, S. Toumanidis, P. Carrilho-Ferreira, N. Cortez-Dias, C. Jorge, D. Silva, J. Silva Marques, R. Placido, L. Santos, S. Ribeiro, M. Fiuza, F. Pinto, V. Stoickov, S. Ilic, M. Deljanin Ilic, W. Kim, J. Woo, J. Bae, K. Kim, M. Descalzo, J. Rodriguez, S. Moral, I. Otaegui, P. Mahia, L. Garcia Del Blanco, T. Gonzalez Alujas, J. Figueras, A. Evangelista, D. Garcia-Dorado, M. Takeuchi, K. Kaku, K. Otani, M. Iwataki, H. Kuwaki, N. Haruki, H. Yoshitani, Y. Otsuji, M. Kukucka, M. Pasic, A. Unbehaun, S. Dreysse, A. Mladenow, H. Kuppe, R. Hetzer, N. Rajamannan, A. Tanrikulu, L. Kristiansson, S. Gustafsson, K. Lindmark, M. Y. Henein, C. Evdoridis, P. Stougiannos, M. Thomopoulos, M. Fosteris, P. Spanos, G. Sionis, D. Giatsios, A. Paschalis, C. Sakellaris, A. Trikas, Z. Y. Yong, K. Boerlage-Van Dijk, K. Koch, M. Vis, B. Bouma, J. Piek, J. Baan, L. Abid, Z. Frikha, K. Makni, N. Maazoun, D. Abid, M. Hentati, S. Kammoun, P. Barbier, A. Staron, C. Cefalu', G. Berna, P. Gripari, D. Andreini, G. Pontone, M. Pepi, L. Ring, B. Rana, S. Ho, F. Wells, A. Dogan, O. Karaca, G. Guler, E. Guler, H. Gunes, E. Alizade, H. Agus, G. Gol, O. Esen, A. Esen, M. Turkmen, E. Agricola, G. Ingallina, M. Ancona, S. Maggio, M. Slavich, V. Tufaro, M. Oppizzi, A. Margonato, C. Orsborne, B. Irwin, K. Pearce, S. Ray, C. Garcia Alonso, N. Vallejo, C. Labata, J. Lopez Ayerbe, A. Teis, E. Ferrer, R. Nunez Aragon, F. Gual, M. Pedro Botet, A. Bayes Genis, C. M. Santos, M. Carvalho, M. Andrade, H. Dores, S. Madeira, G. Cardoso, A. Ventosa, C. Aguiar, R. Ribeiras, M. Mendes, M. Petrovic, G. Milasinovic, B. Vujisic-Tesic, I. Nedeljkovic, D. Zamaklar-Trifunovic, I. Petrovic, G. Draganic, M. Banovic, M. Boricic, H. Villarraga, C. Molini-Griggs Bs, P. Silen-Rivera Bs, B. Payne Mph Ms, Y. Koshino Md Phd, J. Hsiao Md, V. Monivas Palomero, S. Mingo Santos, C. Mitroi, I. Garcia Lunar, P. Garcia Pavia, V. Castro Urda, J. Toquero, J. Gonzalez Mirelis, M. Cavero Gibanel, I. Fernandez Lozano, Z. Oko-Sarnowska, H. Wachowiak-Baszynska, A. Katarzynska-Szymanska, O. Trojnarska, S. Grajek, D. Bellavia, P. Pellikka, A. Dispenzieri, J. K. Oh, V. Polizzi, F. Pitrolo, F. Musumeci, F. Miller, R. Ancona, S. Comenale Pinto, P. Caso, S. Severino, C. Cavallaro, F. Vecchione, A. D'onofrio, R. Calabro', A. M. Maceira Gonzalez, C. Ripoll, J. Cosin-Sales, B. Igual, J. Salazar, V. Belloch, J. Cosin-Aguilar, B. Pinamonti, A. Iorio, M. Bobbo, M. Merlo, G. Barbati, L. Massa, G. Faganello, A. Di Lenarda, G. F. Sinagra, T. Ishizu, Y. Seo, M. Enomoto, Y. Kameda, N. Ishibashi, M. Inoue, K. Aonuma, A. Saleh, A. Matsumori, H. Negm, H. Fouad, A. Onsy, E. Hamodraka, I. Paraskevaidis, M. Kallistratos, V. Lezos, T. Zamfir, C. Manetos, D. Mavropoulos, L. Poulimenos, D. Kremastinos, A. Manolis, R. Citro, F. Rigo, Q. Ciampi, M. Patella, G. Provenza, C. Zito, E. Tagliamonte, F. Rotondi, F. Silvestri, E. Bossone, P. Beltran Correas, C. Gutierrez Landaluce, M. Gomez Bueno, J. Segovia Cubero, C. Beladan, F. Matei, B. Popescu, A. Calin, M. Rosca, A. Boanta, R. Enache, O. Savu, C. Usurelu, C. Ginghina, A. O. Ciobanu, R. Dulgheru, S. Magda, R. Dragoi, M. Florescu, D. Vinereanu, S. Robalo Martins, C. Calisto, S. Goncalves, I. Barrigoto, J. Carvalho De Sousa, A. Almeida, A. Nunes Diogo, L. Sargento, M. Satendra, C. Sousa, N. Lousada, R. Palma Reis, V. Schiano Lomoriello, R. Esposito, A. Santoro, R. Raia, P. Schiattarella, E. Dores, M. Galderisi, N. Mansencal, V. Caille, A. Dupland, S. Perrot, K. Bouferrache, A. Vieillard-Baron, R. Jouffroy, P. Moceri, E. Liodakis, M. Gatzoulis, W. Li, K. Dimopoulos, M. Sadron, P. E. Seguela, B. Arnaudis, Y. Dulac, T. Cognet, P. Acar, Y. Shiina, H. Uemura, K. Kupczynska, J. Kasprzak, B. Michalski, P. Lipiec, V. Carvalho, A. M. G. Almeida, C. David, J. Marques, P. Ferreira, M. Amaro, P. Costa, A. Diogo, V. Tritakis, I. Ikonomidis, J. Lekakis, S. Tzortzis, N. Kadoglou, I. Papadakis, P. Trivilou, C. Koukoulis, M. Anastasiou-Nana, T. Bombardini, S. Gherardi, G. Arpesella, M. Maccherini, W. Serra, G. Magnani, R. Del Bene, E. Pasanisi, U. Startari, L. Panchetti, A. Rossi, M. Piacenti, M. Morales, I. El Hajjaji, R. El Mahmoud, F. Digne, O. Dubourg, G. Agoston, A. Moreo, L. Pratali, A. Moggi Pignone, A. Pavellini, M. Doveri, F. Musca, A. Varga, F. Faita, S. Rimoldi, C. Sartori, Y. Alleman, C. Salinas Salmon, M. Villena, U. Scherrer, R. Baptista, S. Serra, G. Castro, R. Martins, M. Salvador, P. Monteiro, J. Silva, L. Szudi, A. Temesvary, B. Fekete, I. Kassai, L. Szekely, S. S. Abdel Moneim, M. Martinez, S. Mankad, M. Bernier, A. Dhoble, K. Chandrasekaran, J. Oh, S. Mulvagh, G. R. Hong, J. Y. Kim, S. C. Lee, S. H. Choi, I. S. Sohn, H. S. Seo, J. H. Choi, K. I. Cho, S. J. Yoon, S. J. Lim, P. Wejner-Mik, J. Kusmierek, A. Plachcinska, R. Szuminski, S. Stoebe, A. Tarr, T. Trache, A. Hagendorff, C. Jenkins, H. Kuhl, H. Nesser, T. Marwick, A. Franke, J. Niel, L. Sugeng, S. Soderberg, P. Lindqvist, J. Necas, S. Kovalova, S. K. Saha, A. Kiotsekoglou, R. Toole, S. Govind, A. Gopal, M.-S. Amzulescu, A. Florian, J. Bogaert, S. Janssens, J. Voigt, V. Parisi, M. Losi, L. Parrella, C. Contaldi, E. Chiacchio, A. Caputi, A. Scatteia, A. Buonauro, S. Betocchi, R. Rimbas, S. Mihaila, M. Caputo, R. Navarri, P. Innelli, R. Urselli, E. Capati, P. Ballo, F. Furiozzi, R. Favilli, R. Lindquist, A. Miller, C. Reece, P. O'leary, F. Cetta, B. W. Eidem, M. Cikes, H. Gasparovic, B. Bijnens, V. Velagic, T. Kopjar, B. Biocina, D. Milicic, A. Ta-Shma, A. Nir, Z. Perles, S. Gavri, J. Golender, A. Rein, G. Pinnacchio, L. Barone, I. Battipaglia, A. Cosenza, L. Marinaccio, I. Coviello, G. Scalone, A. Sestito, G. Lanza, F. Crea, S. Cakal, E. Eroglu, B. Ozkan, S. Kulahcioglu, M. Bulut, A. Koyuncu, G. Acar, G. Alici, C. Dundar, F. Labombarda, E. Zangl, A. Pellissier, D. Bougle, P. Maragnes, P. Milliez, E. Saloux, S. Lagoudakou, E. Gialafos, A. Tsokanis, A. Nagy, T. Kovats, H. Vago, A. Toth, B. Sax, A. Kovacs, M. F. Elnoamany, H. Badran, I. Abdelfattah, T. Khalil, M. Salama, T. Butz, C. Taubenberger, F. Thangarajah, A. Meissner, M. Van Bracht, M. Prull, H. Yeni, G. Plehn, H. Trappe, R. Rydman, D. Bone, M. Alam, K. Caidahl, F. Larsen, Z. Gasior, Z. Tabor, P. Sengupta, D. Liu, M. Niemann, K. Hu, S. Herrmann, S. Stoerk, C. Morbach, S. Knop, W. Voelker, G. Ertl, F. Weidemann, P. Cawley, C. Hamilton-Craig, L. Mitsumori, J. Maki, C. Otto, M. Astrom Aneq, E. Nylander, T. Ebbers, J. Engvall, P. Arvanitis, F. Flachskampf, O. Duvernoy, F. De Torres Alba, S. Valbuena Lopez, G. Guzman Martinez, J. Gomez De Diego, J. Rey Blas, E. Armada Romero, E. Lopez De Sa, M. Moreno Yanguela, J. Lopez Sendon, N. Trikalinos, G. Siasos, A. Aggeli, A. Tomaszewski, A. Kutarski, M. Tomaszewski, O. Vriz, C. Driussi, M. Bettio, D. Pavan, F. Antonini Canterin, A. Doltra Magarolas, J. Fernandez-Armenta, E. Silva, N. Solanes, M. Rigol, A. Barcelo, L. Mont, A. Berruezo, J. Brugada, M. Sitges, F. L. Ciciarello, S. Mandolesi, F. Fedele, L. Agati, A. Marceca, S. Rhee, S. Shin, S. Kim, K. Yun, N. Yoo, N. Kim, S. Oh, J. Jeong, and N. Alabdulkarim
Subjects: education.field_of_study, medicine.medical_specialty, business.industry, Multiple sclerosis, Population, Hemodynamics, General Medicine, Cerebro, medicine.disease, Internal medicine, Cardiology, Medicine, Radiology, Nuclear Medicine and imaging, Cardiology and Cardiovascular Medicine, education, business
Published: 2011

18. Poster Session 1: Thursday 8 December 2011, 08:30-12:30 * Location: Poster Area

Author: S. Vijayan, M. Khanji, A. Ionescu, C. Podoleanu, A. Frigy, A. Ugri, A. Varga, D. Podoleanu, A. Incze, E. Carasca, D. Dobreanu, O. Mjolstad, H. Dalen, T. Graven, J. Kleinau, B. Hagen, H. Fu, T. Liu, J. Li, C. Liu, C. Zhou, G. Li, R. Bordese, M. Capriolo, D. Brero, I. Salvetti, M. Cannillo, M. Antolini, W. Grosso Marra, S. Frea, M. Morello, F. Gaita, F. Maffessanti, E. Caiani, D. Muraru, F. Tuveri, L. Dal Bianco, L. Badano, A. Majid, A. Soesanto, B. Ario Suryo Kuncoro, R. Sukmawan, M. H. Ganesja, T. Benedek, M. Chitu, J. Beata, Z. Suciu, I. Kovacs, O. Bucur, I. Benedek, A. Hrynkiewicz-Szymanska, F. Szymanski, G. Karpinski, K. Filipiak, Z. Radunovic, L. Lande Wekre, K. Steine, O. Bech-Hanssen, B. Rundqvist, F. Lindgren, N. Selimovic, J. Jedrzychowska-Baraniak, R. Jozwa, B. Larysz, J. Kasprzak, T. Ripp, V. Mordovin, E. Ripp, A. Ciobanu, R. Dulgheru, R. Dragoi, S. Magda, M. Florescu, S. Mihaila, R. Rimbas, M. Cinteza, D. Vinereanu, C. Benavides-Vallve, B. Pelacho, O. Iglesias, S. Castano, A. Munoz-Barrutia, F. Prosper, C. Ortiz De Solorzano, A. Manouras, A. Sahlen, R. Winter, P. Vardas, L. Brodin, S. I. Sarvari, K. H. Haugaa, W. Zahid, B. Bendz, L. Aaberge, T. Edvardsen, G. Di Bella, S. Pedri, R. Donato, A. Madaffari, C. Zito, D. Stapf, M. Schreckenberg, S. Carerj, H. Yoshikawa, M. Suzuki, Y. Kusunose, G. Hashimoto, T. Otsuka, M. Nakamura, K. Sugi, J. Grapsa, D. Dawson, W. Gin-Sing, L. Howard, J. Gibbs, P. Nihoyannopoulos, B. Smith, T. Coulter, A. Rendon, W. Gorissen, A. Shiran, I. Asmer, S. Adawi, M. Ganaeem, J. Shehadeh, M. Cameli, M. Lisi, F. Righini, M. Maccherini, G. Sani, M. Galderisi, S. Mondillo, D. Kalimanovska-Ostric, T. Nastasovic, I. Jovanovic, B. Milakovic, M. Dostanic, M. Stosic, I. Sasic, K. Sveen, T. Nerdrum, K. Hanssen, K. Dahl-Jorgensen, E. Holte, J. Vegsundvaag, T. Hole, K. Hegbom, R. Wiseth, I. Ikonomidis, J. Lekakis, V. Tritakis, I. Papadakis, N. Kadoglou, S. Tzortzis, P. Trivilou, C. Koukoulis, I. Paraskevaidis, M. Anastasiou-Nana, M. K. Smedsrud, S. Sarvari, O. Gjesdal, M. Beraldo, E. Solda', U. Cucchini, D. Peluso, M. Tuveri, A. Al Mamary, S. Iliceto, H. Dores, J. Abecasis, M. Carvalho, M. Santos, M. Andrade, R. Ribeiras, C. Reis, E. Horta, R. Gouveia, M. Mendes, D. Zaliaduonyte-Peksiene, V. Mizariene, G. Cesnaite, E. Tamuleviciute, R. Jurkevicius, J. Vaskelyte, R. Zaliunas, K. Smarz, B. Zaborska, T. Jaxa-Chamiec, P. Maciejewski, A. Budaj, D. Trifunovic, D. Sobic-Saranovic, S. Stankovic, M. Ostojic, B. Vujisic-Tesic, M. Petrovic, I. Nedeljkovic, M. Banovic, M. Tesic, I. Petrovic, I. Peovska, E. Srbinovska, J. Maksimovic, V. Andova, F. Arnaudova, E. Hristova, M. Otljanska, M. Vavlukis, S. Jovanova, G. Tamborini, L. Fusini, P. Gripari, M. Muratori, G. Pontone, D. Andreini, E. Bertella, S. Ghulam Ali, A. Bartorelli, M. Pepi, M. Cusma-Piccione, J. Salvia, F. Antonini-Canterin, S. Lentini, D. Donato, M. Miceli, G. Oreto, R. Sachner, R. Rubinshtein, M. Shnapp, T. Gaspar, A. Marchese, W. Deste, A. Sanfilippo, P. Aruta, M. Patane, G. Millan, G. Ussia, C. Tamburino, V. Kujacic, S. Obradovic, Z. Crkvenac, A. Bernard, M. Piquemal, G. Muller, P. Arbeille, B. Charbonnier, C. Broyd, J. Davies, G. Mikhail, J. Mayet, D. Francis, M. Rosca, J. Magne, C. Szymanski, B. Popescu, C. Ginghina, L. Pierard, P. Lancellotti, A. Gonzalez-Mansilla, J. Solis, R. Angulo, E. Perez-David, G. Madrid, J. Garcia-Robles, R. Yotti, R. Prieto, J. Bermejo, F. Fernandez-Aviles, Y. Ishikawa, T. Ishida, T. Osaki, M. Matsuyama, H. Yamashita, S. Ozaki, M. Stevanella, E. Votta, F. Veronesi, F. Alamanni, A. Redaelli, S. D. Park, J. Lee, S. Shin, S. Woo, D. Kim, K. Park, J. Kwan, W. Tsang, S. Chandra, L. Weinert, E. Gayat, M. Djelassi, T. Balbach, V. Mor-Avi, R. Lang, P. De Meester, A. Van De Bruaene, M. Delcroix, W. Budts, L. Abid, Z. Frikha, K. Makni, H. Rekik, A. Znazen, H. Mourad, S. Kammoun, L. Sargento, M. Satendra, C. Sousa, S. Lopes, S. Longo, N. Lousada, R. Palma Reis, D. Fouad, R. Shams Eldeen, C. Beladan, A. Calin, F. Voinea, R. Enache, R. Jurcut, I. Coman, M. Ghionea, A. Djordjevic-Dikic, O. Petrovic, M. Boricic, V. Giga, L. Pisciella, C. Lanzillo, M. Minati, S. Caselli, M. Di Roma, S. Fratini, S. Romano, L. Calo', E. Lioy, M. Penco, G. Finocchiaro, B. Pinamonti, M. Merlo, G. Barbati, G. Sinagra, A. Dilenarda, S. Comenale Pinto, R. Ancona, P. Caso, C. Cavallaro, F. Vecchione, A. D'onofrio, M. Fero', R. Calabro', S. Gustafsson, E. Ihse, M. Henein, P. Westermark, O. Suhr, P. Lindqvist, M. Oliva Sandoval, M. Gonzalez Carrillo, M. Garcia Navarro, E. Garcia-Molina Saez, M. Sabater Molina, D. Saura Espin, J. Lacunza Ruiz, J. Gimeno Blanes, G. De La Morena Valenzuela, M. Valdes Chavarri, C. Prinz, L. Faber, D. Horstkotte, H. Hoetz, J. Voigt, F. Gandara, M. Correia, I. Rosario, C. Fonseca, I. Arroja, A. Aleixo, A. Martins, L. Radulescu, D. Dan Radulescu, P. Parv Andreea, D. Duncea Caius, C. Ciuleanu T, M. Mitrea Paulina, F. Cali Quaglia, M. Ribezzo, M. Boffini, M. Rinaldi, A. M. Maceira Gonzalez, J. Cosin-Sales, E. Dalli, J. Diago, J. Aguilar, J. Ruvira, S. Goncalves, A. Gomes, F. Pinto, W.-C. Tsai, Y.-W. Liu, J.-Y. Shih, Y.-Y. Huang, J.-Y. Chen, L.-M. Tsai, J.-H. Chen, S. Ribeiro, D. Doroteia, L. Santos, C. David, G. Vinhas De Sousa, A. Almeida, M. Iwase, Y. Itou, S. Yasukochi, K. Shiino, H. Inuzuka, K. Sugimoto, Y. Ozaki, K. Gieszczyk-Strozik, A. Sikora-Puz, M. Mizia, B. Lasota, A. Chmiel, A. Lis-Swiety, J. Michna, L. Brzezinska-Wcislo, K. Mizia-Stec, Z. Gasior, P. Luijendijk, H. De Bruin-Bon, C. Zwiers, J. Vriend, R. Van Den Brink, B. Mulder, B. Bouma, S. Brigido, P. Gianfagna, A. Proclemer, B. Plicht, P. Kahlert, H. Kaelsch, T. Buck, R. Erbel, T. Konorza, H. Yoon, K. Kim, Y. Ahn, M. Jeong, J. Cho, J. Park, J. Kang, W. Rha, W. W. Jansen Klomp, G. Brandon Bravo Bruinsma, A. Van 'T Hof, S. Spanjersberg, A. Nierich, T. Bombardini, S. Gherardi, E. Picano, A. Ciarka, L. Herbots, E. Eroglu, J. Van Cleemput, W. Droogne, R. Jasityte, B. Meyns, J. D'hooge, J. Vanhaecke, M. Al Barjas, R. Iskreva, R. Morris, J. Davar, Y. Zhao, A. Holmgren, S. Morner, J. Stepanovic, B. Beleslin, M. Nedeljkovic, S. Mazic, V. Stojanov, R. Piatkowski, J. Kochanowski, P. Scislo, M. Grabowski, M. Marchel, M. Roik, D. Kosior, G. Opolski, A. Tomaszewski, A. Kutarski, M. Tomaszewski, S. Eibel, E. Hasheminejad, C. Mukherjee, H. Tschernich, J. Ender, I. Delithanasis, J. Celutkiene, C. Kenny, M. Monaghan, S. Van Den Oord, G. Ten Kate, Z. Akkus, G. Renaud, E. Sijbrands, F. Ten Cate, N. De Jong, J. Bosch, A. Van Der Steen, A. Schinkel, A. Lisowska, M. Knapp, A. Tycinska, R. Sawicki, P. Kralisz, B. Sobkowicz, S.-A. Chang, S.-C. Lee, E.-Y. Kim, S.-H. Hahm, G.-T. Ahn, M.-K. Sohn, S.-J. Park, J.-O. Choi, S.-W. Park, J.-K. Oh, M. O. Gursoy, T. Gokdeniz, M. Astarcioglu, Z. Bayram, B. Cakal, S. Karakoyun, M. Kalcik, G. Kahveci, M. Yildiz, M. Ozkan, V. Skidan, A. Borowski, M. Park, J. Thomas, S. Ranjbar, S. Hassantash, M. Karvandi, M. Foroughi, E. S. Davidsen, D. Cramariuc, O. Bleie, E. Gerdts, K. Matre, M. Cusma' Piccione, G. Bagnato, M. Mohammed, S. Piluso, L. Oreto, T. Bitter, S. Carvalho, M. Canada, M. Santisteban Sanchez De Puerta, M. D. Mesa Rubio, M. Ruiz Ortiz, M. Delgado Ortega, M. L. Pena Pena, M. Puentes Chiachio, J. Suarez De Lezo Cruz-Conde, M. Pan Alvarez-Ossorio, F. Mazuelos Bellido, J. Suarez De Lezo Herreros De Tejada, E. Altekin, A. Yanikoglu, S. Karakas, C. Oncel, B. Akdemir, A. Belgi Yildirim, A. Cilli, H. Yilmaz, L. Lenartowska, M. Furdal, B. Knysz, A. Konieczny, J. Lewczuk, S. Severino, M. Cavallaro, M. Coppola, H. Motoki, A. To, M. Bhargava, O. Wazni, T. Marwick, A. Klein, E. Sinkovskaya, S. Horton, A. Abuhamad, S. Mingo Santos, V. Monivas Palomero, B. Beltran Correas, C. Mitroi, C. Gutierrez Landaluce, I. Garcia Lunar, J. Gonzalez Mirelis, M. Cavero, J. Segovia Cubero, L. Alonso Pulpon, E. Gurel, T. Karaahmet, K. Tigen, C. Kirma, C. Dundar, S. Pala, I. Isiklar, C. Cevik, A. Kilicgedik, Y. Basaran, M. Brambatti, A. Romandini, A. Barbarossa, S. Molini, A. Urbinati, A. Giovagnoli, L. Cipolletta, A. Capucci, S. Park, E. Choi, C. Ahn, S. Hong, M. Kim, D. Lim, W. Shim, J. Xie, F. Fang, Q. Zhang, J. Chan, G. Yip, J. Sanderson, Y. Lam, B. Yan, C. Yu, P. Jorge Perez, A. De La Rosa Hernandez, C. Hernandez Garcia, A. Duque Garcia, A. Barragan Acea, E. Arroyo Ucar, J. Jimenez Rivera, J. Lacalzada Almeida, I. Laynez Cerdena, C. Carminati, R. Capoulade, E. Larose, M. Clavel, J. Dumesnil, M. Arsenault, E. Bedard, P. Mathieu, P. Pibarot, L. Gargani, G. Baldi, F. Forfori, D. Caramella, L. D'errico, A. Abramo, R. Sicari, F. Giunta, W.-N. Lee, B. Larrat, E. Messas, M. Pernot, M. Tanter, V. Velagic, M. Cikes, R. Matasic, I. Skorak, J. Samardzic, D. Puljevic, M. Lovric Bencic, B. Biocina, D. Milicic, B. Roosens, G. Bala, S. Droogmans, J. Hostens, J. Somja, E. Delvenne, J. Schiettecatte, T. Lahoutte, G. Van Camp, B. Cosyns, A. Ghosh, R. Hardy, N. Chaturvedi, J. Deanfield, D. Pellerin, D. Kuh, A. Hughes, A. Malmgren, M. Dencker, M. Stagmo, P. Gudmundsson, Y. Seo, T. Ishizu, K. Aonuma, M. J. Schuuring, J. Vis, A. Van Dijk, J. Van Melle, P. Pieper, H. Vliegen, G. Sieswerda, E. Foukarakis, A. Pitarokilis, P. Kafarakis, A. Kiritsi, E. Klironomos, A. Manousakis, X. Fragiadaki, E. Papadakis, and A. Dermitzakis
Subjects: medicine.medical_specialty, business.industry, Thursday, medicine, Radiology, Nuclear Medicine and imaging, Medical physics, General Medicine, Session (computer science), Cardiology and Cardiovascular Medicine, business, Surgery
Published: 2011

19. Poster Session 5: Saturday 10 December 2011, 08:30-12:30 * Location: Poster Area

Author: L. Gong, Z. Ye, Z. Zeng, M. Xia, Y. Zhong, Y. Yao, E. Lee, A. Ionescu, G. Dwivedi, G. Mahadevan, D. Jiminez, M. Frenneaux, R. Steeds, C. Moore, Z. Samad, K. Jackson, J. Castellucci, J. Kisslo, O. Von Ramm, F. D'ascenzi, V. Zaca', M. Cameli, M. Lisi, B. Natali, A. Malandrino, S. Mondillo, P. Barbier, U. Guerrini, M. Franzosi, L. Castiglioni, E. Nobili, F. Colazzo, T. Li Causi, L. Sironi, E. Tremoli, H. Clausen, S. Macdonald, C. Basaggianis, J. Newton, E. Bennati, R. Reccia, E. Bigio, M. Maccherini, M. Chiavarelli, M. Henein, M. Floria, J. Jamart, C. Arsenescu Georgescu, F. Mantovani, A. Barbieri, F. Bursi, C. Valenti, M. Quaglia, M. Modena, S. Kutty, P. Gribben, A. Padiyath, A. Polak, C. Scott, M. Waiss, D. Danford, O. Bech-Hanssen, N. Selimovic, B. Rundqvist, L. Schmiedel, C. Hohmann, S. Katzke, K. Haacke, T. Rauwolf, R. Strasser, L. R. Tumasyan, K. Adamyan, W. Kosmala, R. Derzhko, M. Przewlocka-Kosmala, A. Mysiak, B. Stachowska, D. Jedrzejuk, G. Bednarek-Tupikowska, L. Chrzanowski, J. Kasprzak, C. Wojciechowska, K. Wita, B. Busz-Papiez, Z. Gasior, K. Mizia-Stec, T. Kukulski, P. Gosciniak, W. Sinkiewicz, H. Moelmen, A. Stoylen, A. Thorstensen, H. Torp, H. Dalen, A. Groves, G. Nicholson, L. Lopez, C.-W. Goh, H. Ahn, Y. Byun, J. Kim, J. Park, J. Lee, B. Kim, K. Rhee, K. Kim, H. Yoon, Y. Hong, H. Park, Y. Ahn, M. Jeong, J. Cho, J. Kang, J. Grapsa, D. Dawson, K. Karfopoulos, G. Jakaj, P. Punjabi, P. Nihoyannopoulos, C. Ruisanchez Villar, P. Lerena Saenz, F. Gonzalez Vilchez, C. Gonzalez Fernandez, F. Zurbano Goni, J. Cifrian Martinez, R. Mons Lera, J. Ruano Calvo, R. Martin Duran, J. Vazquez De Prada Tiffe, R. Pietrzak, B. Werner, D. Voillot, O. Huttin, P. Zinzius, J. Schwartz, J. Sellal, S. Lemoine, C. Christophe, B. Popovic, Y. Juilliere, C. Selton-Suty, K. Ishii, A. Furukawa, T. Nagai, K. Kataoka, Y. Seino, K. Shimada, J. Yoshikawa, A. Tekkesin, O. Yildirimturk, Y. Tayyareci, S. Yurdakul, S. Aytekin, J. Jaroch, K. Loboz-Grudzien, Z. Bociaga, A. Kowalska, E. Kruszynska, M. Wilczynska, K. Dudek, R. Kakihara, C. Naruse, H. Hironaka, T. Tsuzuku, U. Cucchini, D. Muraru, L. Badano, E. Solda', M. Tuveri, O. Al Nono, C. Sarais, S. Iliceto, L. Santos, N. Cortez-Dias, S. Ribeiro, S. Goncalves, C. Jorge, P. Carrilho-Ferreira, D. Silva, J. Silva-Marques, M. Lopes, A. Diogo, K. Hristova, D. Vassilev, P. Pavlov, T. Katova, I. Simova, V. Kostova, R. Esposito, A. Santoro, V. Schiano Lomoriello, R. Raia, D. De Palma, E. Dores, G. De Simone, M. Galderisi, B. Zaborska, E. Makowska, E. Pilichowska, P. Maciejewski, B. Bednarz, W. Wasek, S. Stec, A. Budaj, L. Spinelli, C. Morisco, E. Assante Di Panzillo, S. Crispo, S. Di Marino, B. Trimarco, F. Farina, P. Innelli, A. Rapacciuolo, B. Polgar, F. Banyai, L. Rokusz, I. Tomcsanyi, M. Vaszily, E. Nieszner, T. Borsanyi, G. Kerecsen, I. Preda, R. G. Kiss, S. Bull, J. Suttie, D. Augustine, J. Francis, T. Karamitsos, H. Becher, B. Prendergast, S. Neubauer, S. Myerson, F. Lodge, C. Broyd, P. Milton, G. Mikhail, J. Mayet, J. Davies, D. Francis, M.-A. Clavel, P.-V. Ennezat, S. Marechaux, J. Dumesnil, A. Bellouin, S. Bergeron, P. Meimoun, T. Le Tourneau, A. Pasquet, P. Pibarot, S. Herrmann, S. Stoerk, M. Niemann, K. Hu, W. Voelker, G. Ertl, F. Weidemann, V. Aytekin, P. Kogoj, J. Ambrozic, M. Bunc, G. Di Salvo, A. Rea, B. Castaldi, S. Gala, A. D'aiello, A. Mormile, F. Pisacane, G. Pacileo, M. Russo, R. Calabro, L. Nguyen, S.-E. Ricksten, A. Jeppsson, H. Schersten, K. Boerlage-Van Dijk, Z. Yong, B. Bouma, K. Koch, M. Vis, J. Piek, J. Baan, S. Scandura, G. Ussia, A. Caggegi, V. Cammalleri, K. Sarkar, S. Mangiafico, M. Chiaranda', S. Imme', A. Pistritto, C. Tamburino, L. Ring, S. Nair, F. Wells, L. Shapiro, R. Rusk, B. Rana, G. Madrid Marcano, J. Solis Martin, A. Gonzalez Mansilla, L. Bravo, C. Menarguez Palanca, P. Munoz, E. Bouza, R. Yotti, J. Bermejo Thomas, F. Fernandez Aviles, T. Tamayo, M. Denes, O. Balint, A. Csepregi, A. Csillik, T. Erdei, A. Temesvari, J. Fernandez-Pastor, A. Linde-Estrella, F. Cabrera-Bueno, J. Pena-Hernandez, A. Barrera-Cordero, F. Alzueta-Rodriguez, E. De Teresa-Galvan, M. Merlo, M. Pinamonti, G. Finocchiaro, S. Pyxaras, G. Barbati, A. Buiatti, A. Dilenarda, G. Sinagra, R. Kuperstein, D. Freimark, S. Hirsch, M. Feinberg, M. Arad, C. Mitroi, I. Garcia Lunar, V. Monivas Palomero, S. Mingo Santos, P. Beltran Correas, E. Gonzalez Lopez, P. Garcia Pavia, J. Gonzalez Mirelis, M. Cavero Gibanel, L. Alonso Pulpon, B. Pinamonti, A. Zaidi, S. Ghani, N. Sheikh, S. Gati, R. Howes, R. Sharma, S. Sharma, M. Calcagnino, C. O'mahony, C. Coats, M. Cardona, A. Garcia, E. Murphy, R. Lachmann, A. Mehta, D. Hughes, P. Elliott, G. Di Bella, A. Madaffari, R. Donato, A. Mazzeo, M. Casale, C. Zito, G. Vita, S. Carerj, D. Marek, J. Indrakova, Z. Rusinakova, T. Skala, E. Kocianova, M. Taborsky, F. Musca, B. De Chiara, O. Belli, S. Cataldo, C. Brunati, G. Colussi, G. Quattrocchi, G. Santambrogio, F. Spano, A. Moreo, L. Rustad, K. Nytroen, L. Gullestad, B. Amundsen, S. Aakhus, N. Maroz-Vadalazhskaya, V. Shumavetc, S. Kurganovich, Y. Seljun, A. Ostrovskiy, Y. Ostrovskiy, P. Segers, A. Orda, B. Karolko, M. M. P. Driessen, J. B. Eising, C. Uiterwaal, C. K. Van Der Ent, F. J. Meijboom, Q. Shang, L. Tam, J. Sun, J. Sanderson, Q. Zhang, E. Li, C. Yu, E. Arroyo Ucar, A. De La Rosa Hernandez, C. Hernandez Garcia, P. Jorge Perez, J. Lacalzada Almeida, J. Jimenez Rivera, A. Duque Garcia, A. Barragan Acea, I. Laynez Cerdena, M. Kaldararova, I. Simkova, J. Pacak, P. Tittel, J. Masura, M. Tadic, B. Ivanovic, M. Zlatanovic, N. Damjanov, S. Maggiolini, G. Gentile, A. Bozzano, S. Suraci, E. Meles, C. Carbone, A. Tempesta, C. Malafronte, L. Piatti, F. Achilli, P. Luijendijk, A. Stevens, H. De Bruin-Bon, J. Vriend, R. Van Den Brink, H. Vliegen, B. Mulder, V. Chow, A. Ng, T. Chung, L. Kritharides, M. Iancu, M. Serban, I. Craciunescu, A. Hodo, I. Ghiorghiu, B. Popescu, C. Ginghina, G. Styczynski, C. A. Szmigielski, A. Kaczynska, J. Leszczynski, G. Rosinski, A. Kuch-Wocial, M. Slavich, M. Ancona, A. Fisicaro, M. Oppizzi, E. Marone, L. Bertoglio, G. Melissano, A. Margonato, R. Chiesa, E. Agricola, M. Mohammed, M. Cusma-Piccione, S. Piluso, S. Arcidiaco, R. Nava, R. Giuffre, L. Ciraci, M. Ferro, V. Uusitalo, M. Luotolahti, M. Pietila, M. Wendelin-Saarenhovi, J. Hartiala, M. Saraste, J. Knuuti, A. Saraste, J. Kochanowski, P. Scislo, R. Piatkowski, M. Grabowski, M. Marchel, M. Roik, D. Kosior, G. Opolski, P. E. Bartko, S. Graf, A. Khorsand, R. Rosenhek, I. Burwash, R. Beanlands, H. Baumgartner, G. Mundigler, S. Kudrnova, A. Apor, H. Huttl, F. Mori, G. Santoro, A. Oddo, G. Rosso, F. Meucci, F. Pieri, G. Squillantini, G. Gensini, M. Postula, D.-G. Park, J.-Y. Hong, S.-E. Kim, J.-H. Lee, K.-R. Han, D.-J. Oh, L. Dal Bianco, M. Beraldo, D. Peluso, A. Al Mamary, C. Aggeli, I. Felekos, E. Poulidakis, P. Pietri, G. Roussakis, G. Siasos, C. Stefanadis, H. Hoshiba, C. Miyasaka, H. Sato, A. Yamanaka, A. Lilli, M. Baratto, M. Magnacca, A. Comella, R. Poddighe, E. Talini, M. Canale, M. Chioccioli, J. Del Meglio, G. Casolo, V. A. Kuznetsov, N. N. Melnikov, D. V. Krinochkin, A. Calin, R. Enache, C. Beladan, M. Rosca, L. Lupascu, F. Purcarea, C. Calin, M. Gurzun, R. Dulgheru, A. Ciobanu, S. Magda, S. Mihaila, R. Rimbas, A. Margulescu, M. Cinteza, D. Vinereanu, A. N. Sumin, O. Arhipov, J. Yoon, J. Moon, S. Rim, E. Nyktari, A. Patrianakos, G. Solidakis, E. Psathakis, F. Parthenakis, P. Vardas, M. Kordybach, M. Kowalski, E. Kowalik, P. Hoffman, K. V. Nagy, V. Kutyifa, E. Edes, B. Merkely, A. Gerlach, C. Rost, M. Schmid, M. Rost, F. Flachskampf, W. Daniel, O. Breithardt, E. Altekin, S. Karakas, A. Yanikoglu, A. Er, A. Baktir, I. Demir, N. Deger, L. Klitsie, M. Hazekamp, A. Roest, A. Van Der Hulst, B. Gesink- Van Der Veer, I. Kuipers, N. Blom, A. Ten Harkel, K. Farsalinos, D. Tsiapras, S. Kyrzopoulos, E. Avramidou, D. Vasilopoulou, V. Voudris, T. Florianczyk, M. Kalinowski, M. Szulik, W. Streb, B. Rybus-Kalinowska, A. Sliwinska, J. Stabryla, M. Kukla, J. Nowak, Z. Kalarus, M. Florescu, D. Mihalcea, L. Magda, B. Suran, O. Enescu, R. Mincu, G. Salerno, G. Scognamiglio, A. D'andrea, G. Dinardo, R. Gravino, B. Sarubbi, G. Disalvo, J.-N. Liao, S. Sung, C. Chen, S. Park, S. Shin, M. Kim, S. Shim, F. Helvacioglu, O. Ulusoy, C. Duran, R. Kirschner, T. Simor, G. Ambrosio, T. Tran, S. Raman, R. C. Vidal Perez, F. Carreras, R. Leta, S. Pujadas, A. Barros, A. Hidalgo, X. Alomar, G. Pons-Llado, M. Olofsson, K. Boman, A. Ledakowicz-Polak, L. Polak, M. Zielinska, A. Fontana, V. Schirone, A. Mauro, A. Zambon, C. Giannattasio, G. Trocino, M. Dekleva, H. Dungen, S. Inkrot, G. Gelbrich, J. Suzic Lazic, M. Kleut, N. Markovic Nikolic, F. Waagstein, S. Khoor, N. Balogh, I. Simon, K. Fugedi, I. Kovacs, M. Khoor, G. Florian, A. Kocsis, T. Szuszai, J. O'driscoll, A. Saha, R. Smith, S. Gupta, Z. Lenkey, B. Gaszner, M. Illyes, Z. Sarszegi, I. G. Horvath, B. Magyari, F. Molnar, A. Cziraki, M. F. Elnoamany, H. Badran, H. Ebraheem, A. Reda, and N. Elsheekh
Subjects: Speckle pattern, Acoustics, Radiology, Nuclear Medicine and imaging, General Medicine, Deformation (meteorology), Cardiology and Cardiovascular Medicine, Tracking (particle physics), Geology
Published: 2011

20. Poster session I * Thursday 9 December 2010, 08:30-12:30

Author: V. A. Kuznetsov, A. O. Kozhurina, A. V. Plusnin, M. Szulik, B. Sredniawa, W. Streb, R. Lenarczyk, J. Stabryla-Deska, A. Sedkowska, O. Kowalski, Z. Kalarus, T. Kukulski, T. M. Katova, A. Nesheva, I. Simova, K. Hristova, V. Kostova, L. Boiadjiev, N. Dimitrov, M. P. Papamichalis Michalis, S. G. Sitafidis George, B. D. Dimopoulos Basilios, G. K. Kelepesis Glafkos, D. E. Economou Dimitrios, J. S. Skoularigis John, F. T. Triposkiadis Filippos, C. H. Attenhofer Jost, M. Pfyffer, B. Naegeli, P. Levis, A. Faeh-Gunz, H. P. Brunner-Larocca, M. S. Velasco Del Castillo, A. Cacicedo, J. J. Onaindia, J. Gonzalez Ruiz, A. Subinas, J. A. Alarcon, O. Quintana, I. Rodriguez, E. Laraudogoitia, Y.-Y. Lam, M. Y. Henein, A. Mazzone, A. Vianello, S. Perlini, A. I. Corciu, S. Cappelli, A. Cerillo, D. Chiappino, S. Berti, M. Glauber, S. Herrmann, M. Niemann, S. Stoerk, J. Strotmann, W. Voelker, G. Ertl, F. Weidemann, Z. Y. Yong, K. Boerlage - Van Dijk, K. T. Koch, M. M. Vis, B. J. Bouma, J. P. S. Henriques, R. Cocchieri, B. A. J. M. De Mol, J. J. Piek, J. Baan, N. G. J. Keenan, C. Cueff, C. Cimadevilla, E. Brochet, L. Lepage, D. Detaint, B. Iung, A. Vahanian, D. Messika-Zeitoun, T. Otsuka, M. Suzuki, H. Yoshikawa, G. Hashimoto, T. Osaki, T. Tsuchida, M. Matsuyama, H. Yamashita, S. Ozaki, K. Sugi, C. J. Garcia Alonso, N. Vallejo Camazon, E. Ferrer Sistach, M. L. Camara, J. Lopez Ayerbe, C. Bosch Carabante, M. Espriu Simon, F. Gual Capllonch, A. Bayes Genis, G. Deswarte, C. Vanesson, A. S. Polge, D. Huchette, T. Modine, P. Marboeuf, N. Lamblin, C. Bauters, G. Deklunder, T. Le Tourneau, A. Agricola, M. Gullace, S. Stella, R. D'amato, M. Slavich, M. Oppizzi, M. Ancona, A. Margonato, F. Le Ven, Y. Etienne, Y. Jobic, I. Frachon, P. Castellant, M. Fatemi, J. J. Blanc, M. Muratori, P. Montorsi, F. Maffessanti, P. Gripari, G. Teruzzi, S. Ghulam Ali, L. Fusini, F. Celeste, M. Pepi, B. Goebel, K. Haugaa, K. Meyer, S. Otto, A. Lauten, C. Jung, T. Edvardsen, H. R. Figulla, T. C. Poerner, H. Aksoy, S. Okutucu, B. Evranos, K. Aytemir, E. B. Kaya, G. Kabakci, L. Tokgozoglu, H. Ozkutlu, A. Oto, N. Valeur, H. H. Pedersen, R. Videbaek, C. Hassager, J. H. Svendsen, L. Kober, M. K. Tigen, T. Karaahmet, E. Gurel, S. Pala, C. Dundar, Y. Basaran, C. I. Caldararu, E. Ene, M. Dorobantu, R. G. Vatasescu, M. Cikes, B. Bijnens, H. Gasparovic, F. Siric, V. Velagic, D. Lovric, J. Samardzic, B. Ferek-Petric, D. Milicic, B. Biocina, J. Kjaergaard, S. Ghio, M. St John Sutton, O. Moreau, G. Kervio, C. Thebault, C. Leclercq, E. Donal, C. Mornos, D. Rusinaru, L. Petrescu, D. Cozma, A. Ionac, S. Pescariu, S. I. Dragulescu, M. Z. Petrovic, B. Vujisic-Tesic, G. Milasinovic, M. T. Petrovic, I. Nedeljkovic, D. Zamaklar-Trifunovic, Z. Calovic, V. Jelic, M. Boricic, I. Petrovic, P. Kuchynka, T. Palecek, S. Simek, E. Nemecek, J. Horak, D. Hulinska, J. Schramlova, I. Vitkova, V. Aster, A. Linhart, L. Paluszkiewicz, D. Guersoy, S. Ozegowski, S. Spiliopoulos, R. Koerfer, G. Tenderich, M. Gaggl, G. Heinze, G. Sunder-Plassmann, S. Graf, M. Zehetmayer, T. Voigtlaender, C. Mannhalter, E. Paschke, G. Fauler, G. Mundigler, M. Tesic, D. Trifunovic, A. Djordjevic-Dikic, O. Petrovic, M. Petrovic, B. Beleslin, M. Ostojic, G. Draganic, C. E. Correia, B. Rodrigues, L. F. Santos, D. Moreira, P. Gama, L. Nunes, C. Nascimento, O. Dionisio, O. Santos, C. Prinz, O. Oldenburg, T. Bitter, C. Piper, D. Horstkotte, L. Faber, A. Nemes, H. Gavaller, M. Csanady, T. Forster, M. Calcagnino, C. O'mahony, K. Tsovolas, P. D. Lambiase, P. Elliott, A. S. Olezac, A. Bensaid, J. Nahum, E. Teiger, J. L. Dubois-Rande, P. Gueret, P. Lim, C. Langer, M. Kansal, P. Surapaneni, P. P. Sengupta, S. J. Lester, S. R. Ommen, S. W. Ressler, R. T. Hurst, V. Monivas Palomero, S. Mingo Santos, C. Mitroi, I. Garcia Lunar, P. Garcia Pavia, J. Gonzalez Mirelis, L. Ruiz Bautista, V. Castro Urda, J. Toquero Ramos, I. Fernandez Lozano, A. Sommer, S. H. Poulsen, J. Mogensen, L. Thuesen, H. Egeblad, R. Montisci, M. Ruscazio, A. Vacca, P. Garau, F. Tuveri, C. Soro, A. Matthieu, L. Meloni, W. Kosmala, M. Przewlocka-Kosmala, A. Wojnalowicz, A. Mysiak, T. H. Marwick, R. Yotti, C. Ripoll, J. Bermejo, Y. Benito, T. Mombiela, D. Rincon, A. Barrio, R. Banares, F. Fernandez-Aviles, A. Tomaszewski, A. Kutarski, M. Tomaszewski, R. Ticulescu, O. Vriz, L. Sparacino, B. A. Popescu, C. Ginghina, G. L. Nicolosi, S. Carerj, F. Antonini-Canterin, E. Agricola, L. Bertoglio, G. Melissano, R. Chiesa, S. Garcia Blas, D. Iglesias Del Valle, T. Lopez Fernandez, J. J. Gomez De Diego, M. C. Monedero Martin, F. J. Dominguez, M. Moreno Yanguela, J. L. Lopez Sendon, S. Adhya, F. D. Murgatroyd, M. Monaghan, L. Spinarova, J. Meluzin, P. Hude, J. Krejci, H. Podrouzkova, M. Pesl, R. Panovsky, L. Dusek, M. Orban, J. Korinek, C. Hammerstingl, M. Schwiekendik, G. Nickenig, D. Momcilovic, L. Lickfett, C. C. Beladan, A. Calin, M. Rosca, D. Muraru, F. Voinea, E. Popa, F. Matei, F. Curea, G. Di Salvo, G. Pacileo, S. Gala, B. Castaldi, A. F. D'aiello, A. Mormile, L. Baldini, M. G. Russo, R. Calabro, P. S. Halvorsen, G. Dahle, J. F. Bugge, B. Bendz, L. Aaberge, K. A. Rein, A. Fiane, J. Bergsland, E. Fosse, S. Aakhus, L. P. Koopman, N. Chahal, C. Slorach, W. Hui, T. Sarkola, C. Manlhiot, T. J. Bradley, E. T. Jaeggi, B. W. Mccrindle, L. Mertens, F. A. D'aiello, A. Mormilw, A. Rea, K. O'Connor, G. Romano, J. Magne, L. Pierard, P. Lancellotti, T. Arita, K. Ando, A. Isotani, Y. Soga, M. Iwabuchi, M. Nobuyoshi, M. Wiesen, D. Skowasch, F. Breunig, M. Beer, K. Hu, C. Wanner, M. A. Morel, Y. F. Bernard, V. Descotes-Genon, N. Meneveau, F. Schiele, A. Vitarelli, M. Bernardi, A. Scarno, F. Caranci, V. Padella, O. Dettori, L. Capotosto, M. Vitarelli, V. De Cicco, P. Bruno, G. Bajraktari, P. Lindqvist, U. Gustafsson, A. Holmgren, M. Hassan, K. Said, E. Baligh, H. Farouk, D. Osama, M. F. Elmahdy, A. Elfaramawy, K. Sorour, M. Luckie, A. Zaidi, A. Fitzpatrick, R. S. Khattar, J. Schwartz, O. Huttin, B. Popovic, P. Y. Zinzius, C. Christophe, O. Marcon, L. Groben, Y. Juilliere, F. Chabot, C. Selton-Suty, B. Krastev, E. T. K. Kinova, N. I. Z. Zlatareva, A. R. G. Goudev, A. J. Teske, B. W. De Boeck, F. A. Mohames Hoesein, V. Van Driel, P. Loh, M. J. Cramer, P. A. Doevendans, F. Dillenburg, K. M. Abd El Salam, E. M. M. Ho, M. Hall, L. Hemeryck, K. Bennett, K. Scott, G. King, R. T. Murphy, A. Mahmud, A. S. Brown, H. Dalen, A. Thorstensen, P. R. Romundstad, S. A. Aase, A. Stoylen, L. Vatten, T. Bochenek, K. Wita, Z. Tabor, A. Doruchowska, M. Lelek, M. Trusz-Gluza, E. Hamodraka, I. Paraskevaidis, A. Karamanou, C. Michalakeas, H. Vrettou, E. Kapsali, D. Tsiapras, I. Lekakis, M. Anastasiou-Nana, D. Kremastinos, L. Sirugo, V. E. Bottari, S. Licciardi, A. Blundo, A. Atanasio, I. P. Monte, C. S. Park, J. H. Kim, J. S. Cho, M. J. Kim, E. J. Cho, S. H. Ihm, H. O. Jung, H. K. Jeon, H. J. Youn, K. S. Kim, A. Fontana, L. Taravella, A. Zambon, G. Trocino, C. Giannattasio, A. Kalinin, M. Alekhin, G. Bahs, A. Lejnieks, A. Kalvelis, A. Kalnins, P. Shipachovs, E. Zakharova, G. Blumentale, M. Trukshina, T. Biering-Sorensen, R. Mogelvang, S. Haahr-Pedersen, P. Schnohr, P. Sogaard, J. Skov Jensen, L. Gargani, G. Agoston, E. Capati, L. Badano, A. Moreo, M. F. Costantino, M. L. Caputo, S. Mondillo, R. Sicari, E. Picano, E. G. Malev, E. V. Timofeev, S. V. Reeva, E. V. Zemtsovsky, R. Piazza, R. Enache, A. Roman-Pognuz, E. Leiballi, R. Pecoraro, H. Sadeghian, M. Lotfi_Tokaldany, M. Rezvanfard, A. Kasemisaeid, S. Majidi, M. Montazeri, M. Saber-Ayad, Y. S. Nassar, A. Farhan, A. Moussa, A. El-Sherif, R. M. Cooper, J. D. Somauroo, R. E. Shave, K. L. Williams, J. Forster, C. George, T. Bett, D. C. Gaze, K. P. George, N. Mansencal, A. Dupland, V. Caille, S. Perrot, K. Bouferrache, A. Vieillard-Baron, R. Jouffroy, S. G. Cioroiu, O. S. Alexe, E. Bobescu, H. Rus, V. Schiano Lomoriello, R. Esposito, A. Santoro, R. Raia, F. Farina, R. Ippolito, M. Galderisi, E. H. Aburawi, P. Malcus, A. Thuring, A. Maxedius, E. Pesonen, S. V. Nair, E. Joyce, L. Lee, J. Shrimpton, E. Newman, P. R. James, C. Jurcut, S. Caraiola, R. O. Jurcut, S. Giusca, D. Nitescu, M. S. Amzulescu, I. Copaci, C. Tanasescu, J. Silva Marques, D. Silva, F. Ferreira, P. C. Ferreira, A. G. Almeida, J. Martim Martins, M. G. Lopes, L. Bergenzaun, M. Chew, A. Ersson, P. Gudmundsson, H. Ohlin, A. Borowiec, R. Dabrowski, J. Wozniak, S. Jasek, T. Chwyczko, I. Kowalik, E. Musiej-Nowakowska, H. Szwed, Y. L. Wen, J. Tian, L. Yan, H. Cheng, H. Yang, B. Luo, J. Wang, H. Kozman, D. Villarreal, K. Liu, A. Karavidas, D. Tsiachris, G. Lazaros, V. Matzaraki, G. Xylomenos, G. Levendopoulos, S. Arapi, A. Perpinia, E. Matsakas, V. Pyrgakis, Y. W. Liu, C. T. Su, W. C. Tsai, J. W. Huang, K. Y. Hung, J. H. Chen, M. Larsson, F. Kremer, T. Kouznetsova, A. Bjallmark, B. Lind, L.-A. Brodin, J. D'hooge, M. Caputo, G. Antonelli, M. Lisi, E. Giacomin, S. Moustafa, M. Alharthi, Y. Deng, K. Chandrasekaran, F. Mookadam, S. Y. Hayashi, M. M. Nascimento, B. Lindholm, A. Seeberger, J. Nowak, M. C. Riella, L. A. Brodin, A. Theodosis, E. Fousteris, G. Tsiaousis, A. Krommydas, P. Margetis, Z. Katidis, D. Beldekos, S. Argirakis, A. Melidonis, S. Foussas, O. Khaleva, O. Onyshchenko, E. Lukaschuk, N. Sherwi, N. Nikitin, J. G. F. Cleland, N. Risum, C. Jons, N. T. Olsen, M. B. Kronborg, M. T. Jensen, T. Fritz-Hansen, N. E. Bruun, M. V. Hojgaard, J. Petrini, M. Yousry, A. Rickenlund, J. Liska, A. Franco-Cereceda, A. Hamsten, P. Eriksson, K. Caidahl, M. J. Eriksson, N. Elmstedt, K. Ferm-Widlund, M. Westgren, E. Szymczyk, J. D. Kasprzak, B. Wozniakowski, A. Rotkiewicz, K. Szymczyk, L. Stefanczyk, B. Michalski, P. Lipiec, L. Ring, T. Eller, P. Deegan, R. Rusk, J. A. Urbano Moral, J. A. Arias, J. T. Kuvin, A. R. Patel, N. G. Pandian, H. Bellsham-Revell, A. J. Bell, O. Miller, G. F. Greil, J. Simpson, R. Ancona, S. Comenale Pinto, P. Caso, S. Severino, L. Nunziata, T. Roselli, C. Dussault, S. Lafitte, G. Habib, P. Reant, G. Derumeaux, H. Thibault, A. Kaladaridis, I. A. Agrios, C. P. Pamboucas, S. M. Mesogitis, N. V. Vasiladiotis, D. B. Bramos, S. T. T. Toumanidis, A. R. Martiniello, G. Santangelo, G. Pedrizzetti, G. Tonti, C. Cioppa, M. Cavallaro, V. Calvi, and R. Chianese
Subjects: Speckle pattern, Longitudinal strain, business.industry, Carotid arteries, Medicine, Radiology, Nuclear Medicine and imaging, General Medicine, Cardiology and Cardiovascular Medicine, business, Tracking (particle physics), Biomedical engineering
Abstract: Radial and longitudinal strain assessment in the carotid artery wall using speckle tracking
Published: 2010

21. Poster session II * Thursday 9 December 2010, 14:00-18:00

Author: P. A. Pabari, A. Kyriacou, M. Moraldo, B. Unsworth, R. Baruah, N. Sutaria, A. Hughes, J. Mayet, D. P. Francis, T. Uejima, K. Loboz, F. Antonini-Canterin, C. Polombo, S. Carerj, D. Vinereanu, A. Evangelista, G. Leftheriotis, A. G. Fraser, A. Kiotsekoglou, M. Govindan, S. C. Govind, S. K. Saha, A. J. Camm, P. M. Azcarate, S. Castano, M. Rodriguez-Manero, M. Arraiza, B. Levy, J. Barba, G. Rabago, G. Bastarrika, A. Nemes, R. Takacs, T. Varkonyi, H. Gavaller, I. Baczko, T. Forster, T. Wittmann, J. G. Papp, C. Lengyel, A. Varro, L. R. Tumasyan, K. G. Adamyan, O. Savu, T. Mieghem, P. Dekoninck, L. Gucciardo, R. Jurcut, S. Giusca, B. A. Popescu, C. Ginghina, J. Deprest, J. U. Voigt, M. Versiero, M. Galderisi, R. Esposito, A. Rapacciuolo, G. Esposito, R. Raia, T. Morgillo, F. Piscione, G. De Simone, M. A. Oraby, F. A. Maklady, E. M. Mohamed, A. Z. Eraki, D. Zaliaduonyte-Peksiene, E. Tamuleviciute, J. Janenaite, J. Marcinkeviciene, V. Mizariene, S. Bucyte, J. Vaskelyte, D. Trifunovic, I. Nedeljkovic, D. Popovic, M. Ostojic, B. Vujisic-Tesic, M. Petrovic, S. Stankovic, D. Sobic-Saranovic, M. Banovic, A. Dikic-Djordjevic, K. Savino, A. Lilli, E. Grikstaite, V. Giglio, E. Bordoni, G. Maragoni, C. Cavallini, G. Ambrosio, B. Jakovljevic, B. Beleslin, M. Nedeljkovic, O. Petrovic, S. Moral, J. Rodriguez-Palomares, M. Descalzo, G. Marti, V. Pineda, P. Mahia, L. Gutierrez, T. Gonzalez-Alujas, D. Garcia-Dorado, F. Schnell, E. Donal, C. Thebault, A. Bernard, H. Corbineau, H. Le Breton, J. Kochanowski, P. Scislo, R. Piatkowski, M. Roik, M. Marchel, D. Kosior, G. Opolski, A. M. Lesniak-Sobelga, E. Wicher-Muniak, M. Kostkiewicz, M. Olszowska, E. Suchon, P. Klimeczek, P. Banys, M. Pasowicz, W. Tracz, P. Podolec, A. Laynez, D. E. Hoefsten, B. B. Loegstrup, B. Norager, J. E. Moller, A. Flyvbjerg, K. Egstrup, W. Streb, M. Szulik, J. Nowak, E. Markowicz-Pawlus, A. Duszanska, A. Sedkowska, Z. Kalarus, T. Kukulski, L. Spinelli, C. Morisco, E. Assante Di Panzillo, F. Buono, S. Crispo, B. Trimarco, A. A. Hawary, G. M. Nasr, M. M. Fawzy, L. Faber, W. Scholtz, J. Boergermann, M. Wiemer, G. Kleikamp, N. Bogunovic, Z. Dimitriadis, J. Gummert, D. Hering, D. Horstkotte, F. Luca', S. Gelsomino, R. Lorusso, S. Caciolli, R. Carella, G. Bille', G. De Cicco, V. Pazzagli, G. F. Gensini, A. Borowiec, R. Dabrowski, J. Janas, A. Kraska, B. Firek, I. Kowalik, H. Szwed, K. A. Marcus, C. L. De Korte, T. Feuth, J. M. Thijssen, L. Kapusta, J. Dahl, L. Videbaek, M. K. Poulsen, P. A. Pellikka, K. Veien, L. I. Andersen, T. Haghfelt, M. Haberka, K. Mizia - Stec, T. Adamczyk, M. Mizia, A. Chmiel, P. Pysz, M. Sosnowski, Z. Gasior, M. Trusz - Gluza, M. Tendera, T. Niklewski, K. Wilczek, P. Chodor, T. Podolecki, A. Frycz-Kurek, M. Zembala, S. Yurdakul, O. Yildirimturk, Y. Tayyareci, K. Memic, I. C. C. Demiroglu, S. Aytekin, C. J. Garcia Alonso, E. Ferrer Sistach, L. Delgado, J. Lopez Ayerbe, N. Vallejo Camazon, F. Gual Capllonch, M. Espriu Simon, X. Ruyra, A. Caballero Parrilla, A. Bayes Genis, L. Lecuyer, A. Berrebi, E. Florens, M. Noghin, C. Huerre, P. Achouh, R. Zegdi, J. N. Fabiani, B. De Chiara, A. Moreo, F. Musca, F. De Marco, E. Lobiati, O. Belli, F. Mauri, S. Klugmann, A. Caballero, N. Vallejo, A. Gonzalez Guardia, R. Nunez Aragon, C. Bosch, E. Ferrer, M. L. Pedro Botet, F. Gual, M. Cusma-Piccione, C. Zito, G. Oreto, R. Giuffre, M. C. Todaro, C. M. Barbaro, S. Lanteri, C. Longordo, J. Salvia, A. Bensaid, R. Gallet, E. Fougeres, P. Lim, J. Nahum, J. F. Deux, P. Gueret, E. Teiger, J. L. Dubois-Rande, J. L. Monin, F. Behramoglu, Z. Colakoglu, V. Aytekin, C. Demiroglu, L. Gargani, E. Poggianti, R. Bucalo, M. Rizzo, F. Agrusta, P. Landi, R. Sicari, E. Picano, A. Sutandar, B. B. Siswanto, I. Irmalita, G. Harimurti, S. Y. Hayashi, M. M. Nascimento, B. Lindholm, B. Lind, A. Seeberger, M. A. Pachaly, M. C. Riella, A. Bjallmark, L. A. Brodin, L. Poanta, M. Porojan, D. L. Dumitrascu, I. Ikonomidis, S. Tzortzis, J. Lekakis, D. T. Kremastinos, I. Paraskevaidis, I. Andreadou, M. Nikolaou, P. Katsibri, M. Anastasiou-Nana, A. M. Maceira Gonzalez, C. Ripoll, J. Cosin-Sales, B. Igual, J. Salazar, V. Belloch, J. Cosin-Aguilar, D. J. Pennell, M. Masaki, J. N. Pulido, T. Yuasa, S. Gillespie, B. Afessa, D. R. Brown, S. V. Mankad, J. K. Oh, A. L. Gurghean, A. M. Mihailescu, I. Tudor, C. Homentcovschi, M. Muraru, I. V. Bruckner, C. E. Correia, B. Rodrigues, D. Moreira, L. F. Santos, P. Gama, O. Dionisio, C. Cabral, O. Santos, T. Bombardini, S. Gherardi, G. Arpesella, S. Valente, I. Calamai, E. Pasanisi, S. Sansoni, P. Szymanski, P. Dobrowolski, M. Lipczynska, A. Klisiewicz, P. Hoffman, D. Stepowski, B. Kurtz, G. Grezis-Soulie, A. Savoure, F. Anselme, F. Bauer, J. Castillo, N. Herszkowicz, C. Ferreira, A. Goscinska, K. Mizia-Stec, W. Poborski, O. Azevedo, I. Quelhas, J. Guardado, M. Fernandes, C. S. Miranda, P. Gaspar, A. Lourenco, R. Medeiros, J. Almeida, S. L Bennani, V. Algalarrondo, S. Dinanian, J. Guiader, C. Juin, D. Adams, M. S. Slama, J. J. Onaindia, O. Quintana, S. Velasco, E. Astigarraga, A. Cacicedo, J. Gonzalez, I. Rodriguez, M. Sadaba, M. Eneriz, E. Laraudogoitia Zaldumbide, I. Nunez-Gil, M. Luaces, J. Zamorano, J. C. Garcia Rubira, D. Vivas, B. Ibanez, P. Marcos Alberca, C. Fernandez Golfin, J. Alonso, C. Macaya, J. Silva Marques, A. G. Almeida, V. Carvalho, C. Jorge, D. Silva, M. Gato Varela, S. Martins, D. Brito, M. G. Lopes, E. Tripodi, B. Miserrafiti, V. Montemurro, R. Scali, P. Tripodi, A. Winkler, A. Madej, I. Hausmanowa-Petrusewicz, M. Fijalkowski, A. Koprowski, M. Jaguszewski, R. Galaska, M. Taszner, A. Rynkiewicz, R. Citro, F. Rigo, G. Provenza, Q. Ciampi, M. M. Patella, A. D'andrea, O. Vriz, C. Astarita, E. Bossone, F. Heggemann, T. H. Walter, T. H. Kaelsch, T. Sueselbeck, T. H. Papavassiliu, M. Borggrefe, D. Haghi, T. Monk-Hansen, C. Have Dall, S. Bisgaard Christensen, M. Snoer, F. Gustafsson, H. Rasmusen, E. Prescott, G. Finocchiaro, B. Pinamonti, M. Merlo, G. Barbati, A. Di Lenarda, R. Bussani, G. Sinagra, T. Butz, C. N. Lang, A. Meissner, G. Plehn, H. Yeni, C. Langer, H. J. Trappe, X. Gu, X. Y. Gu, Y. H. He, Z. A. Li, J. C. Han, J. Chen, P. Gaudron, M. Niemann, S. Herrmann, K. Hu, B. Bijnens, H. Hillenbrand, M. Beer, G. Ertl, F. Weidemann, A. Mazzone, M. Mariani, I. Foffa, A. Vianello, S. Del Ry, S. Bevilacqua, M. G. Andreassi, M. Glauber, S. Berti, M. Grabowski, M. Postula, A. Dragulescu, G. Van Arsdell, O. Al-Radi, C. Caldarone, L. Mertens, K. J. Lee, R. P. Casula, H. Yadav, A. Cherian, A. D. Hughes, A. Vitarelli, S. D'orazio, B. L. Nguyen, G. Iorio, D. Battaglia, F. Caranci, V. Padella, L. Capotosto, L. Alessandroni, F. Barilla, C. Cardin, S. Hascoet, M. Saudron, G. Caudron, B. Arnaudis, P. Acar, M. M. Sun, X. H. Shu, C. Z. Pan, X. Y. Fang, D. H. Kong, F. Fang, Q. Zhang, Y. S. Chan, J. M. Xie, W. K. Yip, Y. Y. Lam, J. E. Sanderson, C. M. Yu, M. Rosca, K. O' Connor, G. Romano, J. Magne, A. Calin, D. Muraru, L. Pierard, P. Lancellotti, A. Roushdy, I. Elfiky, G. El Shahid, A. Elfiky, M. El Sayed, K. Wierzbowska-Drabik, L. Chrzanowski, A. Kapusta, E. Plonska-Goscinak, M. Krzeminska-Pakula, M. Kurpesa, T. Rechcinski, E. Trzos, J. D. Kasprzak, M. K. Ersboll, N. Valeur, U. M. Mogensen, M. Andersen, C. Hassager, P. Sogaard, L. V. Kober, M. Kloeckner, D. Hayat, C. Dussault, N. Lellouche, N. Elbaz, A. Demopoulos, G. Hatzigeorgiou, E. Leontiades, A. Motsi, G. Karatasakis, G. Athanassopoulos, P. Zycinski, J. Kasprzak, M. C. Vazquez Alvarez, C. Medrano Lopez, M. Camino Lopez, S. Granja, J. L. Zunzunegui Martinez, E. Maroto Alvaro, W.-C. Tsai, J.-Y. Chen, Y.-W. Liu, C.-C. Lin, L.-M. Tsai, D. C. Gomes, S. Robalo Martins, M. R. Gois, S. Ribeiro, A. Nunes Diogo, P. Sengupta, G. Di Bella, G. Caracciolo, S. Lentini, E. Kinova, N. Zlatareva, A. Goudev, N. Papagiannis, M. Mpouki, A. Papagianni, M. Vorria, G. Mpenetos, D. Lytra, E. Papadopoulou, P. Sgourakis, J. Malakos, J. Kyriazis, V. Kodali, R. Toole, A. S. Gopal, J. Celutkiene, A. Rudys, V. Grabauskiene, S. Glaveckaite, E. Sadauskiene, Z. Lileikiene, N. Bickauskaite, E. Ciburiene, V. Skorniakov, A. Laucevicius, C. H. Attenhofer Jost, M. Pfyffer, R. Lindquist, J. L. F. Santos, O. R. C. Coelho, C. M. Mady, M. H. P. Picard, V. M. C. Salemi, L. Funk, M. W. Prull, J.-Y. Shih, Y.-Y. Huang, K. O'connor, M. Moonen, L. A. Pierard, D. C. Cozma, C. Mornos, A. Ionac, L. Petrescu, D. Dragulescu, R. Dan, I. Popescu, S. I. Dragulescu, T. G. Von Lueder, A. Hodt, G. F. Gjerdalen, T. E. Andersen, E. E. Solberg, K. Steine, T. Van Mieghem, M. Rostek, W. Pikto-Pietkiewicz, M. Dluzniewski, A. Antoniewicz, S. Poletajew, A. Borowka, T. Pasierski, S. K. Malyutina, M. Ryabikov, J. Ragino, A. Ryabikov, S. Sitia, L. Tomasoni, F. Atzeni, L. Gianturco, P. Sarzi-Puttini, V. De Gennaro Colonna, M. Turiel, F. R. Gutierrez, G. Lefhtheriotis, R. T. Hurst, M. R. Nelson, F. Mookadam, V. Thota, U. Emani, M. Al Harthi, J. Stepanek, S. Cha, S. J. Lester, E. M. M. Ho, L. Hemeryck, M. Hall, K. Scott, K. Bennett, A. Mahmud, C. Daly, G. King, R. T. Murphy, A. S. Brown, A. J. Teske, J. D'Hooge, P. Claus, F. Rademakers, L. Santos, N. Cortez-Dias, S. Goncalves, M. Almeida Ribeiro, A. Bordalo E Sa, C. Magnino, P. Marcos-Alberca, A. Milan, C. Almeria, V. Caniadas, J. L. Rodrigo, L. Perez De Isla, J. L. Zamorano, U. Gustafsson, M. Larsson, P. Lindqvist, L. Brodin, A. Waldenstrom, B. Roosens, S. Hernot, S. Droogmans, G. Van Camp, T. Lahoutte, B. Cosyns, C. M. Rao, D. Aguglia, G. Casciola, C. Imbesi, A. Marvelli, M. Sgro, D. Benedetto, R. Tripepi, C. Zoccali, F. A. Benedetto, L. P. Badano, M. Cardillo, L. Del Mestre, P. Gianfagna, A. Proclemer, H. D. Tschernich, B. Mora, E. Base, U. Weber, J. Dumfarth, C. Mukherjee, H. S. Skaltsiotis, A. K. Kaladaridis, D. B. Bramos, G. K. Kottis, A. A. Antoniou, I. A. Agrios, D. T. Takos, N. V. Vasiladiotis, K. P. Pamboucas, S. T. T. Toumanidis, A. Shim, P. Lipec, B. Michalski, B. Wozniakowski, L. Stefanczyk, A. Rotkiewicz, M. Cameli, M. Lisi, M. Padeletti, E. Bigio, S. Bernazzali, C. Tsoulpas, M. Maccherini, M. Henein, S. Mondillo, I. Garcia Lunar, S. Mingo Santos, V. Monivas Palomero, C. Mitroi, P. Beltran Correas, L. Ruiz Bautista, A. Muniz Lozano, M. Gonzalez Gonzalez, B. Stegemann, K. Willson, R. Zeppellini, A. Iavernaro, M. Zadro, M. Carasi, R. De Domenico, T. Rigo, E. Artuso, G. Erente, A. Ramondo, T. T. Le, F. Q. Huang, Y. Gu, and R. S. Tan
Subjects: Cardiac function curve, medicine.medical_specialty, medicine.anatomical_structure, business.industry, Ventricle, Internal medicine, medicine, Cardiology, Radiology, Nuclear Medicine and imaging, General Medicine, Cardiology and Cardiovascular Medicine, Rotation, business
Published: 2010

22. Pulmonary Artery Pulsatility Index as a Predictor of Right Ventricular Disfunction After Left Ventricular Assist Device Implantation

Author: J F Oteo Dominguez, A. Durante Lopez, S. Mingo Santos, F. Hernandez Perez, L. Alonso Pulpon, S. Serrano Fiz, V Monivas Palomero, M. Gomez Bueno, J. Segovia Cubero, S. Vilches Soria, and J. Goirigolzarri Artaza
Subjects: Pulmonary and Respiratory Medicine, Transplantation, medicine.medical_specialty, business.industry, medicine.medical_treatment, Pulsatility index, Internal medicine, Ventricular assist device, medicine.artery, Pulmonary artery, medicine, Cardiology, Surgery, Cardiology and Cardiovascular Medicine, business
Published: 2017

23. Should We Amplify Cardiac Response Criteria in Patients with Cardiac Light-Chain Amyloidosis Treated with Bortezomib?

Author: A. Durante, Susana Mingo, P. Garcia Pavia, Inés Sayago, Luis Alonso-Pulpón, V Monivas Palomero, J. Segovia Cubero, J. Vázquez, and F. Hernández
Subjects: Pulmonary and Respiratory Medicine, Cardiac response, Transplantation, medicine.medical_specialty, business.industry, Bortezomib, Amyloidosis, Immunoglobulin light chain, medicine.disease, Internal medicine, Cardiology, Medicine, Surgery, In patient, Cardiology and Cardiovascular Medicine, business, medicine.drug
Published: 2017

24. Endophthalmitis, pneumonia, and a heart murmur

Author: J Toquero, P Ortiz, R Fuentes, and V Monivas
Subjects: Pediatrics, medicine.medical_specialty, Fatal outcome, genetic structures, Miscellanea, Eye Infections, Bacterial, Endophthalmitis, Fatal Outcome, medicine, Endocarditis, Humans, Heart Murmurs, business.industry, Endocarditis, Bacterial, Eye infection, Amoxicillin, Middle Aged, Pneumonia, Pneumococcal, medicine.disease, eye diseases, Surgery, Pneumonia, Heart murmur, Female, medicine.symptom, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: A 50 year old woman was admitted to the emergency room because of loss of vision in her right eye. She was a healthy woman until three weeks earlier when she developed fever and cough. A seven day course of amoxicillin was prescribed, but she continued with the symptoms. The …
Published: 2005

25. 2D strain: ready to reduce the number of endomyocardial byopsies in heart trasplant recipients

Author: I. Garcia Lunar, P. Beltran Correas, M. A. Cavero Gibanel, C. Mitroi, S. Mingo Santos, M. Gomez Bueno, V. Monivas Palomero, J. Segovia Cubero, B. Rivero, and J. Gonzalez Mirelis
Subjects: Heart transplantation, medicine.medical_specialty, Univariate analysis, Longitudinal strain, business.industry, medicine.medical_treatment, Diastole, medicine.disease, Transplant rejection, Internal medicine, medicine, Cardiology, Rejection (Psychology), Cardiology and Cardiovascular Medicine, business, 2d strain
Published: 2013

26. 2D Strain in left ventricular non compaction: the clue for differential diagnosis with hypertrophic cardiomyopathy

Author: S. Mingo Santos, I. Garcia Lunar, M. A. Cavero Gibanel, Pablo García-Pavía, F. Dominguez Rodriguez, S. Cuenca Parra, I. Zegri Reiriz, and V. Monivas Palomero
Subjects: medicine.medical_specialty, medicine.diagnostic_test, business.industry, Hypertrophic cardiomyopathy, Cardiomyopathy, Magnetic resonance imaging, Dilated cardiomyopathy, Myocardial Disorder, medicine.disease, Parasternal short axis view, Internal medicine, medicine, Cardiology, Differential diagnosis, Cardiology and Cardiovascular Medicine, business, 2d strain
Abstract: Introduction: Left ventricular non compaction (LVNC) is a rare cardiomyopathy. Differential diagnosis from other myocardial disorders such as hypertrophic cardiomyopathy (HCM) may be challenging. It has been described that myocardial strain helps to differentiate LVNC from dilated cardiomyopathy (DCM) and controls. Our purpose is to compare deformation and rotation of LVNC with HCM and controls. Methods: We included 27 patients with LVNC (40.7% with EF≥45%), diagnosed by echocardiography (n=5), magnetic resonance imaging (n=6) or both tests (n=16), 43 HCM and 15 controls. Longitudinal strain (LStrain) was evaluated using 12 individual segments from 2 and 4 chamber views. Parasternal short axis view was used for evaluation of basal and apical rotation (R). 12 individual segments were analyzed for LStrain evaluation. In the LVNC group 255 individual segments were studied, of whom 59 were not compacted (23.1%). Results: L Strain was reduced in LVNC and HCM compared to controls (table 1). A reduction in apical R and torsion was specifically observed in the LVNC patients. Within this group, L Strain and apical rotation values were even lower when EF was
Published: 2013

27. Response predictors in cardiac resynchronization therapy

Author: J. Toquero Ramos, I. Fernandez Lozano, C. Mitroi, V. Castro Urda, I. Garcia Lunar, S. Cuenca Parra, S. Mingo Santos, V Monivas Palomero, F. Dominguez Rodriguez, and B. Rivero Arribas
Subjects: medicine.medical_specialty, Short axis, Ischemic cardiomyopathy, Ejection fraction, business.industry, Left bundle branch block, medicine.medical_treatment, Cardiac resynchronization therapy, medicine.disease, QRS complex, Internal medicine, cardiovascular system, Cardiology, medicine, End-diastolic volume, Cardiology and Cardiovascular Medicine, Reverse remodeling, business
Abstract: Cardiac resynchronization therapy (CRT) has shown to improve morbidity and survival in those with reduced ejection fraction (LVEF). However, up to 30% of patients do not exhibit improvement in echo. We hypothesized that new parameters meassured by 2D strain combined with traditional ones could predict response. Methods: We included 28 consecutive patients. All studies were performed baseline and after 1 year follow-up. Images were obtained in 4,2-chamber and short axis views. For the assessment of longS and circS curves, we analyzed 14 segments. Results: Age 62.5±10.6, 86.2% men, QRS 160.9±22 ms, LVEF 27.4%±5.9, ischemic cardiomyopathy 30.8%, LBBB 82.6%. The percentage of echo responders (R) were 54% (defined as an improvement in LVEF of 5%). Baseline diferences between R and NON R are shown in the table. View this table: Table 1 Conclusions: This study identifies patient characteristics associated with response to CRT such as LBBB, smaller left atrial, interventricular asinchrony and novel parameters as greater strain values in lead placement segment, and a classical activation pattern meassured by 2D strain. Combined assessment of factors associated with reverse remodeling can be used for improved selection of patients.
Published: 2013

28. Defining the best echocardiographic parameter to predict acute rejection after heart transplantation

Author: C. Mitroi, M. Sanchez Garcia, J. Gonzalez Mirelis, B. Rivero, V. Monivas Palomero, S. Mingo Santos, J. Segovia Cubero, P. Beltran Correas, I. Garcia Lunar, and E. Gonzalez Lopez
Subjects: Heart transplantation, Univariate analysis, medicine.medical_specialty, Multivariate analysis, Longitudinal strain, business.industry, medicine.medical_treatment, Gold standard (test), Endomyocardial biopsy, Surgery, Allograft rejection, Internal medicine, Cardiology, Medicine, Cardiology and Cardiovascular Medicine, business, Isovolumic relaxation time
Abstract: Acute allograft rejection (AR) is the major cause of morbidity and mortality the first year after heart transplantation (HT), beeing endomyocardial biopsy (EB) the gold standard procedure to diagnose it. Our group has previously developed a protocol to evaluate echocardiographic parameters and 2D strain in the first year after HT. Our aim was to evaluate which is the best non-invasive measurement to predict AR. Methods: We prospectively included 34 HT recipients between 2009-12. A median of 7 Echocardiograms and EB were performed for each patient during the first year after HT (the same day). We measured left ventricular (LV) longitudinal strain (Long.S) in 4 and 2-chamber views using speckle tracking. Right ventricular (RV) strain was obtained from a 4-chamber view. AR by EB was graded according to ISHLT recommendations. Results: We analyzed a total of 224 EB and echo exams. AR was detected in 59 EBs (48 1R, 8 2R and 3 3R). 3 different LV parameters and 2 RV measures were significantly associated with AR on univariate analysis, comparing AR vs no-rejection: Interventricular septal thickness (IVST) 12.4±2.1 vs 11.3±1.8, p
Published: 2013

29. Even normal cold ischemia times can induce early allograft disfunction

Author: E. Gonzalez Lopez, M. Gomez Bueno, S. Mingo Santos, C. Mitroi, I. Garcia Lunar, M. Sanchez Garcia, B. Rivero, P. Beltran Correas, V Monivas Palomero, and J. Segovia Cubero
Subjects: medicine.medical_specialty, Aorta, business.industry, Ischemia, Tricuspid valve anulus, medicine.disease, Cold Ischemia Time, Endomyocardial biopsy, Transplant rejection, Surgery, Internal medicine, medicine.artery, Cardiology, Medicine, Systole, Primary graft failure, Cardiology and Cardiovascular Medicine, business
Published: 2013

30. Right ventricle deformation parameters predict allograft rejection in heart transplantation, utility in day-to-day practice

Author: S. Mingo Santos, I. Garcia Lunar, J. Segovia Cubero, V. Monivas Palomero, S. Cuenca Parra, C. Mitroi, P. Beltran Correas, M. A. Cavero Gibanel, E. Gonzalez Lopez, and M. Sanchez Garcia
Subjects: Heart transplantation, medicine.medical_specialty, Receiver operating characteristic, Longitudinal strain, business.industry, medicine.medical_treatment, medicine.disease, Surgery, Endomyocardial biopsy, Transplant rejection, medicine.anatomical_structure, Allograft rejection, Ventricle, Internal medicine, Cardiology, Medicine, Cardiology and Cardiovascular Medicine, business, Subclinical infection
Abstract: Allograft rejection (AR) is a limiting factor of survival the first year after heart transplantation (HT). The only validated method to detect subclinical AR is endomyocardial biopsy (EB) which is invasive and high-risked. Recent advances in strain imaging with speckle tracking (ST) may allow early detection of AR without performing EB. Our aim was to study RV performance in HT and its relationship with AR. Methods: We included 34 patients from 2010 to present. Longitudinal strain (Long.S) by ST and classical RV parameters were obtained concurrently with EB in the first year after HT. Results: 224 echo studies and EBs were performed. There were 48 (21.4%) 1R AR episodes (ISHLT grading), 8 (3.6%) 2R and 3 (1.3%) 3R. RV free-wall Long.S better than -20% excludes AR with 96.1% sensitivity, 57.7% specificity and a negative predictive value of 91.8% (p
Published: 2013

31. Poster Session 1

Author: A. Deshmukh, S. S. Sharma, F. G. Gobal, S. S. Singla, P. H. Hebbar, H. P. Paydak, M. Igarashi, H. Tada, Y. Sekiguchi, H. Yamasaki, K. Kuroki, T. Machino, K. Yoshida, K. Aonuma, J. Shavadia, H. Otieno, G. Yonga, A. Jinah, J. F. Qvist, P. H. Soerensen, U. Dixen, M. A. Ramirez-Marrero, B. Perez-Villardon, D. Gaitan-Roman, M. Jimenez-Navarro, J. L. Delgado-Prieto, E. De Teresa-Galvan, M. De Mora-Martin, P. B. Hebbar, W. X. Wei, S. Bardari, M. Zecchin, R. Salame', L. Vitali Serdoz, A. Di Lenarda, N. Guerrini, G. Barbati, G. Sinagra, K. Hanazawa, K. Kaitani, Y. Nakagawa, I. Lenaerts, R. Driesen, N. Hermida, H. Heidbuchel, S. Janssens, J. L. Balligand, K. R. Sipido, R. Willems, R. Sehra, D. Krummen, C. Briggs, S. Narayan, Y. Tanaka, K. Hirao, T. Nakamura, O. Inaba, A. Yagishita, K. Higuchi, H. Hachiya, M. Isobe, E. Kallergis, E. M. Kanoupakis, H. E. Mavrakis, C. A. Goudis, N. E. Maliaraki, P. E. Vardas, K. Kiuchi, C. Piorkowski, S. Kircher, T. Gaspar, N. Watanabe, A. Bollmann, G. Hindricks, K. Wauters, A. Grosse, S. Raffa, M. Brunelli, J. C. Geller, A. P. Maggioni, L. Gonzini, G. Gussoni, G. Vescovo, M. Gulizia, S. Pirelli, G. Mathieu, G. Di Pasquale, R. Salame, S. Magnani, T. Sakamoto, K. Kumagai, E. Fuke, S. Nishiuchi, T. Hayashi, Y. Miki, S. Naito, S. Oshima, I. E. Hof, E. Vonken, B. K. Velthuis, M. Meine, R. N. W. Hauer, K. P. Loh, J. O. Na, C. U. Choi, E. J. Kim, S. W. Rha, C. G. Park, H. S. Seo, D. J. Oh, H. E. Lim, D. Wichterle, V. Bulkova, M. Fiala, J. Chovancik, J. Simek, P. Peichl, R. Cihak, J. Kautzner, A. Glick, S. Viskin, B. Belhassen, A. Navarrete, F. Conte, A. Ishti, D. Sai, M. Moran, Z. Chitovova, H. Ahmed, K. Mares, J. Skoda, L. Sediva, J. Petru, V. Y. Reddy, P. Neuzil, M. Schmidt, U. Dorwarth, A. Leber, M. Wankerl, J. Krieg, F. Straube, S. Reif, E. Hoffmann, E. Mikhaylov, V. Tikhonenko, D. Lebedev, S. Y. Shin, H. S. Yong, J. I. Choi, S. H. Kim, S. Matsuo, T. Yamane, M. Hioki, K. Ito, R. Narui, T. Date, K. Sugimoto, M. Yoshimura, S. Rolf, P. Sommer, R. Batalov, S. Popov, I. Antonchenko, T. Suslova, S. Fichtner, U. Czudnochowsky, H. L. Estner, S. Ammar, T. Reents, C. Jilek, G. Hessling, I. Deisenhofer, E. Pokushalov, A. Romanov, G. Corbucci, S. Artemenko, D. Losik, V. Shabanov, A. Turov, D. Elesin, M. Abramov, P. Sanders, P. Jais, K. Roberts-Thomson, K. Fukumoto, S. Takatsuki, T. Kimura, N. Nishiyama, Y. Aizawa, T. Sato, S. Miyoshi, K. Fukuda, Y. Roux, J. Tenkorang, P. Carroz, J. Schlaepfer, P. Pascale, A. Forclaz, M. Fromer, E. Pruvot, L. Sknouril, R. Nevralova, M. Dorda, J. Januska, R. Santi, C. Geller, K. Nakamura, K. Kasseno, K. Taniguchi, A. Wutzler, M. Huemer, A. Parwani, L. H. Boldt, D. Blaschke, R. Dietz, W. Haverkamp, B. Coutu, R. Malanuk, M. Ait Said, A. Vicentini, S. Schade, K. Ando, A. Rousseauplasse, T. Deering, B. C. Picarra, A. R. Santos, P. Dionisio, P. Semedo, R. Matos, M. Leitao, A. Jacinto, M. Trinca, C. Wan, J. Glad, S. Szymkiewicz, M. Habibovic, H. Versteeg, A. J. M. Pelle, D. A. M. J. Theuns, L. Jordaens, S. S. Pedersen, S. Pakarinen, L. Toivonen, J. Taggeselle, A. Frey, A. Birkenhagen, S. Kohler, S. K. G. Maier, N. Lobitz, S. Paule, J. Becher, G. Mustafa, A. Ibrahim, G. King, B. Foley, B. Wilkoff, R. Freedman, D. Hayes, S. Kalbfleisch, S. Kutalek, R. Schaerf, I. A. Fazal, M. Tynan, C. J. Plummer, J. M. Mccomb, A. Oto, K. Aytemir, H. Yorgun, U. Canpolat, E. B. Kaya, L. Tokgozoglu, G. Kabakci, H. Ozkutlu, S. Greenberg, F. Hamati, R. Styperek, J. Alonso, D. Peress, O. Bolanos, R. Augostini, M. Pelini, S. Zhang, S. Stoycos, S. Witsaman, K. Mowrey, J. Bremer, A. Oza, G. Ciconte, P. Mazzone, G. Paglino, A. Marzi, P. Vergara, N. Sora, S. Gulletta, P. Della Bella, M. Nagashima, M. Goya, Y. Soga, K. Hiroshima, K. Andou, K. Hayashi, Y. An, M. Nobuyoshi, A. Kutarski, B. Malecka, R. Pietura, P. Osmancik, D. Herman, P. Stros, V. Kocka, P. Tousek, H. Linkova, M. Bortnik, E. Occhetta, G. Dell'era, A. Degiovanni, L. Plebani, P. N. Marino, M. V. Gorev, D. G. Alimov, P. Raju, S. Kully, S. Ugni, S. Furniss, G. Lloyd, N. R. Patel, M. W. Richards, C. E. Warren, M. H. Anderson, M. Hero, J. L. Rey, S. Ouali, S. Azzez, S. Kacem, S. Hammas, H. Ben Salem, E. Neffeti, F. Remedi, E. Boughzela, M. B. Kronborg, P. T. Mortensen, S. H. Poulsen, J. C. Nielsen, E. N. Simantirakis, J. E. Kontaraki, E. G. Arkolaki, S. I. Chrysostomakis, E. G. Nyktari, A. P. Patrianakos, R. C. Funck, C. Harink, H. H. Mueller, S. Koelsch, B. Maisch, V. Bolzani, P. Costandi, R. E. Shehada, N. Butala, B. Coppola, M. Taborsky, P. Heinc, M. Fedorco, V. Doupal, A. Di Cori, G. Zucchelli, E. Soldati, L. Segreti, R. De Lucia, S. Viani, L. Paperini, M. G. Bongiorni, K. J. Gutleben, W. Kranig, C. Barr, M. M. Morgenstern, M. Simon, Y. H. Dalal, M. Landolina, A. Pierantozzi, T. Agricola, M. Lunati, E. Pisano', G. Lonardi, G. Bardelli, G. Zucchi, B. Thibault, M. Dubuc, E. Karst, K. Ryu, P. Paiement, M. D. Carlson, T. Farazi, H. Alhous, L. Mont, J. M. Porres, J. Alzueta, X. Beiras, I. Fernandez-Lozano, A. Macias, R. Ruiz, J. Brugada, S. M. Viani, M. Seifert, T. Schau, V. Moeller, J. Meyhoefer, C. Butter, V. Ganiere, V. Niculescu, G. Domenichini, C. Stettler, P. Defaye, H. Burri, M. Stockburger, E. De Teresa, G. Lamas, M. Desaga, C. Koenig, E. Cobo, X. Navarro, U. Wiegand, M. Blich, S. Carasso, M. Suleiman, I. Marai, L. Gepstein, M. Boulos, M. Sasov, B. Liska, P. Margitfalvi, T. Malacky, M. Svetlosak, E. Goncalvesova, R. Hatala, Y. Takaya, T. Noda, Y. Yamada, H. Okamura, K. Satomi, W. Shimizu, N. Aihara, S. Kamakura, A. Proclemer, S. Boveda, H. Oswald, P. Scipione, A. Da Costa, W. Brzozowski, A. Tomaszewski, A. Wysokinski, E. Arbelo, D. Tamborero, B. Vidal, J. M. Tolosana, M. Sitges, M. Matas, G. L. Botto, C. D. Dicandia, M. Mantica, C. La Rosa, A. D' Onofrio, G. Molon, G. Raciti, R. Verlato, P. W. X. Foley, S. Chalil, K. Ratib, R. E. A. Smith, F. Printzen, A. Auricchio, F. Leyva, R. Abu Sham'a, J. Buber, D. Luria, R. Kuperstein, M. Feinberg, H. Granit, M. Eldar, M. Glikson, K. Vondrak, E. Nof, I. Lipchenca, R.- G. Vatasescu, C. Iorgulescu, C. Caldararu, A. Vasile, S. Bogdan, D. Constantinescu, M. Dorobantu, H. Sakaguchi, A. Miyazaki, T. Yamamoto, K. Fujimoto, S. Ono, H. Ohuchi, M. Martinelli, S. Martins, R. Molina, S. Siqueira, S. A. D. Nishioka, G. L. Peixoto, R. Alkmim-Teixeira, R. Costa, M. M. Meine, A. E. Tuinenburg, P. A. Doevendans, J. Denollet, K. Goscinska-Bis, I. Zupan, H. Van Der, F. Anselme, H. Hartog, M. Block, A. Borri, L. Padeletti, M. Toniolo, G. Zanotto, A. Rossi, E. Raytcheva, L. Tomasi, C. Vassanelli, I. Fernandez Lozano, C. Mitroi, J. Toquero Ramos, V. Castro Urda, V. Monivas Palomero, A. Corona Figueroa, L. Ruiz Bautista, L. Alonso Pulpon, A. S. Jadidi, F. Sacher, A. S. Shah, D. Scherr, N. Derval, M. Hocini, M. Haissaguerre, S. Castrejon Castrejon, C. Largo-Aramburu, J. Sachar, E. Gang, A. Estrada, D. Doiny, E. De Miguel, J. L. Merino, N. Trevisi, A. Ricco, F. Petracca, F. Baratto, A. Bisceglie, G. Maccabelli, A. El-Damaty, J. Sapp, J. Warren, P. Macinnis, M. Horacek, B. Dinov, R. Schoenbauer, F. Braunschweig, A. Arya, D. Andreu, A. Berruezo, J. T. Ortiz, E. Silva, T. M. De Caralt, J. Fernandez-Armenta, A. Perez-Silva, M. Ortega, J. L. Lopez-Sendon, F. Regoli, F. Faletra, G. Nucifora, E. Pasotti, T. Moccetti, C. Klersy, M. Casella, A. Dello Russo, M. Moltrasio, M. Zucchetti, G. Fassini, L. Di Biase, A. Natale, C. Tondo, N. Matsuhashi, H. J. Weig, G. Kerst, S. Weretk, P. Seizer, M. P. Gawaz, J. Schreieck, G. Sarquella-Brugada, F. Prada, C. M. Salling, C. Kolb, M. Pytkowski, A. Maciag, M. Farkowski, A. Jankowska, I. Kowalik, A. Kraska, H. Szwed, P. Maury, A. Duparc, P. Mondoly, A. Rollin, R. Pap, M. Kohari, G. Bencsik, A. Makai, L. Saghy, T. Forster, E. Ebrille, M. Scaglione, C. Raimondo, D. Caponi, P. Di Donna, A. Blandino, S. D. L. Delcre, F. Gaita, I. Roca Luque, L. D. S. Dos, N. R. G. Rivas, A. P. D. Pijuan, J. Perez, J. Casaldaliga, D. G. D. Garcia-Dorado, A. M. M. Moya, H. Sato, T. Yagi, T. Yambe, F. Streitner, C. Dietrich, E. Mahl, N. Schoene, C. Veltmann, M. Borggrefe, J. Kuschyk, P. P. Sadarmin, K. C. K. Wong, K. Rajappan, Y. Bashir, T. R. Betts, C. Leclercq, R. Martins, J. C. Daubert, P. Mabo, M. Koide, G. Hamano, T. Taniguchi, M. Yamato, N. Sasaki, K. Hirooka, Y. Ikeda, Y. Yasumura, W. Dichtl, T. Wolber, U. Paoli, S. Bruellmann, T. Berger, M. Stuehlinger, F. Duru, F. Hintringer, E. Kanoupakis, H. Mavrakis, E. Koutalas, I. Saloustros, C. Goudis, G. Chlouverakis, P. Vardas, J. M. Herre, M. Saeed, L. Saberi, S. Neuman, K. Yamaji, M. Iwabuchi, A. Baranchuk, F. Femenia, R. Miranda Hermosilla, J. C. Lopez Diez, J. L. Serra, M. Valentino, E. Retyk, N. Galizio, W. Kwasniewski, A. Filipecki, W. Orszulak, D. Urbanczyk-Swic, M. Trusz - Gluza, O. Piot, B. Degand, A. Donofrio, P. Scanu, A. Quesada, A. Kloppe, D. Mijic, H. Bogossian, M. Zarse, B. Lemke, J. Tyler, G. Comfort, T. F. Deering, A. E. Epstein, S. M. G. Greenberg, D. S. Goldman, J. Rhude, J. P. Majewski, J. Lelakowski, I. Tomala, C. M. Santos, R. S. Miranda, P. J. Sousa, D. M. Cavaco, P. P. Adragao, R. E. Knops, A. A. Wilde, M. Belhameche, J. S. Hermida, E. Dovellini, G. Frohlig, P. Siot, G. Z. Duray, C. W. Israel, J. Brachmann, K. H. Seidl, M. Foresti, F. Birkenhauer, S. H. Hohnloser, C. Ferreira, P. Mateus, H. Ribeiro, S. Carvalho, A. Ferreira, J. Moreira, W. Kadro, H. Rahim, M. Turkmani, M. Abu Lebdeh, A. Altabban, N. Cerrato, S. Rivera, F. Scazzuso, G. Albina, A. Klein, R. Laino, V. Sammartino, A. Giniger, T. Kvantaliani, M. Akhvlediani, M. Namdar, J. Steffel, S. Jetzer, F. Bayrak, G. B. Chierchia, R. Jenni, P. Brugada, Z. Bakos, M. M. Medvedev M, J. C. Jonas Carlsson, F. H. Fredrik Holmqvist, P. P. Pyotr Platonov, T. Nurbaev, M. Pirnazarov, A. Nikishin, P. Aagaard, A. Sahlen, L. Bergfeldt, E. Simeonidou, S. Kastellanos, C. Varounis, C. Michalakeas, C. Koniari, A. Nikolopoulou, M. Anastasiou-Nana, Y. Furukawa, T. Yamada, T. Morita, K. Tanaka, Y. Iwasaki, M. Kawasaki, Y. Kuramoto, M. Fukunami, C. Blanche, N. Tran, F. Rigamonti, M. Zimmermann, E. Okisheva, D. Tsaregorodtsev, V. Sulimov, D. Novikova, T. Popkova, E. Udachkina, Y. Korsakova, A. Volkov, A. Novikov, E. Alexandrova, E. Nasonov, P. Arsenos, K. Gatzoulis, G. Manis, P. Dilaveris, T. Gialernios, E. Kartsagoulis, S. Asimakopoulos, C. Stefanadis, M. Marocolo, O. Barbosa Neto, A. C. Carvalho, S. R. Marques Neto, G. R. Mota, P. R. B. Barbosa, A. Fernandez-Fernandez, S. Manzano Fernandez, F. J. Pastor-Perez, O. Barquero-Perez, R. Goya-Esteban, M. Salar, J. L. Rojo-Alvarez, A. Garcia-Alberola, M. Takigawa, M. Kawamura, T. Aiba, T. Sakaguchi, H. Itoh, M. Horie, T. Igarashi, J. Negishi, N. Toyota, O. Yamada, M. Papavasileiou, F. Cabrera Bueno, M. J. Molina Mora, J. Alzueta Rodriguez, A. Barrera Cordero, E. De Teresa Galvan, A. S. Revishvili, T. Dzhordzhikiya, O. Sopov, G. Simonyan, O. Lyadzhina, E. Fetisova, V. Kalinin, J. C. Balt, R. C. Steggerda, L. V. A. Boersma, M. C. E. F. Wijffels, E. F. D. Wever, J. M. Ten Berg, R. P. Ricci, L. Morichelli, A. D'onofrio, D. Vaccari, L. Calo', G. Buja, N. Rovai, A. Gargaro, J. Sperzel, G. Speca, L. Santini, J. Haarbo, K. Dubin, M. Carlson, A. Garcia Quintana, H. Mendoza-Lemes, L. Garcia Perez, S. Led Ramos, E. Caballero Dorta, M. Matinez De Espronceda, V. Piro Mastracchio, L. Serrano Arriezu, L. Sciarra, M. Marziali, E. Marras, M. Rebecchi, G. Allocca, E. Lioy, P. Delise, V. E. Santobuono, M. Iacoviello, F. Nacci, G. Luzzi, A. Puzzovivo, M. Memeo, F. Quadrini, S. Favale, M. E. Trucco, M. Arce, J. Palazzolo, W. Uribe, R. Maggi, T. Furukawa, F. Croci, A. Solano, M. Brignole, A. Lebreiro, A. Sousa, A. S. Correia, P. Lourenco, S. Oliveira, M. Paiva, J. Freitas, M. J. Maciel, N. Linker, G. Rieger, C. Garutti, N. Edvardsson, R. Salguero Bodes, M. De Riva Silva, A. Fontenla Cerezuela, M. Lopez Gil, E. Mejia Martinez, A. Jurado Roman, S. Garcia Alvarez, F. Arribas Ynsaurriaga, N. R. Petix, A. Del Rosso, V. Guarnaccia, A. Zipoli, F. Rabajoli, G. Foglia Manzillo, C. Tolardo, C. Checchinato, S. Chiaravallotti, M. Santarone, M. T. Spinnler, C. Podoleanu, A. Frigy, D. Dobreanu, C. Ginghina, and E. Carasca
Subjects: Lv function, medicine.medical_specialty, business.industry, Physiology (medical), Internal medicine, Cardiology, Medicine, Cardiology and Cardiovascular Medicine, business, Predictive value, Value (mathematics), Surgery
Abstract: was higher in the NRG (p 0.70 was the more accurate RT-MCE value to predict LV regional recovery with positive predictive value of 70% and negative predictive value of 56% (p
Published: 2011

32. Poster Session 3

Author: G. M. T. Fabbri, S. Baldasseroni, D. Panuccio, M. Zoni Berisso, M. Scherillo, D. Lucci, G. Di Pasquale, G. Mathieu, I. Burazor, M. Burazor, Z. Perisic, V. Atanaskovic, V. Erakovic, A. Stojkovic, T. Vogtmann, C. Schoebel, S. Sogorski, M. Sebert, J. Schaarschmidt, I. Fietze, G. Baumann, T. Penzel, C. Mornos, A. Ionac, D. Cozma, D. Dragulescu, A. Mornos, L. Petrescu, L. Pescariu, B. Brembilla-Perrot, H. Khachab, F. Lamberti, C. Bellini, R. Remoli, T. Cogliandro, R. Nardo, F. Bellusci, V. Mazzuca, A. Gaspardone, L. E. Aguinaga Arrascue, A. Bravo, P. Garcia Freire, P. Gallardo, E. Hasbani, R. Quintana, J. Dantur, K. Inoue, A. Ueoka, Y. Tsubakimoto, T. Sakatani, A. Matsuo, H. Fujita, M. Kitamura, M. Wegrzynowska, E. Konduracka, A. Z. Pietrucha, D. Mroczek-Czernecka, A. Paradowski, I. Bzukala, J. Nessler, O. Igawa, M. Adachi, H. Atarashi, Y. Kusama, E. Kodani, R. Okazaki, A. Nakagomi, Y. Endoh, J. L. Baez-Escudero, A. S. Dave, C. M. Sasaridis, M. Valderrabano, R. Tilz, R. Bai, L. Di Biase, G. J. Gallinghouse, D. Gibson, A. Pisapia, O. Wazni, A. Natale, A. Arujuna, R. Karim, A. Rinaldi, M. Cooklin, K. Rhode, R. Razavi, M. O'neill, J. Gill, S. Kusa, Y. Komatsu, K. Kakita, K. Takayama, H. Taniguchi, K. Otomo, Y. Iesaka, S. Ammar, T. Reents, S. Fichtner, J. Wu, P. Zhu, C. Kolb, G. Hessling, I. Deisenhofer, G. Gilbert, P. Mohanty, J. Cunningham, T. Metz, R. Horton, S. Tao, Y. Yamauchi, H. Okada, S. Maeda, T. Obayashi, M. Isobe, J. Chan, S. Johar, T. Wong, V. Markides, W. Hussain, M. Konstantinidou, E. Wissner, A. Fuernkranz, Y. Yoshiga, A. Metzner, K.- H. Kuck, F. Ouyang, K. Kettering, F. Gramley, H. Mollnau, C. Weiss, S. Bardeleben, L. Biasco, M. Scaglione, D. Caponi, P. Di Donna, D. Sergi, N. Cerrato, A. Blandino, F. Gaita, M. Fiala, D. Wichterle, L. Sknouril, V. Bulkova, J. Chovancik, R. Nevralova, J. Pindor, J. Januska, J. I. Choi, J. E. Ban, N. Yasutsugu, J. S. Park, J. S. Jung, H. E. Lim, S. W. Park, Y. H. Kim, M. Kuhne, T. Reichlin, P. Ammann, B. Schaer, S. Osswald, C. Sticherling, M. Ohe, M. Goya, K. Hiroshima, K. Hayashi, Y. Makihara, M. Nagashima, M. Fukunaga, Y. An, U. Dorwarth, M. Schmidt, M. Wankerl, J. Krieg, F. Straube, E. Hoffmann, S. Kathan, P. Defaye, A. Mbaye, R. Cassagneau, V. Gagniere, P. Jacon, E. Pokushalov, A. Romanov, S. Artemenko, V. Shabanov, D. Elesin, I. Stenin, A. Turov, D. Losik, K. Kondo, J. Miake, A. Yano, K. Ogura, M. Kato, C. Shigemasa, Y. Sekiguchi, H. Tada, K. Yoshida, Y. Naruse, H. Yamasaki, M. Igarashi, T. Machino, K. Aonuma, S. Chen, S. Liu, G. Chen, W. Meng, F. Zhang, Y. Yan, L. Sciarra, S. Dottori, C. Lanzillo, E. De Ruvo, L. De Luca, M. Minati, E. Lioy, L. Calo', J. Lin, Z. Nie, M. Zhu, X. Wang, J. Zhao, W. Hu, H. Tao, J. Ge, B. Johansson, B. Houltz, N. Edvardsson, H. Schersten, T. Karlsson, B. Wandt, E. Berglin, R. H. Hoyt, B. P. Jenson, S. A. I. P. Trines, J. Braun, A. Tjon Joek Tjien, K. Zeppenfeld, G. Tavilla, R. J. M. Klautz, M. J. Schalij, R. Krausova, R. Cihak, P. Peichl, J. Kautzner, J. Pirk, I. Skalsky, J. Maly, K. Imai, T. Sueda, K. Orihashi, B. C. Picarra, A. R. Santos, P. Dionisio, P. Semedo, R. Matos, M. Leitao, M. Banha, M. Trinca, D. H. J. Elder, J. George, R. Jain, C. C. Lang, A. M. Choy, M. Konert, S. Loescher, A. Hartmann, E. Aversa, R. Chirife, E. Sztyglic, H. Mazzetti, O. Mascheroni, M. C. Tentori, R. M. Pop, A. D. Margulescu, R. Dulgheru, O. Enescu, C. Siliste, D. Vinereanu, A. Menezes Junior, A. R. Castro Carneiro, B. L. De Oliveira, A. N. Shah, B. Kantharia, R. De Lucia, E. Soldati, L. Segreti, A. Di Cori, G. Zucchelli, S. Viani, L. Paperini, M. G. Bongiorni, A. Kutarski, M. Czajkowski, R. Pietura, B. Malecka, J. Heintze, L. Eckardt, A. Bauer, M. Meine, L. Van Erven, P. E. Bloch Thomsen, M. P. Lopez Chicharro, O. Merhi, Y. Soga, K. Andou, M. Nobuyoshi, A. Gonzalez-Mansilla, R. Martin-Asenjo, L. Unzue, J. Torres, E. Garralda, R. R. Coma, J. E. Rodriguez Garcia, T. Yaegashi, H. Furusho, T. Kato, A. Chikata, S. Takashima, S. Usui, M. Takamura, S. Kaneko, M. Chudzik, P. Mitkowski, A. Przybylski, J. Lewek, T. Smukowski, A. Maciag, S. Castrejon Castrejon, A. Perez-Silva, A. Estrada, D. Doiny, M. Ortega, J. L. Lopez-Sendon, J. L. Merino, C. O'mahony, C. Coats, M. Cardona, A. Garcia, M. Calcagnino, R. Lachmann, D. Hughes, P. M. Elliott, S. Conti, G. P. Pruiti, E. Puzzangara, S. A. Romano, A. Di Grazia, G. P. Ussia, C. Tamburino, V. Calvi, A. Radinovic, S. Sala, A. Latib, M. Mussardo, S. Sora, G. Paglino, M. Gullace, A. Colombo, M.- A. G. Ohlow, B. Lauer, A. Wagner, M. Schreiber, B. Buchter, A. Farah, J. T. Fuhrmann, J. C. Geller, R. M. Nascimento Cardoso, L. A. Batista Sa, L. F. C. Campos Filho, S. V. Rodrigues, M. V. F. Dutra, T. R. S. A. Borges, D. R. Portilho, T. Deering, A. Bernardes, A. Veiga, O. Gartenlaub, A. Goncalves, A. Jimenez, A. Rousseauplasse, J. C. Deharo, H. Striekwold, G. Gosselin, H. Sitbon, V. Martins, G. Molon, F. Ayala-Paredes, M. J. Sancho-Tello, I. A. Fazal, S. Brady, J. Cronin, S. Mcnally, M. Tynan, C. J. Plummer, J. M. Mccomb, J. E. Val-Mejias, R. M. Oliveira, R. Costa, M. Martinelli Filho, K. R. Silva, L. M. Menezes, W. T. Tamaki, W. Mathias, N. A. G. Stolf, T. Misawa, I. Ohta, T. Shishido, T. Miyasita, T. Miyamoto, J. Nitobe, T. Watanabe, I. Kubota, B. Thibault, A. Ducharme, C. Simpson, C. Stuglin, C. E. Gagne, R. Williams, S. Mcnicoll, M. S. Silvetti, F. Drago, D. Penela, B. Bijnens, A. Doltra, E. Silva, A. Berruezo, L. Mont, M. Sitges, R. Mcintosh, O. Baumann, P. Raju, S. Gurunathan, S. Furniss, N. Patel, N. Sulke, G. Lloyd, M. Mor, S. Dror, Y. Tsadok, N. Bachner-Hinenzon, A. Katz, N. Liel-Cohen, Y. Etzion, R. Mlynarski, A. Mlynarska, J. Wilczek, M. Sosnowski, A. M. Sinha, D. Sinha, G. Noelker, J. Brachmann, F. Weidemann, G. Ertl, M. Jones, N. Searle, M. Cocker, E. Ilsley, P. Foley, R. Khiani, K. E. Nelson, A. J. Turley, W. A. Owens, S. A. James, N. J. Linker, V. Velagic, M. Cikes, B. Pezo Nikolic, D. Puljevic, J. Separovic-Hanzevacki, M. Lovric-Bencic, B. Biocina, D. Milicic, H. Kawata, L. Chen, H. Phan, K. Anand, G. Feld, U. Birgesdotter-Green, I. Fernandez Lozano, C. Mitroi, J. Toquero Ramos, V. Castro Urda, V. Monivas Palomero, A. Corona Figueroa, L. Hernandez Reina, L. Alonso Pulpon, A. Gate-Martinet, A. Da Costa, P. Rouffiange, A. Cerisier, L. Bisch, C. Romeyer-Bouchard, K. Isaaz, M.- A. Morales, E. Bianchini, U. Startari, F. Faita, T. Bombardini, V. Gemignani, M. Piacenti, S. Adhya, R. H. Kamdar, L. M. Millar, C. Burchardt, F. D. Murgatroyd, D. Klug, C. Kouakam, L. Guedon-Moreau, C. Marquie, S. Benard, S. Kacet, N. Cortez-Dias, P. Carrilho-Ferreira, D. Silva, S. Goncalves, M. Valente, P. Marques, L. Carpinteiro, J. Sousa, T. Keida, T. Nishikido, M. Fujita, T. Chinen, T. Kikuchi, K. Nakamura, H. Ohira, M. Takami, D. Anjo, A. Meireles, C. Gomes, C. Roque, A. Pinheiro Vieira, V. Lagarto, H. Reis, S. Torres, D. F. Ortega, L. D. Barja, J. P. Montes, E. Logarzo, P. Bonomini, N. Mangani, C. Paladino, T. Chwyczko, E. Smolis-Bak, M. Sterlinski, M. Pytkowski, B. Firek, A. Jankowska, H. Szwed, I. Nakajima, T. Noda, H. Okamura, K. Satomi, T. Aiba, W. Shimizu, N. Aihara, S. Kamakura, W. Brzozowski, A. Tomaszewski, A. Wysokinski, E. G. Bertoldi, L. E. Rohde, L. I. Zimerman, M. Pimentel, C. A. Polanczyk, G. Boriani, M. Lunati, M. Gasparini, M. Landolina, G. Lonardi, D. Pecora, M. Santini, S. Valsecchi, B. J. Rubinstein, D. Y. Wang, S. E. Cabreriza, M. E. Richmond, A. Rusanov, T. A. Quinn, B. Cheng, H. M. Spotnitz, H. M. Kristiansen, G. Vollan, T. Hovstad, H. Keilegavlen, S. Faerestrand, U. Brigesdotter-Green, A. M. R. Nawar, D. A. L. I. A. Ragab, R. A. N. I. A. Eluhsseiny, A. H. M. E. D. Abdelaziz, E. Nof, R. Abu Shama, J. Buber, R. Kuperstein, M. S. Feinberg, D. Barlev, M. Eldar, M. Glikson, H. Badran, R. Samir, M. Tawfik, M. Amin, H. Eldamnhoury, S. Khaled, J. M. Tolosana, A. M. Martin, A. Hernandez-Madrid, A. Macias, I. Fernandez-Lozano, J. Osca, A. Quesada, L. Padeletti, G. L. Botto, T. De Santo, A. Szwed, J. G. Martinez, B. Degand, G. Q. Villani, C. Leclercq, P. Ritter, I. Watanabe, K. Nagashima, Y. Okumura, M. Kofune, K. Ohkubo, T. Nakai, A. Hirayama, E. Mikhaylov, M. Vander, D. Lebedev, M. Zarse, H. Suleimann, H. Bogossian, J. Stegelmeyer, I. Ninios, Z. Karosienne, A. Kloppe, B. Lemke, S. John, T. Gaspar, S. Rolf, P. Sommer, G. Hindricks, C. Piorkowski, J. Fernandez-Armenta, L. L. Mont, H. Zeljko, D. Andreu, C. Herzcku, T. Boussy, J. Brugada, T. Obayahi, J. Hegrenes, E. Lim, V. Mediratta, R. Bautista, L. Teplitsky, C. F. B. Van Huls Van Taxis, A. P. Wijnmaalen, M. Gawrysiak, J. D. Schuijf, J. J. Bax, Y. Huo, S. Richter, A. Arya, A. Bollmann, F. Akca, T. Bauernfeind, B. Schwagten, N. M. S. De Groot, L. Jordaens, T. Szili-Torok, S. Miller, G. Kastner, P. Maury, P. Della Bella, E. Delacretaz, F. Sacher, G. Maccabelli, R. Brenner, A. Rollin, P. Jais, P. Vergara, N. Trevisi, A. Ricco, F. Petracca, C. Bisceglia, F. Baratto, R. Salguero Bodes, A. Fontenla Cerezuela, M. De Riva Silva, M. Lopez Gil, E. Mejia Martinez, A. Jurado Roman, M. Montero Alvarez, F. Arribas Ynsaurriaga, A. Baszko, K. Krzyzanowski, W. Bobkowski, R. Surmacz, E. Zinka, A. Siwinska, A. Szyszka, A. Perez Silva, A. Estrada Mucci, M. Ortega Molina, J. L. Lopez Sendon, J. L. Merino Llorens, K. Kaitani, K. Hanazawa, C. Izumi, Y. Nakagawa, I. Yamanaka, T. Hirahara, Y. Sugawara, C. Suga, J. Ako, S. Momomura, N. Galizio, J. Gonzalez, F. Robles, A. Palazzo, L. Favaloro, M. Diez, E. Guevara, A. Fernandez, S. Greenberg, A. Epstein, D. S. Goldman, C. Sangli, J. A. Keeney, K. Lee, S. R. D. Piers, J. B. Van Rees, J. Thijssen, C. J. W. Borleffs, E. T. Van Der Velde, C. H. Leclercq, M. Hero, M. Mizobuchi, Y. Enjoji, Y. Yazaki, K. Shibata, A. Funatsu, T. Kobayashi, S. Nakamura, G. Amit, B. Pertzov, D. Zahger, L. Medesani, R. Rana, F. Albano, H. Fraguas, S. S. Pedersen, M. T. Hoogwegt, D. A. M. J. Theuns, K. C. Van Den Broek, F. B. Tekle, M. Habibovic, M. Alings, P. Van Der Voort, J. Denollet, H. Vrazic, C. Jilek, H. Lesevic, S. Tzeis, V. Semmler, M. R. Gold, M. C. Burke, G. H. Bardy, N. Varma, B. Pavri, B. Stambler, J. Michalski, T. R. U. S. T. Investigators, E. Safak, D. Schmitz, T. Konorza, C. Wende, A. Schirdewan, J. Neuzner, T. Simmers, A. Erglis, R. Gradaus, J. Goetzke, L. Coutrot, K. Goehl, V. Bazan Gelizo, N. Grau, E. Valles, M. Felez, C. Sanjuas, J. Bruguera, J. Marti-Almor, S. Y. Chu, P. W. Li, W. H. Ding, C. Schukro, L. Leitner, J. Siebermair, G. Stix, T. Pezawas, J. Kastner, M. Wolzt, H. Schmidinger, N. A. T. H. A. L. I. E. Behar, G. Kervio, B. Petit, P. Maison-Balnche, S. Bodi, P. Mabo, P. W. X. Foley, E. Mutch, J. Brashaw-Smith, L. Ball, F. Leyva, D. H. Kim, M. J. Lee, W. S. Lee, S. D. Park, S. H. Shin, S. I. Woo, J. Kwan, K. S. Park, Y. Munetsugu, K. Tanno, M. Kikuchi, H. Ito, F. Miyoshi, M. Kawamura, Y. Kobayashi, S. Man, A. M. Algra, C. A. Schreurs, E. E. Van Der Wall, S. C. Cannegieter, C. A. Swenne, K. Iitsuka, T. Kondo, K. Goebbert, Z. Karossiene, D. Goldman, B. Kallen, E. Kerpi, J. Sardo, P. Arsenos, K. Gatzoulis, G. Manis, P. Dilaveris, D. Tsiachris, D. Mytas, S. Asimakopoulos, C. Stefanadis, S. Sideris, E. Kartsagoulis, O. Barbosa, M. Marocolo Junior, R. Silva Cortes, R. A. Moraes Brandolis, L. F. Oliveira, L. A. Pertili Rodrigues De Resende, M. A. Vieira Da Silva, V. J. Dias Da Silva, R. A. Hegazy, I. A. Sharaf, F. Fadel, H. Bazaraa, R. Esam, M. S. Deshko, V. A. Snezhitsky, T. P. Stempen, K. Kuroki, M. Igawa, K. Kuga, L. Ferreira Santos, T. Dionisio, L. Nunes, J. Machado, S. Castedo, C. Henriques, A. Matos, J. Oliveira Santos, K. Kraaier, M. A. G. M. Olimulder, M. A. Galjee, P. F. H. M. Van Dessel, J. Van Der Palen, A. A. M. Wilde, M. F. Scholten, F. Chouchou, L. Poupard, C. Philippe, I. Court-Fortune, J.- C. Barthelemy, F. Roche, T. S. Dolgoshey, G. A. Madekina, S. Sugiura, E. Fujii, M. Senga, K. Dohi, E. Sugiura, M. Nakamura, M. Ito, C. Eitel, J. Mendell, K. Lasseter, M. Shi, L. Urban, R. Hatala, P. Hlivak, M. De Melis, C. Garutti, G. Corbucci, H. Mlcochova, R. Maxian, E. Arbelo, A. Dogac, C. Luepkes, M. Ploessnig, C. Chronaki, L. Hinterbuchner, A. Guillen, S. S. Bun, D. G. Latcu, F. Franceschi, S. Prevot, L. Koutbi, P. Ricard, N. Saoudi, N. Nazari, A. Alizadeh, S. Sayah, M. Hekmat, M. Assadian, A. Ahmadzadeh, M. Wnuk, J. Jedrzejczyk-Spaho, O. Kruszelnicka, W. Piwowarska, A. Fedorowski, P. Burri, S. Juul-Moller, O. Melander, P. Mitro, P. Murin, P. Kirsch, V. Habalova, E. Slaba, E. Matyasova, M. A. Barlow, R. J. Blake, P. Rostoff, E. Wojewodka Zak, L. Froidevaux, F. P. Sarasin, M. Louis-Simonet, O. Hugli, B. Yersin, J. Schlaepfer, C. Mischler, E. Pruvot, E. Occhetta, F. Frascarelli, A. Burali, and E. Dovellini
Subjects: Oncology, medicine.medical_specialty, business.industry, nutritional and metabolic diseases, medicine.disease, Logistic regression, Breast cancer, Physiology (medical), Internal medicine, medicine, lipids (amino acids, peptides, and proteins), skin and connective tissue diseases, Cardiology and Cardiovascular Medicine, business
Abstract: Results: Out of 664159 women there were 22938 patients with hyperlipidaemia (3.5%) and 9312 patients with breast cancer. Out of the hyperlipidaemia patients, 530 patients developed breast cancer (2.3%) compared with 8782 patients developing breast cancer without hyperlipidaemia (1.4%). A logistic regression model accounting for time from first presentation to development of breast cancer showed that the presence of hyperlipidaemia increases the outcome of breast cancer by 1.64 times (95% C.I. 1.50-1.79). Conclusions: Whilst we appreciate numerous limitations of our methods, coupled with the main findings of the recent basic science research, our analysis further augments the case for the role of cholesterol in the development of breast cancer. Our data from a large clinical relevant sample further strengthens the argument to prospectively trial statins in the management of breast cancer.
Published: 2011

33. 206. Reparación mitral como tratamiento de la insuficiencia mitral crónica. Estudio de 119 casos

Author: S. Ramis, J. López, P. Martínez, E. Castedo, V. Moñivas, S. Serrano-Fiz, C. García-Montero, R.J. Burgos, and J. Ugarte
Subjects: Medicine, Surgery, RD1-811
Abstract: Siempre que sea técnicamente posible, la reparación valvular (RV) es la técnica de elección en el tratamiento de la insuficiencia mitral. Presentamos la experiencia de nuestro servicio en el abordaje quirúrgico de la insuficiencia mitral mediante la aplicación de distintas técnicas reparadoras. Métodos: Se han intervenido un total de 119 pacientes desde 1997-2010, realizándose un estudio descriptivo retrospectivo de dicha serie. Resultados: Del total de pacientes un 62% eran hombres, 38% eran mujeres, con una edad media de 61,4 años. En cuanto a la etiología de la insuficiencia mitral, en un 76% era degenerativa, 12,8% isquémica, 6,4% endocardítica, 2,4% reumática y 2,4% por miocardiopatía dilatada. Existía disfunción ventricular grave en 12,8% de los casos, produciéndose un fallecimiento en el postoperatorio inmediato. El resultado posquirúrgico medido por ecocardiografía transesofágica (ETE) intraoperatoriamente fue insuficiencia mitral grado 0-1 en 94,4% de los casos. La mortalidad a los 30 días de cirugía fue de 6,4%. La necesidad de intervención, con el tiempo, relacionada con la propia cirugía fue del 3,2%. La serie presenta un seguimiento medio de 48,5 meses, y en la actualidad están exentos de anticoagulación un 73% de los pacientes de la serie. Conclusiones: La cirugía de reparación mitral es una técnica segura y eficaz que permite corregir adecuadamente el vicio valvular. Su morbimortalidad hospitalaria es baja, presentando excelentes resultados a corto y medio plazo, además de evitar todas las complicaciones propias de las prótesis.
Published: 2010
Full Text: View/download PDF

34. TRIVALVE Score: A Risk Score for Mortality/Hospitalization Prediction in Patients Undergoing Transcatheter Tricuspid Valve Intervention.

Author: Russo G, Pedicino D, Pires Marafon D, Adamo M, Alessandrini H, Andreas M, Braun D, Connelly KA, Denti P, Estevez-Loureiro R, Fam N, Hahn RT, Harr C, Hausleiter J, Himbert D, Kalbacher D, Ho E, Latib A, Lentini N, Lubos E, Ludwig S, Lurz P, Metra M, Monivas V, Nickenig G, Pastorino R, Pedrazzini G, Pozzoli A, Praz F, Rodes-Cabau J, Besler C, Rommel KP, Schofer J, Scotti A, Piayda K, Sievert H, Tang GHL, Thiele H, Schlotter F, von Bardeleben RS, Webb JG, Windecker S, Leon M, Enriquez-Sarano M, Maisano F, Crea F, and Taramasso M
Subjects: Humans, Risk Assessment, Male, Female, Risk Factors, Aged, Time Factors, Aged, 80 and over, Treatment Outcome, Reproducibility of Results, Clinical Decision-Making, Middle Aged, Predictive Value of Tests, Registries, Tricuspid Valve physiopathology, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Patient Readmission, Tricuspid Valve Insufficiency mortality, Tricuspid Valve Insufficiency physiopathology, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency surgery, Cardiac Catheterization adverse effects, Cardiac Catheterization mortality, Cardiac Catheterization instrumentation, Decision Support Techniques, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation mortality, Heart Valve Prosthesis Implantation instrumentation, Severity of Illness Index
Abstract: Background: Transcatheter tricuspid valve intervention (TTVI) has been increasingly adopted in recent years for the treatment of patients with tricuspid regurgitation (TR). However, no dedicated risk stratification has been established for patients undergoing TTVI., Objectives: The aim of the present study was to propose a dedicated risk score for patients affected by severe TR undergoing TTVI., Methods: The score was derived from the TRIVALVE (International Multisite Transcatheter Tricuspid Valve Therapies Registry; NCT03416166) registry, according to data availability. A stepwise model approach was used on predictor variables to develop a scoring system for predicting 12-month mortality or rehospitalization using multivariable logistic regression. Internal discrimination, calibration, and validation were assessed using receiver-operating characteristic curve analysis and bootstrapping with 1,000 resamples., Results: A total of 483 patients were included in the study, with an overall 12-month mortality or rehospitalization rate of 19% (n = 94). The final risk score, ranging from 0 to 4.5, included the following 5 parameters (adjusted for age and gender): 1) atrial fibrillation at baseline; 2) glomerular filtration rate <30 mL/min; 3) elevated gamma-glutamyl transferase/bilirubin levels; 4) signs of right heart failure; and 5) left ventricular ejection fraction <50%. The bias-corrected area under the receiver-operating characteristic curve was 68% (95% CI: 62%-75%). A cutoff value of 2.5 demonstrated sensitivity of 65.4% and specificity of 60.5% for the outcome., Conclusions: The present study proposes a dedicated risk score for patients undergoing TTVI, providing an additional and simple tool for heart teams to select the best therapy for patients affected by severe TR., Competing Interests: Funding Support and Author Disclosures Dr Russo has received a fellowship training grant from the European Association of Percutaneous Cardiovascular Interventions, sponsored by Edwards Lifesciences. Dr Adamo has received personal fees from Abbott Vascular, Medtronic, and Novartis. Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; has stock options with NaviGate; and is chief scientific officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. Dr Andreas is a proctor, consultant, and speaker for Edwards Lifesciences, Abbott, Medtronic, Boston Scientific, and Zoll; and has received institutional research grants from Edwards Lifesciences, Abbott, Medtronic, and LSI Solutions. Dr Denti has received speaker honoraria from Abbott and Edwards Lifesciences. Dr Estevez-Loureiro is a consultant for Abbott Vascular, Boston Scientific, and Edwards Lifesciences. Dr Nickenig has received honoraria for lectures or advisory board membership from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Schofer is a consultant for Edwards Lifesciences. Dr Sievert has received study honoraria to the institution, travel expenses, and consulting fees from 4tech Cardio, Abbott, Ablative Solutions, Adona Medical, Akura Medical, Ancora Heart, Append Medical, Axon, Bavaria Medizin Technologie, Bioventrix, Boston Scientific, Cardiac Dimensions, Cardiac Success, Cardimed, Cardionovum, CeloNova Biosciences, Contego, Coramaze, CroíValve, CSL Behring, CVRx, Dinova, Edwards Lifesciences, EndoBar, Endologix, EndoMatic, Esperion Therapeutics, Hangzhou Nuomao Medtech, Holistick Medical, InterShunt Technologies, Intervene, K2, Laminar, Life Tech Care, Magenta, Maquet Getinge Group, Metavention, Mitralix, Mokita, Neurotronic, NXT Biomedical, Occlutech, Recor, Renal Guard, Shifamed, Terumo, Trisol, Vascular Dynamics, Vectorious Medtech, Venus, Venock, Vivasure Medical, Vvital Biomed, and WhiteSwell. Dr Tang has served as a physician proctor for Medtronic; has served as a consultant for Medtronic, Abbott Structural Heart, and NeoChord; has served on the transcatheter aortic valve replacement advisory board for Abbott Structural Heart; and has served on the physician advisory board for JenaValve. Dr von Bardeleben has served for trials and as a principal investigator for Abbott, Edwards Lifesciences, and Medtronic. Dr Windecker has received research, travel, or educational grants to the institution from Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, Cardiovalve, CorFlow Therapeutics, CSL Behring, Daiichi-Sankyo, Edwards Lifesciences, Guerbet, Infraredx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohme, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi, Servier, Sinomed, Terumo, Vifor, and V-Wave; has served as an advisory board member and/or a member of the steering or executive groups of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis, with payments to the institution but no personal payments; and is a member of the steering or executive committee groups of several investigator-initiated trials that receive funding from industry, without impact on his personal remuneration. Dr Enriquez-Sarano is a consultant for Edwards Lifesciences, ChemImage, Cryolife, and HighLife. Dr Maisano is a consultant for Abbott Vascular, Medtronic, Edwards Lifesciences, Perifect, Xeltis, Transseptal Solutions, Magenta, and Cardiovalve; has received grant support from Abbott Vascular, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; has received royalties from Edwards Lifesciences and 4Tech; and is a cofounder and shareholder of Transseptal Solutions, 4Tech, Cardiovalve, Magenta, Perifect, Coregard and SwissVortex. Dr Taramasso has received consultancy fees from Abbott Vascular, Edwards Lifesciences, 4Tech, Boston Scientific, CoreMedic, Mitraltech, and SwissVortex (outside the submitted work). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

35. Mitral regurgitation evolution after transcatheter tricuspid valve interventions - a sub-analysis of the TriValve Registry.

Author: Cannata F, Sticchi A, Russo G, Stankowski K, Hahn RT, Alessandrini H, Andreas M, Braun D, Connelly KA, Denti P, Estevez-Loureiro R, Fam N, Harr C, Hausleiter J, Himbert D, Kalbacher D, Adamo M, Latib A, Lubos E, Ludwig S, Lurz P, Monivas V, Nickenig G, Pedrazzini G, Pozzoli A, Praz F, Rodes-Cabau J, Rommel KP, Schofer J, Sievert H, Tang G, Thiele H, Kresoja KP, Metra M, Stephan von Bardeleben R, Webb J, Windecker S, Leon M, Maisano F, De Marco F, Pontone G, and Taramasso M
Abstract: Aims: Transcatheter tricuspid valve interventions (TTVI) are increasingly used to treat patients with significant tricuspid regurgitation (TR). The evolution of concurrent mitral regurgitation (MR) severity after TTVI is currently unknown and may be pivotal for clinical decision-making. The aim of this study was to assess the evolution of MR after TTVI and to identify predictors of MR worsening and improvement., Methods and Results: This analysis is a substudy of the Trivalve Registry, an international registry designed to collect data on TTVI. This substudy included all patients with echocardiographic data on MR evolution and excluded those with a concomitant tricuspid and mitral transcatheter valve intervention or with a history of mitral valve intervention. The co-primary outcomes were MR improvement and worsening at two timepoints: pre-discharge and 2-month follow-up. This analysis included 359 patients with severe TR, mostly(80%) treated with tricuspid transcatheter edge-to-edge repair(T-TEER). MR improvement was found in 106(29.5%) and 99(34%) patients, while MR worsening in 34(9.5%) and 33(11%) patients at pre-discharge and 2-month follow-up, respectively. Annuloplasty and heterotopic replacement were associated with MR worsening. Independent predictors of MR improvement were: atrial fibrillation, T-TEER, acute procedural success, TR reduction, LVEDD>60 mm and beta-blocker therapy. Patients with moderate-to-severe/severe MR following TTVI showed significantly higher death rates., Conclusion: MR degree variation is common after TTVI, with most cases showing improvement. Clinical and procedural characteristics may predict the MR evolution, in particular procedural success and T-TEER play key roles in MR outcomes. TTVI may be beneficial even in the presence of functional MR., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Published: 2024
Full Text: View/download PDF

36. Effects of tricuspid transcatheter edge-to-edge repair on tricuspid annulus diameter - Data from the TriValve registry.

Author: Russo G, Hahn RT, Alessandrini H, Andreas M, Badano LP, Braun D, Connelly KA, Denti P, Estevez-Loureiro R, Fam N, Gavazzoni M, Hausleiter J, Himbert D, Kalbacher D, Latib A, Lubos E, Ludwig S, Lurz P, Monivas V, Nickenig G, Pedicino D, Pedrazzini G, Pozzoli A, Praz F, Rodes-Cabau J, Rommel KP, Schofer J, Sievert H, Tang G, Thiele H, Unterhuber M, von Bardeleben RS, Webb J, Windecker S, Leon M, Maisano F, and Taramasso M
Subjects: Humans, Male, Female, Aged, Aged, 80 and over, Treatment Outcome, Heart Valve Prosthesis Implantation methods, Middle Aged, Echocardiography methods, Registries, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Tricuspid Valve Insufficiency surgery, Tricuspid Valve Insufficiency diagnostic imaging, Cardiac Catheterization methods
Abstract: Aims: T-TEER is an effective therapy for the treatment of tricuspid regurgitation (TR). However, the effects of leaflets clipping on tricuspid valve annulus (TA) have not been investigated in detail. The aim of this study is to investigate the effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on TA diameter., Methods and Results: The TriValve registry (Transcatheter Tricuspid Valve Therapies, NCT03416166) collected 556 patients from 22 European and North American centres undergoing transcatheter tricuspid valve interventions from 2016 to 2022. Patients undergoing T-TEER with available pre- and post-procedural data on TA diameter measured in the apical 4-chamber view on transthoracic echocardiography were selected for this study. Primary end-point was the reduction of TA diameter after T-TEER. A total of 186 patients were included in the study. In 115 patients (62%) TA diameter was reduced by at least 1 mm as compared to baseline. A significant reduction of TA dimension was observed following T-TEER (mean 2.3 mm [from pre-procedural diameter 46.7 mm to post-procedural diameter 44.4 mm], p < 0.001). In particular, the greatest reduction was observed in those with T-TEER in antero-septal commissure (mean 2.7 mm [from 47.1 mm to 44.4 mm], p < 0.001) as compared to those combining both antero-septal and postero-septal commissures (mean 1.4, from 46.0 mm to 44.6 mm, P = 0.06). A significant reduction of TA dimension was recorded in patients with 1 or 2 clips implanted but not in those patients with ≥3 clips implanted., Conclusions: In almost two third of patients T-TEER reduces TA diameter in addition to leaflet approximation., Condensed Abstract: The effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on tricuspid valve annulus (TA) have not been studied in details. This study investigates TA diameter as measured in apical 4-chamber view on transthoracic echocardiography before and after T-TEER. A total of 186 patients from the TriValve registry were included in the study. The study results show that 62% of patients have a TA reduction after T-TEER, especially in those receiving 1 or 2 clips in the antero-septal commissure. These suggest that T-TEER reduces tricuspid regurgitation not only by approximation of leaflets, but also by TA diameter reduction., (Copyright © 2024 Elsevier B.V. All rights reserved.)
Published: 2024
Full Text: View/download PDF

37. Prediction of Mortality and Heart Failure Hospitalization After Transcatheter Tricuspid Valve Interventions: Validation of TRISCORE.

Author: Adamo M, Russo G, Pagnesi M, Pancaldi E, Alessandrini H, Andreas M, Badano LP, Braun D, Connelly KA, Denti P, Estevez-Loureiro R, Fam N, Gavazzoni M, Hahn RT, Harr C, Hausleiter J, Himbert D, Kalbacher D, Ho E, Latib A, Lubos E, Ludwig S, Lupi L, Lurz P, Monivas V, Nickenig G, Pedicino D, Pedrazzini G, Pozzoli A, Marafon DP, Pastorino R, Praz F, Rodes-Cabau J, Besler C, Schöber AR, Schofer J, Scotti A, Piayda K, Sievert H, Tang GHL, Sticchi A, Messika-Zeitoun D, Thiele H, Schlotter F, von Bardeleben RS, Webb J, Dreyfus J, Windecker S, Leon M, Maisano F, Metra M, and Taramasso M
Subjects: Humans, Cardiac Catheterization methods, Treatment Outcome, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Multicenter Studies as Topic, Registries, Heart Failure diagnosis, Heart Failure therapy, Heart Failure etiology, Heart Valve Prosthesis Implantation, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency surgery
Abstract: Background: Data on the prognostic role of the TRI-SCORE in patients undergoing transcatheter tricuspid valve intervention (TTVI) are limited., Objectives: The aim of this study was to evaluate the performance of the TRI-SCORE in predicting outcomes of patients undergoing TTVI., Methods: TriValve (Transcatheter Tricuspid Valve Therapies) is a large multicenter multinational registry including patients undergoing TTVI. The TRI-SCORE is a risk model recently proposed to predict in-hospital mortality after tricuspid valve surgery. The TriValve population was stratified based on the TRI-SCORE tertiles. The outcomes of interest were all-cause death and all-cause death or heart failure hospitalization. Procedural complications and changes in NYHA functional class were also reported., Results: Among the 634 patients included, 223 patients (35.2%) had a TRI-SCORE between 0 and 5, 221 (34.8%) had 6 or 7, and 190 (30%) had ≥8 points. Postprocedural blood transfusion, acute kidney injury, new atrial fibrillation, and in-hospital mortality were more frequent in the highest TRI-SCORE tertile. Postprocedure length of stay increased with a TRI-SCORE increase. A TRI-SCORE ≥8 was associated with an increased risk of 30-day all-cause mortality and all-cause mortality and the composite endpoint assessed at a median follow-up of 186 days (OR: 3.00; 95% CI: 1.38-6.55; HR: 2.17; 95% CI: 1.78-4.13; HR: 2.08, 95% CI: 1.57-2.74, respectively) even after adjustment for procedural success and EuroSCORE II or Society of Thoracic Surgeons Predicted Risk of Mortality. The NYHA functional class improved across all TRI-SCORE values., Conclusions: In the TriValve registry, the TRI-SCORE has a suboptimal performance in predicting clinical outcomes. However, a TRISCORE ≥8 is associated with an increased risk of clinical events and a lack of prognostic benefit after successful TTVI., Competing Interests: Funding Support and Author Disclosures Dr Adamo has received speaker honoraria from Abbott. Dr Russo has received a fellowship training grant from the EAPCI sponsored by Edwards Lifesciences. Dr Badano is on the Speaker Bureau of GE Healthcare, Philips Medical Systems, and EsaOte SpA; is currently serving on the Clinical Event Committee of Edwards Lifesciences; and is the director of the echocardiography core laboratory at the Istituto Auxologico Italiano, IRCCS for multiple industry-sponsored trials for which he receives no direct industry compensation. Dr Andreas is a proctor/consultant/speaker for Edwards Lifesciences, Abbott, Medtronic, Boston Scientific, Zoll; and has received institutional research grants from Edwards Lifesciences, Abbott, Medtronic, and LSI. Dr Denti has received speaker honoraria from Abbott and Edwards Lifesciences. Dr Estevez-Loureiro is a consultant for Abbott Vascular, Boston Scientific, and Edwards Lifesciences. Dr Gavazzoni is a proctor for Abbott. Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; has stock options with Navigate; and is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials for which she receives no direct industry compensation. Dr Nickenig has received honoraria for lectures or advisory boards from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Schofer is a consultant for Edwards Lifesciences. Dr Sievert has received study honoraria to institution, travel expenses, and consulting fees from 4tech Cardio, Abbott, Ablative Solutions, Adona Medical, Akura Medical, Ancora Heart, Append Medical, Axon, Bavaria Medizin Technologie GmbH, Bioventrix, Boston Scientific, Cardiac Dimensions, Cardiac Success, Cardimed, Cardionovum, Celonova, Contego, Coramaze, Croivalve, CSL Behring LLC, CVRx, Dinova, Edwards Lifesciences, Endobar, Endologix, Endomatic, Esperion Therapeutics, Inc, Hangzhou Nuomao Medtech, Holistick Medical, Intershunt, Intervene, K2, Laminar, Lifetech, Magenta, Maquet Getinge Group, Metavention, Mitralix, Mokita, Neurotronic, NXT Biomedical, Occlutech, Recor, Renal Guard, Shifamed, Terumo, Trisol, Vascular Dynamics, Vectorious Medtech, Venus, Venock, Vivasure Medical, Vvital Biomed, and Whiteswell. Dr Tang has served as a physician proctor for Medtronic; has served as a consultant for Medtronic, Abbott Structural Heart, and NeoChord; has served on the TAVR Advisory Board for Abbott Structural Heart; and has served on the Physician Advisory Board for JenaValve. Dr von Bardeleben has served for trials and principal investigator for Abbott, Edwards Lifesciences, and Medtronic. Dr Windecker has received research, travel, or educational grants to the institution from Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, and V-Wave; has served as an Advisory Board member and/or member of the Steering/Executive Group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis with payments to the institution but no personal payments; and is a member of the Steering/Executive Committee Group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Dr Maisano is a consultant for Abbott Vascular, Medtronic, Edwards Lifesciences, Perifect, Xeltis, Transseptal Solutions, Magenta, and Cardiovalve; has received grant support from Abbott Vascular, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; has received royalties from Edwards Lifesciences and 4Tech; and is cofounder/shareholder of Transseptal Solutions, 4Tech, Cardiovalve, Magenta, Perifect, Coregard, and SwissVortex. Dr Metra has received consulting fees from Abbott Vascular, Actelion, Amgen, AstraZeneca, Bayer, Edwards Therapeutics, Livanova, Servier, Vifor Pharma, and WindTree Therapeutics. Dr Taramasso has received consultancy fees from Abbott Vascular, Edwards Lifesciences, 4Tech, Boston Scientific, CoreMedic, Mitraltech, and SwissVortex outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

38. Characteristics and outcomes of patients with atrial versus ventricular secondary tricuspid regurgitation undergoing tricuspid transcatheter edge-to-edge repair - Results from the TriValve registry.

Author: Russo G, Badano LP, Adamo M, Alessandrini H, Andreas M, Braun D, Connelly KA, Denti P, Estevez-Loureiro R, Fam N, Gavazzoni M, Hahn RT, Harr C, Hausleiter J, Himbert D, Kalbacher D, Ho E, Latib A, Lubos E, Ludwig S, Lurz P, Monivas V, Nickenig G, Pedicino D, Pedrazzini G, Pozzoli A, Pires Marafon D, Pastorino R, Praz F, Rodes-Cabau J, Besler C, Schofer J, Scotti A, Piayda K, Sievert H, Tang GHL, Thiele H, Schlotter F, von Bardeleben RS, Webb J, Windecker S, Leon M, Maisano F, Metra M, and Taramasso M
Subjects: Humans, Stroke Volume, Treatment Outcome, Cardiac Catheterization methods, Ventricular Function, Left, Registries, Tricuspid Valve Insufficiency complications, Tricuspid Valve Insufficiency surgery, Heart Valve Prosthesis Implantation methods, Heart Failure etiology
Abstract: Aim: Functional or secondary tricuspid regurgitation (STR) is the most common phenotype of tricuspid regurgitation (TR) with atrial STR (ASTR) and ventricular STR (VSTR) being recently identified as two distinct entities. Data on tricuspid transcatheter edge-to-edge repair (T-TEER) in patients with STR according to phenotype (i.e. ASTR vs. VSTR) are lacking. The aim of this study was to assess characteristics and outcomes of patients with ASTR versus VSTR undergoing T-TEER., Methods and Results: Patients with STR undergoing T-TEER were selected from the Transcatheter Tricuspid Valve Therapies (TriValve) registry. ASTR was defined by (i) left ventricular ejection fraction ≥50%, (ii) atrial fibrillation, and (iii) systolic pulmonary artery pressure <50 mmHg. Patients not matching these criteria were classified as VSTR. Patients with primary TR and cardiac implantable electronic device were excluded. Key endpoints included procedural success and survival at follow-up. A total of 298 patients were enrolled in the study: 65 (22%) with ASTR and 233 (78%) with VSTR. Procedural success was similar in the two groups (80% vs. 83% for ASTR vs. VSTR, p = 0.56) and TEER was effective in reducing TR in both groups (from 97% of patients with baseline TR ≥3+ to 23% in ASTR and to 15% in VSTR, all p = 0.001). At 12-month follow-up, survival was significantly higher in the ASTR versus VSTR cohort (91% vs. 72%, log-rank p = 0.02), with VSTR being an independent predictor of mortality at multivariable analysis (hazard ratio 4.75)., Conclusions: In a real-world, multicentre registry, T-TEER was effective in reducing TR grade in both ASTR and VSTR. At 12-month follow-up, ASTR showed better survival than VSTR., (© 2023 European Society of Cardiology.)
Published: 2023
Full Text: View/download PDF

39. Changes in echocardiographic parameters over time in paradoxical low-flow low-gradient aortic stenosis.

Author: Galian-Gay L, Teixidó-Turà G, Casas G, Ferrer-Sistach E, Mitroi C, Mingo S, Monivas V, Saura D, Vidal B, Moral S, Calvo F, Sánchez V, Gonzalez A, Guzman-Martínez G, Noris Mora M, Arnau Vives MÁ, Peteiro J, Bouzas A, González-Alujas T, Gutiérrez L, Fernandez-Galera R, Valente F, Guala A, Ruiz-Muñoz A, Dux-Santoy L, Oliveró Soldevila R, Avilés AS, Rodríguez Palomares JF, Ferreira-González I, and Evangelista A
Subjects: Humans, Echocardiography, Aortic Valve diagnostic imaging, Ventricular Function, Left, Stroke Volume, Severity of Illness Index, Treatment Outcome, Retrospective Studies, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery
Abstract: Aims: To assess the progression of the disease and evolution of the main echocardiographic variables for quantifying AS in patients with severe low-flow low-gradient (LFLG) AS compared to other severe AS subtypes., Methods and Results: Longitudinal, observational, multicenter study including consecutive asymptomatic patients with severe AS (aortic valve area, AVA < 1.0 cm²) and normal left ventricle ejection fraction (LVEF ≥ 50%). Patients were classified according to baseline echocardiography into: HG (high gradient; mean gradient ≥ 40 mmHg), NFLG (normal-flow low-gradient; mean gradient < 40 mmHg, indexed systolic volume (SVi) > 35mL/m2), or LFLG (mean gradient < 40 mmHg, SVi ≤ 35 mL/m²). AS progression was analyzed by comparing patients' baseline measurements and their last follow-up measurements or those taken prior to aortic valve replacement (AVR). Of the 903 included patients, 401 (44.4%) were HG, 405 (44.9%) NFLG, and 97 (10.7%) LFLG. Progression of the mean gradient in a linear mixed regression model was greater in low-gradient groups: LFLG vs. HG (regression coefficient 0.124, P = 0.005) and NFLG vs. HG (regression coefficient 0.068, P = 0.018). No differences were observed between the LFLG and NFLG groups (regression coefficient 0.056, P = 0.195). However, AVA reduction was slower in the LFLG group compared to the NFLG (P < 0.001). During follow-up, in conservatively-managed patients, 19.1% (n = 9) of LFLG patients evolved to having NFLG AS and 44.7% (n = 21) to having HG AS. In patients undergoing AVR, 58.0% (n = 29) of LFLG baseline patients received AVR with a HG AS., Conclusion: LFLG AS shows an intermediate AVA and gradient progression compared to NFLG and HG AS. The majority of patients initially classified as having LFLG AS changed over time to having other severe forms of AS, and most of them received AVR with a HG AS., Competing Interests: Conflict of interest: None declared., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Published: 2023
Full Text: View/download PDF

40. Prognostic Value of Tricuspid Valve Gradient After Transcatheter Edge-to-Edge Repair: Insights From the TriValve Registry.

Author: Coisne A, Scotti A, Taramasso M, Granada JF, Ludwig S, Rodés-Cabau J, Lurz P, Hausleiter J, Fam N, Kodali SK, Pozzoli A, Alessandrini H, Biasco L, Brochet E, Denti P, Estevez-Loureiro R, Frerker C, Ho EC, Monivas V, Nickenig G, Praz F, Puri R, Sievert H, Tang GHL, Andreas M, Von Bardeleben RS, Rommel KP, Muntané-Carol G, Gavazzoni M, Braun D, Lubos E, Kalbacher D, Connelly KA, Juliard JM, Harr C, Pedrazzini G, Philippon F, Schofer J, Thiele H, Unterhuber M, Himbert D, Alcázar MU, Wild MG, Jorde U, Windecker S, Maisano F, Leon MB, Hahn RT, and Latib A
Abstract: Background: Data regarding the impact of the tricuspid valve gradient (TVG) after tricuspid transcatheter edge-to-edge repair (TEER) are scarce., Objectives: This study sought to evaluate the association between the mean TVG and clinical outcomes among patients who underwent tricuspid TEER for significant tricuspid regurgitation., Methods: Patients with significant tricuspid regurgitation who underwent tricuspid TEER within the TriValve (International Multisite Transcatheter Tricuspid Valve Therapies) registry were divided into quartiles based on the mean TVG at discharge. The primary endpoint was the composite of all-cause mortality and heart failure hospitalization. Outcomes were assessed up to the 1-year follow-up., Results: A total of 308 patients were included from 24 centers. Patients were divided into quartiles of the mean TVG as follows: quartile 1 (n = 77), 0.9 ± 0.3 mm Hg; quartile 2 (n = 115), 1.8 ± 0.3 mm Hg; quartile 3 (n = 65), 2.8 ± 0.3 mm Hg; and quartile 4 (n = 51), 4.7 ± 2.0 mm Hg. The baseline TVG and the number of implanted clips were associated with a higher post-TEER TVG. There was no significant difference across TVG quartiles in the 1-year composite endpoint (quartiles 1-4: 35%, 30%, 40%, and 34%, respectively; P = 0.60) or the proportion of patients in New York Heart Association class III to IV at the last follow-up (P = 0.63). The results were similar after adjustment for clinical and echocardiographic characteristics (composite endpoint quartile 4 vs quartile 1-quartile 3 adjusted HR: 1.05; 95% CI: 0.52-2.12; P = 0.88) or exploring post-TEER TVG as a continuous variable., Conclusions: In this retrospective analysis of the TriValve registry, an increased discharge TVG was not significantly associated with adverse outcomes after tricuspid TEER. These findings apply for the explored TVG range and up to the 1-year follow-up. Further investigations on higher gradients and longer follow-up are needed to better guide the intraprocedural decision-making process., Competing Interests: Funding Support and Author Disclosures Dr Coisne has served as a consultant for Abbott; and has received speaker fees from Abbott and GE Healthcare. Dr Scotti has served as a consultant for NeoChord Inc; and has received consulting fees from NeoChord Inc. Dr Taramasso has served as a consultant for Abbott Vascular, Boston Scientific, 4Tech, and CoreMedic; and has received speaker honoraria from Edwards Lifesciences. Dr Ludwig has received travel compensation from Edwards Lifesciences. Dr Rodés-Cabau has received institutional research grants from Edwards Lifesciences. Dr Lurz has received speaker fees from Abbott. Dr Hausleiter has received speaker honoraria from Abbott Vascular and Edwards Lifesciences. Dr Kodali has served on the scientific advisory board for Microinterventional Devices, Dura Biotech, Thubrikar Aortic Valve, and Supira; has served as a consultant for Meril Lifesciences, Admedus, Medtronic, and Boston Scientific; has served on the steering committee for Edwards Lifesciences and Abbott Vascular; has received honoraria from Meril Lifesciences, Admedus, Abbott Vascular, and Dura Biotech; and owns equity in Dura Biotech, Thubrikar Aortic Valve, Supira, and MID. Dr Alessandrini has received consulting fees from Abbott and Edwards LifeSciences. Dr Brochet has received speaker fees from Abbott Vascular. Dr Denti has served as a consultant for Abbott Vascular, 4Tech, Neovasc, and InnovHeart; and has received honoraria from Abbott and Edwards Lifesciences. Dr Estévez- Loureiro has received speaker fees from Abbott, Boston, and Edwards Lifesciences. Dr Ho has served as a consultant for NeoChord Inc; and has received consulting fees from NeoChord Inc. Dr Praz has received travel expenses from Edwards Lifesciences, Abbott Vascular, and Polares Medical. Dr Sievert has received study honoraria, travel expenses, and consulting fees from 4Tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Bavaria Medizin Technologie, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Celonova, Comed BV, Contego, CVRx, Edwards Lifesciences, Endologix, Hemoteq, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Nuomao Medtech, Occlutech, PFM Medical, ReCor, Renal Guard, Rox Medical, Terumo, Vascular Dynamics, and Vivasure Medical. Dr Tang has served as a consultant, physician advisory board member, and faculty trainer for Abbott Structural Heart; has served as a consultant for Medtronic and NeoChord; and has served as a physician advisory board member for JenaValve. Dr Andreas has served as a proctor/consultant for and has received speaker fees from Abbott, Edwards LifeSciences, Boston, Zoll and Medtronic; and has received institutional grants from Edwards Lifesciences, Abbott, Medtronic, and LSI Solutions. Dr Gavazzoni has served as a consultant for Abbott Vascular. Dr Braun has received speaker honoraria and travel support from Abbott Vascular. Dr Lubos has received grant support and lecture fees from Abbott; and has received lecture fees from Edwards Lifesciences. Dr Kalbacher has received lecture fees from Abbott and Edwards Lifesciences. Dr Connelly has received honoraria from Abbott. Dr Schofer has served as a consultant for Edwards Lifesciences. Dr Windecker reports research, travel, or educational grants to the institution from Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohme, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Aventis, Servier, Sinomed, Terumo, Vifor, and V-Wave. Dr Windecker serves as an unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also a member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. Dr Maisano has served as a consultant for and received consulting fees and honoraria from Abbott Vascular, Edwards Lifesciences, Cardiovalve, SwissVortex, Perifect, Xeltis, Transseptal Solutions, Magenta, Valtech, and Medtronic; has reported being a cofounder of 4Tech; has received research grant support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; has received royalties and owns intellectual property rights from Edwards Lifesciences (FMR surgical annuloplasty); and has reported being a shareholder in Cardiovalve, Swiss Vortex, Magenta, Transseptal Solutions, Occlufit, 4Tech, and Perifect. Dr Leon has received institutional clinical research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Hahn has served as a consultant for Abbott Vascular, Abbott Structural, NaviGate, Philips Healthcare, Medtronic, Edwards Lifesciences, and GE Healthcare; has been the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-supported trials, for which she receives no direct industry compensation; has received speaker fees from Boston Scientific and Baylis Medical; and has received nonfinancial support from 3mensio. Dr Latib has served on the advisory board for Medtronic, Abbott Vascular Boston Scientific, Edwards Lifesciences, Shifamed, NeoChord Inc, V-dyne, and Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023. Published by Elsevier Inc.)
Published: 2023
Full Text: View/download PDF

41. Sex-related characteristics and short-term outcomes of patients undergoing transcatheter tricuspid valve intervention for tricuspid regurgitation.

Author: Scotti A, Coisne A, Taramasso M, Granada JF, Ludwig S, Rodés-Cabau J, Lurz P, Hausleiter J, Fam N, Kodali SK, Rosiene J, Feinberg A, Pozzoli A, Alessandrini H, Biasco L, Brochet E, Denti P, Estévez-Loureiro R, Frerker C, Ho EC, Monivas V, Nickenig G, Praz F, Puri R, Sievert H, Tang GHL, Andreas M, Von Bardeleben RS, Rommel KP, Muntané-Carol G, Gavazzoni M, Braun D, Koell B, Kalbacher D, Connelly KA, Juliard JM, Harr C, Pedrazzini G, Russo G, Philippon F, Schofer J, Thiele H, Unterhuber M, Himbert D, Alcázar MU, Wild MG, Windecker S, Jorde U, Maisano F, Leon MB, Hahn RT, and Latib A
Subjects: Male, Humans, Female, Tricuspid Valve surgery, Treatment Outcome, Registries, Tricuspid Valve Insufficiency, Heart Valve Prosthesis Implantation methods, Heart Failure complications
Abstract: Aims: The impact of sexuality in patients with significant tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI) is unknown. The aim of this study was to investigate sex-specific outcomes in patients with significant TR treated with TTVI vs. medical therapy alone., Methods and Results: The Transcatheter Tricuspid Valve Therapies (TriValve) registry collected data on patients with significant TR from 24 centres who underwent TTVI from 2016 to 2021. A control cohort was formed by medically managed patients with ≥severe isolated TR diagnosed in 2015-18. The primary endpoint was freedom from all-cause mortality. Secondary endpoints were heart failure (HF) hospitalization, New York Heart Association (NYHA) functional status, and TR severity. One-year outcomes were assessed for the TriValve cohort and compared with the control cohort with the inverse probability of treatment weighting (IPTW). A total of 556 and 2072 patients were included from the TriValve and control groups, respectively. After TTVI, there was no difference between women and men in 1-year freedom from all-cause mortality 80.9% vs. 77.9%, P = 0.56, nor in HF hospitalization (P = 0.36), NYHA Functional Classes III and IV (P = 0.17), and TR severity >2+ at last follow-up (P = 0.42). Multivariable Cox-regression weighted by IPTW showed improved 1-year survival after TTVI compared with medical therapy alone in both women (adjusted hazard ratio 0.45, 95% confidence interval 0.23-0.83, P = 0.01) and men (adjusted hazard ratio 0.42, 95% confidence interval 0.18-0.89, P = 0.03)., Conclusion: After TTVI in high-risk patients, there were no sex-related differences in terms of survival, HF hospitalization, functional status, and TR reduction up to 1 year. The IPTW analysis shows a survival benefit of TTVI over medical therapy alone in both women and men., Competing Interests: Conflict of Interest: A.S. has served as a consultant and received consulting fees from NeoChord Inc. A.C. has served as a consultant for Abbott and received speaker fees from Abbott and GE Healthcare. M.T. has served as a consultant for Abbott Vascular, Boston Scientific, 4Tech, and CoreMedic; and has received speaker honoraria from Edwards Lifesciences. S.L. has received travel compensation from Edwards Lifesciences. J.R.C. has received institutional research grants from Edwards Lifesciences. P.L. has received speaker fees from Abbott. J.H. has received speaker honoraria from Abbott Vascular and Edwards Lifesciences. S.K.K. has served on the scientific advisory board for Microinterventional Devices, Dura Biotech, Thubrikar Aortic Valve, and Supira; has served as a consultant for Meril Lifesciences, Admedus, Medtronic, and Boston Scientific; has served on the steering committee for Edwards Lifesciences and Abbott Vascular; has received honoraria from Meril Lifesciences, Admedus, Abbott Vascular, and Dura Biotech; and owns equity in Dura Biotech, Thubrikar Aortic Valve, Supira, and MID. H.A. has received consulting fees from Abbott and Edwards LifeSciences. E.B. has received speaker fees from Abbott Vascular. P.D. has served as a consultant for Abbott Vascular, 4Tech, Neovasc, and InnovHeart; and has received honoraria from Abbott and Edwards Lifesciences. R.E.L. has received speaker fees from Abbott, Boston, and Edwards Lifesciences. E.C.H. has served as a consultant and received consulting fees from NeoChord Inc. F.P. has received travel expenses from Edwards Lifesciences, Abbott Vascular, and Polares Medical. H.S. has received study honoraria, travel expenses, and consulting fees from 4Tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Bavaria Medizin Technologie, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Celonova, Comed BV, Contego, CVRx, Edwards Lifesciences, Endologix, Hemoteq, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Nuomao Medtech, Occlutech, PFM Medical, ReCor, Renal Guard, Rox Medical, Terumo, Vascular Dynamics, and Vivasure Medical. G.H.L.T. has served as a consultant, physician advisory board member, and faculty trainer for Abbott Structural Heart; has served as a consultant for Medtronic and NeoChord; and has served as a physician advisory board member for JenaValve. M.A. has served as a proctor/consultant for and has received speaking fees from Abbott, Edwards LifeSciences, Boston, Zoll, and Medtronic; and has received institutional grants from Edwards Lifesciences, Abbott, Medtronic, and LSI Solutions. M.G. has served as a consultant for Abbott Vascular. D.B. has received speaker honoraria and travel support from Abbott Vascular. D.K. has received lecture fees from Abbott and Edwards Lifesciences. K.A.C. has received honoraria from Abbott. J.S. has served as a consultant for Edwards Lifesciences. S.W. reports research, travel, or educational grants to the institution from Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardinal Health, CardioValve, Corflow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, V-Wave. S.W. serves as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, Bayer, Boston Scientific, Biotronik, Bristol Myers Squibb, Edwards Lifesciences, Janssen, MedAlliance, Medtronic, Novartis, Polares, Recardio, Sinomed, Terumo, V-Wave, and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also member of the steering/executive committee group of several investigator-initiated trials that receive funding by industry without impact on his personal remuneration. F.M. has served as a consultant for and received consulting fees and honoraria from Abbott Vascular, Edwards Lifesciences, Cardiovalve, SwissVortex, Perifect, Xeltis, Transseptal Solutions, Magenta, Valtech, and Medtronic; has reported being a cofounder of 4Tech; has received research grant support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; has received royalties and owns intellectual property rights from Edwards Lifesciences (FMR surgical annuloplasty); and has reported being a shareholder in Cardiovalve, Swiss Vortex, Magenta, Transseptal Solutions, Occlufit, 4Tech, and Perifect. M.B.L. has received institutional clinical research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. R.T.H. has served as a consultant for Abbott Vascular, Abbott Structural, NaviGate, Philips Healthcare, Medtronic, Edwards Lifesciences, and GE Healthcare; has been the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-supported trials, for which she receives no direct industry compensation; has received speaker fees from Boston Scientific and Baylis Medical; and has received nonfinancial support from 3mensio. A.L. has served on the advisory board for Medtronic, Abbott Vascular Boston Scientific, Edwards Lifesciences, Shifamed, NeoChord Inc, V-dyne, and Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Published: 2023
Full Text: View/download PDF

42. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience.

Author: Wild MG, Kreidel F, Hell MM, Praz F, Mach M, Adam M, Reineke D, Ruge H, Ludwig S, Conradi L, Rudolph TK, Bleiziffer S, Kellermair J, Zierer A, Nickenig G, Weber M, Petronio AS, Giannini C, Dahle G, Rein KA, Coisne A, Vincentelli A, Dubois C, Duncan A, Quarto C, Unbehaun A, Amat-Santos I, Cobiella J, Dumonteil N, Estevez-Loureiro R, Fumero A, Geisler T, Lurz P, Mangieri A, Monivas V, Noack T, Franco LN, Pinon MA, Stolz L, Tchétché D, Walter T, Unsöld B, Baldus S, Andreas M, Hausleiter J, and von Bardeleben RS
Subjects: Aged, Aged, 80 and over, Cardiac Catheterization methods, Female, Humans, Male, Mitral Valve diagnostic imaging, Mitral Valve surgery, Retrospective Studies, Treatment Outcome, Heart Failure etiology, Heart Valve Diseases etiology, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation methods, Mitral Valve Insufficiency
Abstract: Aims: Transcatheter mitral valve implantation (TMVI) is a new treatment option for patients with symptomatic mitral valve (MV) disease. Real-world data have not yet been reported. This study aimed to assess procedural and 30-day outcomes of TMVI in a real-world patient cohort., Method and Results: All consecutive patients undergoing implantation of a transapically delivered self-expanding valve at 26 European centres from January 2020 to April 2021 were included in this retrospective observational registry. Among 108 surgical high-risk patients included (43% female, mean age 75 ± 7 years, mean STS-PROM 7.2 ± 5.3%), 25% was treated for an off-label indication (e.g. previous MV intervention or surgery, mitral stenosis, mitral annular calcification). Patients were highly symptomatic (New York Heart Association [NYHA] functional class III/IV in 86%) and mitral regurgitation (MR) was graded 3+/4+ in 95% (38% primary, 37% secondary, and 25% mixed aetiology). Technical success rate was 96%, and MR reduction to ≤1+ was achieved in all patients with successful implantation. There were two procedural deaths and 30-day all-cause mortality was 12%. At early clinical follow-up, MR reduction was sustained and there were significant reductions of pulmonary pressure (systolic pulmonary artery pressure 52 vs. 42 mmHg, p < 0.001), and tricuspid regurgitation severity (p = 0.013). Heart failure symptoms improved significantly (73% in NYHA class I/II, p < 0.001). Procedural success rate according to MVARC criteria was 80% and was not different in patients treated for an off-label indication (74% vs. 81% for off- vs. on-label, p = 0.41)., Conclusion: In a real-world patient population, TMVI has a high technical and procedural success rate with efficient and durable MR reduction and symptomatic improvement., (© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
Published: 2022
Full Text: View/download PDF

43. Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits.

Author: Galian-Gay L, Escalona Silva RA, Teixidó-Turà G, Casas G, Ferrer-Sistach E, Mitroi C, Mingo S, Monivas V, Saura D, Vidal B, Trasca L, Moral S, Calvo F, Castiñeira Busto M, Sánchez V, Gonzalez A, Guzman G, Mora MN, Arnau Vives M, Peteiro J, Bouzas A, Mas-Stachurska A, González-Alujas T, Gutiérrez L, Fernandez-Galera R, Valente F, Guala A, Ruiz-Muñoz A, Avilés CAS, Palomares JFR, Ferreira I, and Evangelista A
Abstract: Objectives: To determine the risk of mortality and need for aortic valve replacement (AVR) in patients with low-flow low-gradient (LFLG) aortic stenosis (AS)., Methods: A longitudinal multicentre study including consecutive patients with severe AS (aortic valve area [AVA] < 1.0 cm 2 ) and normal left ventricular ejection fraction (LVEF). Patients were classified as: high-gradient (HG, mean gradient ≥ 40 mmHg), normal-flow low-gradient (NFLG, mean gradient < 40 mmHg, indexed systolic volume (SVi) > 35 ml/m 2 ) and LFLG (mean gradient < 40 mmHg, SVi ≤ 35 ml/m 2 )., Results: Of 1,391 patients, 147 (10.5%) had LFLG, 752 (54.1%) HG, and 492 (35.4%) NFLG. Echocardiographic parameters of the LFLG group showed similar AVA to the HG group but with less severity in the dimensionless index, calcification, and hypertrophy. The HG group required AVR earlier than NFLG ( p < 0.001) and LFLG ( p < 0.001), with no differences between LFLG and NFLG groups ( p = 0.358). Overall mortality was 27.7% ( CI 95% 25.3-30.1) with no differences among groups ( p = 0.319). The impact of AVR in terms of overall mortality reduction was observed the most in patients with HG (hazard ratio [ HR ]: 0.17; 95% CI : 0.12-0.23; p < 0.001), followed by patients with LFLG ( HR : 0.25; 95% CI : 0.13-0.49; p < 0.001), and finally patients with NFLG ( HR : 0.29; 95% CI : 0.20-0.44; p < 0.001), with a risk reduction of 84, 75, and 71%, respectively., Conclusions: Paradoxical LFLG AS affects 10.5% of severe AS, and has a lower need for AVR than the HG group and similar to the NFLG group, with no differences in mortality. AVR had a lower impact on LFLG AS compared with HG AS. Therefore, the findings of the present study showed LFLG AS to have an intermediate clinical risk profile between the HG and NFHG groups., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Galian-Gay, Escalona Silva, Teixidó-Turà, Casas, Ferrer-Sistach, Mitroi, Mingo, Monivas, Saura, Vidal, Trasca, Moral, Calvo, Castiñeira Busto, Sánchez, Gonzalez, Guzman, Mora, Arnau Vives, Peteiro, Bouzas, Mas-Stachurska, González-Alujas, Gutiérrez, Fernandez-Galera, Valente, Guala, Ruiz-Muñoz, Avilés, Palomares, Ferreira and Evangelista.)
Published: 2022
Full Text: View/download PDF

44. Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair.

Author: Brener MI, Lurz P, Hausleiter J, Rodés-Cabau J, Fam N, Kodali SK, Rommel KP, Muntané-Carol G, Gavazzoni M, Nazif TM, Pozzoli A, Alessandrini H, Latib A, Biasco L, Braun D, Brochet E, Denti P, Lubos E, Ludwig S, Kalbacher D, Estevez-Loureiro R, Connelly KA, Frerker C, Ho EC, Juliard JM, Harr C, Monivas V, Nickenig G, Pedrazzini G, Philippon F, Praz F, Puri R, Schofer J, Sievert H, Tang GHL, Andreas M, Thiele H, Unterhuber M, Himbert D, Alcázar MU, Von Bardeleben RS, Windecker S, Wild MG, Maisano F, Leon MB, Taramasso M, and Hahn RT
Subjects: Aged, Echocardiography, Doppler, Female, Follow-Up Studies, Humans, Male, Postoperative Period, Registries, Retrospective Studies, Tricuspid Valve diagnostic imaging, Tricuspid Valve Insufficiency physiopathology, Ventricular Function, Left, Cardiac Surgical Procedures methods, Pulmonary Artery physiopathology, Pulmonary Wedge Pressure physiology, Stroke Volume physiology, Tricuspid Valve surgery, Tricuspid Valve Insufficiency surgery, Ventricular Function, Right physiology
Abstract: Background: The right ventricular (RV)-pulmonary arterial (PA) coupling ratio relates the efficiency with which RV stroke work is transferred into the PA. Lower ratios indicate an inadequate RV contractile response to increased afterload., Objectives: This study sought to evaluate the prognostic significance of RV-PA coupling in patients with tricuspid regurgitation (TR) who were undergoing transcatheter tricuspid valve repair or replacement (TTVR)., Methods: The study investigators calculated RV-PA coupling ratios for patients enrolled in the global TriValve registry by dividing the tricuspid annular plane systolic excursion (TAPSE) by the PA systolic pressure (PASP) from transthoracic echocardiograms performed before the procedure and 30 days after the procedure. The primary endpoint was all-cause mortality at 1-year follow-up., Results: Among 444 patients analyzed, their mean age was 76.9 ± 9.1 years, and 53.8% of the patients were female. The median TAPSE/PASP ratio was 0.406 mm/mm Hg (interquartile range: 0.308-0.567 mm/mm Hg). Sixty-three patients died within 1 year of TTVR, 21 with a TAPSE/PASP ratio >0.406 and 42 with a TAPSE/PASP ratio ≤0.406. In multivariable Cox regression analysis, a TAPSE/PASP ratio >0.406 vs ≤0.406 was associated with a decreased risk of all-cause mortality (HR: 0.57; 95% CI: 0.35-0.93; P = 0.023). In 234 (52.7%) patients with echocardiograms 30 days after TTVR, a decline in RV-PA coupling was independently associated with reduced odds of all-cause mortality (odds ratio [OR]: 0.42; 95% CI: 0.19-0.93; P = 0.032). The magnitude of TR reduction after TTVR (≥1+ vs <1+; OR: 2.53; 95% CI: 1.06-6.03; P = 0.037) was independently associated with a reduction in post-TTVR RV-PA coupling., Conclusions: RV-PA coupling is a powerful, independent predictor of all-cause mortality in patients with TR undergoing TTVR. These data suggest that the TAPSE/PASP ratio can inform patient selection and prognostication following TTVR., Competing Interests: Funding Support and Author Disclosures Dr Brener has received funding from a National Institute of Health grant (NHLBI-T32HL007343). Dr Lurz has received speaker fees from Abbott. Dr Hausleiter has received speaker honoraria from Abbott Vascular and Edwards Lifesciences. Dr Rodés-Cabau has received institutional research grants from Edwards Lifesciences. Dr Kodali has served on the scientific advisory board for Microinterventional Devices, Dura Biotech, Thubrikar Aortic Valve, and Supira; has served as a consultant for Meril Lifesciences, Admedus, Medtronic, and Boston Scientific; has served on the steering committee for Edwards Lifesciences and Abbott Vascular; has received honoraria from Meril Lifesciences, Admedus, Abbott Vascular, and Dura Biotech; and owns equity in Dura Biotech, Thubrikar Aortic Valve, Supira, and MID. Dr Gavazzoni has served as a consultant for Abbott Vascular. Dr Nazif has served as a consultant for and received consulting honoraria from Edwards Lifesciences, Boston Scientific, Medtronic, and Biotrace Medical. Dr Latib has served on the advisory board for Medtronic and Abbott Vascular; has served on the Speakers Bureau for Abbott Vascular; has served on the scientific advisory board for Millipede; and has served as a consultant for 4Tech, Mitralign, and Millipede. Dr Alessandrini has received consulting fees from Abbott and Edwards LifeSciences. Dr Braun has received speaker honoraria and travel support from Abbott Vascular. Dr Brochet has received speaker fees from Abbott Vascular. Dr Lubos has received grant support and lecture fees from Abbott; and has received lecture fees from Edwards Lifesciences. Dr Denti has served as a consultant for Abbott Vascular, 4Tech, Neovasc, and InnovHeart; and has received honoraria from Abbott and Edwards Lifesciences. Dr Ludwig has received travel compensation from Edwards Lifesciences. Dr Kalbacher has received lecture fees from Abbott and Edwards Lifesciences. Dr Estévez-Loureiro has received speaker fees from Abbott, Boston, and Edwards Lifesciences. Dr Connelly has received honoraria from Abbott. Dr Praz has received travel expenses from Edwards Lifesciences, Abbott Vascular, and Polares Medical. Dr Schofer has served as a consultant for Edwards Lifesciences. Dr Sievert has received study honoraria, travel expenses, and consulting fees from 4Tech Cardio, Abbott, Ablative Solutions, Ancora Heart, Bavaria Medizin Technologie, Bioventrix, Boston Scientific, Carag, Cardiac Dimensions, Celonova, Comed BV, Contego, CVRx, Edwards Lifesciences, Endologix, Hemoteq, Lifetech, Maquet Getinge Group, Medtronic, Mitralign, Nuomao Medtech, Occlutech, PFM Medical, ReCor, Renal Guard, Rox Medical, Terumo, Vascular Dynamics, and Vivasure Medical. Dr Tang has served as a consultant, physician advisory board member, and faculty trainer for Abbott Structural Heart; has served as a consultant for Medtronic and NeoChord; and has served as a physician advisory board member for JenaValve. Dr Andreas has served as a proctor/consultant for and has received speaking fees from Abbott, Edwards LifeSciences, and Medtronic; and has received institutional grants from Edwards Lifesciences, Abbott, Medtronic, and Life Systems International. Dr Windecker has received research and educational grants to the institution from Abbott, Amgen, BMS, Bayer, Boston Scientific, Biotronik, Cardinal Health, CardioValve, CSL Behring, Daiichi-Sankyo, Edwards Lifesciences, Johnson & Johnson, Medtronic, Querbet, Polares, Sanofi, Terumo, and Sinomed; has served as an unpaid advisory board member and/or unpaid member of the steering or executive group of trials funded by Abbott, Abiomed, Amgen, AstraZeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave, and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers; has reported membership on the steering or executive committee group of several investigator-initiated trials that receive funding by industry without an impact on his personal remuneration; and has been an unpaid member of the Pfizer Research Award selection committee in Switzerland. Dr Maisano has served as a consultant for and received consulting fees and honoraria from Abbott Vascular, Edwards Lifesciences, Cardiovalve, SwissVortex, Perifect, Xeltis, Transseptal Solutions, Magenta, Valtech, and Medtronic; has reported being a cofounder of 4Tech; has received research grant support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; has received royalties and owns intellectual property rights from Edwards Lifesciences (FMR surgical annuloplasty); and has reported being a shareholder in Cardiovalve, Swiss Vortex, Magenta, Transseptal Solutions, Occlufit, 4Tech, and Perifect. Dr Leon has received institutional clinical research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Taramasso has served as a consultant for Abbott Vascular, Boston Scientific, 4Tech, and CoreMedic; and has received speaker honoraria from Edwards Lifesciences. Dr Hahn has served as a consultant for Abbott Vascular, Abbott Structural, NaviGate, Philips Healthcare, Medtronic, Edwards Lifesciences, and GE Healthcare; has been the Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-supported trials, for which she receives no direct industry compensation; has received speaker fees from Boston Scientific and Baylis Medical; and has received nonfinancial support from 3mensio. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Published: 2022
Full Text: View/download PDF

45. Outcomes of transcatheter tricuspid valve intervention by right ventricular function: a multicentre propensity-matched analysis.

Author: Schlotter F, Miura M, Kresoja KP, Alushi B, Alessandrini H, Attinger-Toller A, Besler C, Biasco L, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Estevez-Loureiro R, Fam N, Gavazzoni M, Himbert D, Ho EC, Juliard JM, Kalbacher D, Kaple R, Kreidel F, Latib A, Lubos E, Ludwig S, Mehr M, Monivas V, Nazif TM, Nickenig G, Pedrazzini G, Pozzoli A, Praz F, Puri R, Rodés-Cabau J, Rommel KP, Schäfer U, Schofer J, Sievert H, Tang GHL, Thiele H, Unterhuber M, Vahanian A, von Bardeleben RS, von Roeder M, Webb JG, Weber M, Wild MG, Windecker S, Zuber M, Hausleiter J, Maisano F, Leon MB, Hahn RT, Lauten A, Taramasso M, and Lurz P
Subjects: Humans, Treatment Outcome, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Ventricular Function, Right, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency surgery, Ventricular Dysfunction, Right diagnostic imaging, Ventricular Dysfunction, Right therapy
Abstract: Background: Tricuspid regurgitation (TR) has a poor prognosis and limited treatment options and is frequently accompanied by right ventricular (RV) dysfunction. Transcatheter tricuspid valve interventions (TTVI) to reduce TR have been shown to be safe and feasible with encouraging early results. Patient selection for TTVI remains challenging, with the role of right ventricular (RV) function being unknown., Aims: The aims of this study were 1) to investigate survival in a TTVI-treated patient population and a conservatively treated TR population, and 2) to evaluate the outcome of TTVI as compared to conservative treatment stratified according to the degree of RV function., Methods: We studied 684 patients from the multicentre TriValve cohort (TTVI cohort) and compared them to 914 conservatively treated patients from two tertiary care centres. Propensity matching identified 213 pairs of patients with severe TR. As we observed a non-linear relationship of RV function and TTVI outcome, we stratified patients according to tricuspid annular plane systolic excursion (TAPSE) to preserved (TAPSE >17 mm), mid-range (TAPSE 13-17 mm) and reduced (TAPSE <13 mm) RV function. The primary outcome was one-year all-cause mortality., Results: TTVI was associated with a survival benefit in patients with severe TR when compared to matched controls (one-year mortality rate: 13.1% vs 25.8%; p=0.031). Of the three RV subgroups, only in patients with mid-range RV function was TTVI associated with an improved survival (p log-rank 0.004). In these patients, procedural success was associated with a reduced hazard ratio for all-cause mortality (HR 0.22; 95% CI: 0.09, 0.57)., Conclusions: TTVI is associated with reduced mortality compared to conservative therapy and might exert its highest treatment effect in patients with mid-range reduced RV function.
Published: 2021
Full Text: View/download PDF

46. Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery.

Author: Muntané-Carol G, Taramasso M, Miura M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly KA, Sievert H, Denti P, Lubos E, Ludwig S, Kalbacher D, Estevez-Loureiro R, Fam N, Frerker C, Ho E, Juliard JM, Kaple R, Kodali S, Kreidel F, Harr C, Lauten A, Lurz J, Kresoja KP, Monivas V, Mehr M, Nazif T, Nickening G, Pedrazzini G, Philippon F, Praz F, Puri R, Schäfer U, Schofer J, Tang GHL, Khattab AA, Andreas M, Russo M, Thiele H, Unterhuber M, Himbert D, Urena M, von Bardeleben RS, Webb JG, Weber M, Winkel M, Zuber M, Hausleiter J, Lurz P, Maisano F, Leon MB, Hahn RT, and Rodés-Cabau J
Subjects: Aged, Cardiac Catheterization methods, Cardiac Surgical Procedures adverse effects, Female, Follow-Up Studies, Heart Valve Prosthesis Implantation methods, Heart Valve Prosthesis Implantation statistics & numerical data, Humans, Male, Outcome Assessment, Health Care, Patient Readmission statistics & numerical data, Registries statistics & numerical data, Risk Assessment, Risk Factors, Severity of Illness Index, Survival Analysis, Cardiac Catheterization adverse effects, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation adverse effects, Tricuspid Valve surgery, Tricuspid Valve Insufficiency etiology, Tricuspid Valve Insufficiency mortality, Tricuspid Valve Insufficiency surgery, Ventricular Dysfunction, Right diagnosis, Ventricular Dysfunction, Right etiology
Abstract: Background: Scarce data exist on patients with previous left valve surgery (PLVS) undergoing transcatheter tricuspid valve intervention (TTVI). This study sought to investigate the procedural and early outcomes in patients with PLVS undergoing TTVI., Methods: This was a subanalysis of the multicenter TriValve registry including 462 patients, 82 (18%) with PLVS. Data were analyzed according to the presence of PLVS in the overall cohort and in a propensity score-matched population including 51 and 115 patients with and without PLVS, respectively., Results: Patients with PLVS were younger (72 ± 10 vs 78 ± 9 years; p < 0.01) and more frequently female (67.1% vs 53.2%; P = 0.02). Similar rates of procedural success (PLVS 80.5%; no-PLVS 82.1%; P = 0.73), and 30-day mortality (PLVS 2.4%, no-PLVS 3.4%; P = 0.99) were observed. After matching, there were no significant differences in both all-cause rehospitalisation (PLVS 21.1%, no-PLVS 26.5%; P = 0.60) and all-cause mortality (PLVS 9.8%, no-PLVS 6.7%; P = 0.58). At last follow-up (median 6 [interquartile range 1-12] months after the procedure), most patients (81.8%) in the PLVS group were in NYHA functional class I-II (P = 0.12 vs no-PLVS group), and TR grade was ≤ 2 in 82.6% of patients (P = 0.096 vs no-PVLS group). A poorer right ventricular function and previous heart failure hospitalization determined increased risks of procedural failure and poorer outcomes at follow-up, respectively., Conclusions: In patients with PLVS, TTVI was associated with high rates of procedural success and low early mortality. However, about one-third of patients required rehospitalisation or died at midterm follow-up. These results would support TTVI as a reasonable alternative to redo surgery in patients with PLVS and suggest the importance of earlier treatment to improve clinical outcomes., (Copyright © 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
Published: 2021
Full Text: View/download PDF

47. Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry.

Author: Muntané-Carol G, Taramasso M, Miura M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Lubos E, Ludwig S, Kalbacher D, Estevez-Loureiro R, Fam N, Frerker C, Ho E, Juliard JM, Kaple R, Kodali S, Kreidel F, Harr C, Lauten A, Lurz J, Monivas V, Mehr M, Nazif T, Nickening G, Pedrazzini G, Philippon F, Praz F, Puri R, Schäfer U, Schofer J, Sievert H, Tang GHL, Khattab AA, Andreas M, Russo M, Thiele H, Unterhuber M, Himbert D, Urena M, von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Hausleiter J, Lurz P, Maisano F, Leon MB, Hahn RT, and Rodés-Cabau J
Subjects: Aged, Aged, 80 and over, Cardiac Catheterization adverse effects, Female, Humans, Male, New York, Registries, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Heart Valve Prosthesis Implantation, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary etiology, Hypertension, Pulmonary therapy, Tricuspid Valve Insufficiency complications, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency surgery, Ventricular Dysfunction, Right diagnostic imaging, Ventricular Dysfunction, Right etiology, Ventricular Dysfunction, Right therapy
Abstract: Background: Scarce data exist on patients with right ventricular dysfunction (RVD) or pulmonary hypertension (PH) undergoing transcatheter tricuspid valve intervention. This study aimed to determine the early and midterm outcomes and the factors associated with mortality in this group of patients., Methods: This subanalysis of the multicenter TriValve (Transcatheter Tricuspid Valve Therapies) registry included 300 patients with severe tricuspid regurgitation with RVD (n=244), PH (n=127), or both (n=71) undergoing transcatheter tricuspid valve intervention. RVD was defined as a tricuspid annular plane systolic excursion <17 mm, and PH as an estimated pulmonary artery systolic pressure ≥50 mm Hg., Results: Mean age of the patients was 77±9 years (54% women). Procedural success was 80.7%, and 9 patients (3%) died during the hospitalization. At a median follow-up of 6 (interquartile range, 2-12) months, 54 patients (18%) died, and the independent associated factors were higher gamma-glutamyl transferase values at baseline (hazard ratio, 1.02 for each increase of 10 u/L [95% CI, 1.002-1.04]), poorer renal function defined as an estimated glomerular filtration rate <45 mL/min (hazard ratio, 2.3 [95% CI, 1.22-4.33]), and the lack of procedural success (hazard ratio, 2.11 [95% CI, 1.17-3.81]). The grade of RVD and the amount of PH at baseline were not found to be predictors of mortality. Most patients alive at follow-up improved their functional class (New York Heart Association I-II in 66% versus 7% at baseline, P <0.001)., Conclusions: In patients with severe tricuspid regurgitation and RVD/PH, transcatheter tricuspid valve intervention was associated with high procedural success and a relatively low in-hospital mortality, along with significant improvements in functional status. However, about 1 out of 5 patients died after a median follow-up of 6 months, with hepatic congestion, renal dysfunction, and the lack of procedural success determining an increased risk. These results may improve the clinical evaluation of transcatheter tricuspid valve intervention candidates and would suggest a closer follow-up in those at increased risk. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03416166.
Published: 2021
Full Text: View/download PDF

48. Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention.

Author: Miura M, Alessandrini H, Alkhodair A, Attinger-Toller A, Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J, Himbert D, Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A, Lauten A, Monivas V, Mehr M, Muntané-Carol G, Nazif T, Nickenig G, Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodés-Cabau J, Schäfer U, Schofer J, Sievert H, Tang GHL, Thiele H, Rommel KP, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Leon MB, Maisano F, Hahn RT, and Taramasso M
Subjects: Aged, Aged, 80 and over, Disease Progression, Europe, Female, Humans, Male, North America, Patient Readmission, Recovery of Function, Registries, Retrospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Tricuspid Valve diagnostic imaging, Tricuspid Valve physiopathology, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency mortality, Tricuspid Valve Insufficiency physiopathology, Cardiac Catheterization adverse effects, Cardiac Catheterization instrumentation, Cardiac Catheterization mortality, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation instrumentation, Heart Valve Prosthesis Implantation mortality, Tricuspid Valve surgery, Tricuspid Valve Insufficiency surgery
Abstract: Objectives: The aim of this study was to assess the clinical outcome of baseline massive or torrential tricuspid regurgitation (TR) after transcatheter tricuspid valve intervention (TTVI)., Background: The use of TTVI to treat symptomatic severe TR has been increasing rapidly, but little is known regarding the impact of massive or torrential TR beyond severe TR., Methods: The study population comprised 333 patients with significant symptomatic TR from the TriValve Registry who underwent TTVI. Mid-term outcomes after TTVI were assessed according to the presence of massive or torrential TR, defined as vena contracta width ≥14 mm. Procedural success was defined as patient survival after successful device implantation and delivery system retrieval, with residual TR ≤2+. The primary endpoint comprised survival rate and freedom from rehospitalization for heart failure, survival rate, and rehospitalization at 1 year., Results: Baseline massive or torrential TR and severe TR were observed in 154 patients (46.2%) and 179 patients (53.8%), respectively. Patients with massive or torrential TR had a higher prevalence of ascites than those with severe TR (27.3% vs. 20.4%, respectively; p = 0.15) and demonstrated a similar procedural success rate (83.2% vs. 77.3%, respectively; p = 0.21). The incidence of peri-procedural adverse events was low, with no significant between-group differences. Freedom from the composite endpoint was significantly lower in patients with massive or torrential TR than in those with severe TR, which was significantly associated with an increased risk for 1-year death of any cause or rehospitalization for heart failure (adjusted hazard ratio: 1.91; 95% confidence interval: 1.10 to 3.34; p = 0.022). Freedom from the composite endpoint was significantly higher in patients with massive or torrential TR when procedural success was achieved (69.9% vs. 54.2%, p = 0.048)., Conclusions: Baseline massive or torrential TR is associated with an increased risk for all-cause mortality and rehospitalization for heart failure 1 year after TTVI. Procedural success is related to better outcomes, even in the presence of baseline massive or torrential TR. (International Multisite Transcatheter Tricuspid Valve Therapies Registry [TriValve]; NCT03416166)., (Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Published: 2020
Full Text: View/download PDF

49. Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads: Data From the TriValve Registry.

Author: Taramasso M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Louriero R, Fam N, Frerker C, Ho E, Juliard JM, Kaple R, Kodali S, Kreidel F, Kuck KH, Lauten A, Lurz J, Monivas V, Mehr M, Nazif T, Nickening G, Pedrazzini G, Praz F, Puri R, Rodés-Cabau J, Schäfer U, Schofer J, Sievert H, Tang GHL, Khattab AA, Thiele H, Unterhuber M, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Hausleiter J, Lurz P, Maisano F, Leon MB, and Hahn RT
Subjects: Aged, 80 and over, Cardiac Catheterization adverse effects, Cardiac Catheterization mortality, Cardiac Pacing, Artificial adverse effects, Cardiac Pacing, Artificial mortality, Clinical Decision-Making, Electric Countershock adverse effects, Electric Countershock mortality, Europe, Feasibility Studies, Female, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation mortality, Hemodynamics, Hospital Mortality, Humans, Male, Mitral Valve diagnostic imaging, Mitral Valve physiopathology, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency mortality, Mitral Valve Insufficiency physiopathology, North America, Postoperative Complications etiology, Postoperative Complications mortality, Prosthesis Design, Recovery of Function, Registries, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome, Cardiac Catheterization instrumentation, Defibrillators, Implantable, Electric Countershock instrumentation, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation instrumentation, Mitral Valve surgery, Mitral Valve Insufficiency surgery, Pacemaker, Artificial
Abstract: Objectives: The interference of a transtricuspid cardiac implantable electronic device (CIED) lead with tricuspid valve function may contribute to the mechanism of tricuspid regurgitation (TR) and poses specific therapeutic challenges during transcatheter tricuspid valve intervention (TTVI). Feasibility and efficacy of TTVI in presence of a CIED is unclear., Background: Feasibility of TTVI in presence of a CIED lead has never been proven on a large basis., Methods: The study population consisted of 470 patients with severe symptomatic TR from the TriValve (Transcatheter Tricuspid Valve Therapies) registry who underwent TTVI at 21 centers between 2015 and 2018. The association of CIED and outcomes were assessed., Results: Pre-procedural CIED was present in 121 of 470 (25.7%) patients. The most frequent location of the CIED lead was the posteroseptal commissure (44.0%). As compared with patients without a transvalvular lead (no-CIED group), patients having a tricuspid lead (CIED group) were more symptomatic (New York Heart Association functional class III to IV in 95.9% vs. 92.3%; p = 0.02) and more frequently had previous episodes of right heart failure (87.8% vs. 69.0%; p = 0.002). No-CIED patients had more severe TR (effective regurgitant orifice area 0.7 ± 0.6 cm 2 vs. 0.6 ± 0.3 cm 2 ; p = 0.02), but significantly better right ventricular function (tricuspid annular plane systolic excursion = 16.7 ± 5.0 mm vs. 15.9 ± 4.0 mm; p = 0.04). Overall, 373 patients (79%) were treated with the MitraClip (Abbott Vascular, Santa Clara, California) (106 [87.0%] in the CIED group). Among them, 154 (33%) patients had concomitant transcatheter mitral repair (55 [46.0%] in the CIED group, all MitraClip). Procedural success was achieved in 80.0% of no-CIED patients and in 78.6% of CIED patients (p = 0.74), with an in-hospital mortality of 2.9% and 3.7%, respectively (p = 0.70). At 30 days, residual TR ≤2+ was observed in 70.8% of no-CIED and in 73.7% of CIED patients (p = 0.6). Symptomatic improvement was observed in both groups (NYHA functional class I to II at 30 days: 66.0% vs. 65.0%; p = 0.30). Survival at 12 months was 80.7 ± 3.0% in the no-CIED patients and 73.6 ± 5.0% in the CIED patients (p = 0.30)., Conclusions: TTVI is feasible in selected patients with CIED leads and acute procedural success and short-term clinical outcomes are comparable to those observed in patients without a transtricuspid lead., (Copyright © 2020 American College of Cardiology Foundation. All rights reserved.)
Published: 2020
Full Text: View/download PDF

50. Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation.

Author: Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J, Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A, Lauten A, Monivas V, Mehr M, Muntané-Carol G, Nazif T, Nickening G, Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodés-Cabau J, Schäfer U, Schofer J, Sievert H, Tang GHL, Thiele H, Topilsky Y, Rommel KP, Delgado V, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, and Maisano F
Subjects: Aged, Aged, 80 and over, Case-Control Studies, Echocardiography, Europe epidemiology, Female, Humans, Male, North America epidemiology, Tricuspid Valve diagnostic imaging, Tricuspid Valve Insufficiency drug therapy, Tricuspid Valve Insufficiency mortality, Cardiac Surgical Procedures mortality, Endovascular Procedures mortality, Registries, Tricuspid Valve surgery, Tricuspid Valve Insufficiency surgery
Abstract: Background: Tricuspid regurgitation is associated with increased rates of heart failure (HF) and mortality. Transcatheter tricuspid valve interventions (TTVI) are promising, but the clinical benefit is unknown., Objectives: The purpose of this study was to investigate the potential benefit of TTVI over medical therapy in a propensity score matched population., Methods: The TriValve (Transcatheter Tricuspid Valve Therapies) registry collected 472 patients from 22 European and North American centers who underwent TTVI from 2016 to 2018. A control cohort formed by 2 large retrospective registries enrolling medically managed patients with ≥ moderate tricuspid regurgitation in Europe and North America (n = 1,179) were propensity score 1:1 matched (distance ± 0.2 SD) using age, EuroSCORE II, and systolic pulmonary artery pressure. Survival was tested with Cox regression analysis. Primary endpoint was 1-year mortality or HF rehospitalization or the composite., Results: After matching, 268 adequately matched pairs of patients were identified. Compared with control subjects, TTVI patients had lower 1-year mortality (23 ± 3% vs. 36 ± 3%; p = 0.001), rehospitalization (26 ± 3% vs. 47 ± 3%; p < 0.0001), and composite endpoint (32 ± 4% vs. 49 ± 3%; p = 0.0003). TTVI was associated with greater survival and freedom from HF rehospitalization (hazard ratio [HR]: 0.60; 95% confidence interval [CI]: 0.46 to 0.79; p = 0.003 unadjusted), which remained significant after adjusting for sex, New York Heart Association functional class, right ventricular dysfunction, and atrial fibrillation (HR: 0.39; 95% CI: 0.26 to 0.59; p < 0.0001) and after further adjustment for mitral regurgitation and pacemaker/defibrillator (HR: 0.35; 95% CI: 0.23 to 0.54; p < 0.0001)., Conclusions: In this propensity-matched case-control study, TTVI is associated with greater survival and reduced HF rehospitalization compared with medical therapy alone. Randomized trials should be performed to confirm these results., (Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Published: 2019
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

51 results on '"V. Monivas"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources